Alternative splice variants

ABSTRACT

The invention concerns novel nucleic acid sequences and amino acid sequences obtained by alternative splicing, expression vectors, host cell and pharmaceutical compositions comprising said sequences.

FIELD OF THE INVENTION

[0001] The present invention concerns novel nucleic acid sequences, vectors and host cells containing them, amino acid sequences encoded by said sequences, and antibodies reactive with said amino acid sequences, as well as pharmaceutical compositions comprising any of the above. The present invention further concerns methods for screening for candidate activator or deactivators utilizing said amino acid sequences.

BACKGROUND OF THE INVENTION

[0002] Alternative splicing (AS) is an important regulatory mechanism in higher eukaryotes (P. A. Sharp, Cell 77, 805-8152 (1994). It is thought to be one of the important mechanisms for differential expression related to tissue or development stage specificity. It is known to play a major role in numerous biological systems, including human antibody responses, sex determination in Drosophila, and and and (S. Stamm, M. Q. Zhang, T. G. Marr and D. M. Helfman, Nucleic Acids Research 22, 1515-1526 (1994); B. Chabot, Trends Genet. 12, 472-478 (1996); R. E. Breitbart, A. Andreadis, B. Nadal-Ginard, Annual Rev. Biochem., 56, 467-495 (1987); C. W. Smith, J. G. Patton, B. Nadal-Ginard, Annu. Rev. Genet., 27, 527-577 (1989).

[0003] Until recently it was commonly believed that alternative splicing existed in only a small fraction of genes (about 5%). A recent observation based on literature survey of known genes revises this estimate to as high as stating that at least 30% of human genes are alternatively spliced (M. S. Gelfand, I. Dubchak, I. Draluk and M. Zorn, Nucleic Acids Research 27, 301-302 (1999). The importance of the actual frequency of this phenomenon lies not only in the direct impact on the number of proteins created (100,000 human genes, for example, would be translated to a much higher number of proteins), but also in the diversity of functionality derived from the process.

[0004] Several mechanisms at different stages may be held responsible for the complexity of higher eukaryote which include: alternative splicing at the transcription level, RNA editing at the post-transcriptional level, and post-translational modifications are the ones characterized to date.

[0005] Glossary

[0006] In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows:

[0007] “Variant nucleic acid sequence”—the sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 26, sequences having at least 90% identity (see below) to said sequence and fragments (see below) of the above sequences of least 20 b.p. long. These sequences are sequences coding for a novel, naturally occurring, alternative splice variant of the native and known genes. It should be emphasized that the novel variants of the present invention are naturally occurring sequences resulting from alternative splicing of genes and not merely truncated, mutated or fragmented forms of known sequences.

[0008] “Variant product—also referred at times as the “variant protein” or “variant polypeptide”—is an amino acid sequence encoded by the variant nucleic acid sequence which is a naturally occurring mRNA sequence obtained as a result of alternative splicing. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having chemically modified amino acids (see below) such as a glycopeptide or glycoprotein. The variant products are shown in any one of SEQ ID NO: 27 to SEQ ID NO: 52. The term also includes homologies (see below) of said sequences in which one or more amino acids has been added, deleted, substituted (see below) or chemically modified (see below) as well as fragments (see below) of this sequence having at least 10 amino acids.

[0009] “Nucleic acid sequence”—a sequence composed of DNA nucleotides, RNA nucleotides or a combination of both types and may includes natural nucleotides, chemically modified nucleotides and synthetic nucleotides.

[0010] “Amino acid sequence”—a sequence composed of any one of the 20 naturally appearing amino acids, amino acids which have been chemically modified (see below), or composed of synthetic amino acids.

[0011] “Fragment of variant nucleic acid sequence”—novel short stretch of nucleic acid sequences of at least 20 b.p., which does not appear as a continuous stretch in the original nucleic acid sequence (see below). The fragment may be a sequence which was previously undescribed in the context of the published RNA and which affects the amino acid sequence encoded by the known gene. For example, where the variant nucleic includes a sequence which was not included in the original sequence (a sequence but which was an intron in the original sequence) the fragment is that additional sequence. The fragment may also be a region which is not an intron, which was not present in the original sequence. Another example is when the variant lacks a non-terminal region which was present in the original sequence. The two stretches of nucleotides spanning this region (upstream and downstream) are brought together by splicing in the variant, but are spaced from each by the region in the original sequence and are thus not continuous. A continuous stretch of nucleic acids comprising said two sparing stretches of nucleotides is not present in the original sequence and thus falls under the definition of fragment.

[0012] “Fragments of variant products”—novel amino acid sequences coded by the “fragment of variant nucleic acid sequence” defined above.

[0013] “Homologues of variants”—amino acid sequences of variants in which one or more amino acids has been added, deleted or replaced. The addition, deletion or replacement should be in regions or adjacent to regions where the variant differs from the original sequence (see below).

[0014] “Conservative substitution”—refers to the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. [Six general classes of amino acid side chains have been categorized and include: 15 Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, Gln, or Glu, is a conservative substitution.

[0015] “Non-conservative substitution”—refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

[0016] “Chemically modified”—when referring to the product of the invention, means a product (protein) where at least one of its amino acid resides is modified either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the numerous known modifications typical, but not exclusive examples include: acetylation, acylation, amidation, ADP-ribosylation, glycosylation, GPI anchor formation, covalent attachment of a lipid or lipid derivative, methylation, myristlyation, pegylation, prenylation, phosphorylation, ubiqutination, or any similar process.

[0017] “Biologically active”—refers to the variant product having some sort of biological activity, for example, some physiologically measurable effect on target cells, molecules or tissues.

[0018] “Immunologically active” defines the capability of a natural, recombinant or synthetic varient product, or any fragment thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. Thus, for example, an immunologically active fragment of variant product denotes a fragment which retains some or all of the immunological properties of the variant product, e.g can bind specific anti-variant product antibodies or which can elicit an immune response which will generate such antibodies or cause proliferation of specific immune cells which produce variant.

[0019] “Optimal alignment”—is defined as an alignment giving the highest percent identity score. Such alignment can be performed using a variety of commercially available sequence analysis programs, such as the local alignment program LALIGN using a ktup of 1, default parameters and the default PAM. A preferred alignment is the one performed using the CLUSTAL-W program from MacVector (TM), operated with an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM similarity matrix. If a gap needs to be inserted into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired with a corresponding amino acid residue (i.e., the calculation does not consider residues in the second sequences that are in the “gap” of the first sequence). In case of alignments of known gene sequences with that of the new variant, the optimal alignment invariably included aligning the identical parts of both sequences together, then keeping apart and unaligned the sections of the sequences that differ one from the other.

[0020] “Having at least 90% identity”—with respect to two amino acid or nucleic acid sequence sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 90% amino acid sequence identity means that 90% of the amino acids in two or more optimally aligned polypeptide sequences are identical, however this definition explicitly excludes sequences which are 100% identical with the original sequence from which the variant of the invention was varied.

[0021] “Isolated nucleic acid molecule having an variant nucleic acid sequence”—is a nucleic acid molecule that includes the coding variant nucleic acid sequence. Said isolated nucleic acid molecule may include the variant nucleic acid sequence as an independent insert; may include the variant nucleic acid sequence fused to an additional coding sequences, encoding together a fusion protein in which the variant coding sequence is the dominant coding sequence (for example, the additional coding sequence may code for a signal peptide); the variant nucleic acid sequence may be in combination with non-coding sequences, e.g., introns or control elements, such as promoter and terminator elements or 5′ and/or 3′ untranslated regions, effective for expression of the coding sequence in a suitable host; or may be a vector in which the variant protein coding sequence is a heterologous.

[0022] “Expression vector”—refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression vectors are known and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art.

[0023] “Deletion”—is a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

[0024] “Insertion” or “addition”—is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring sequence.

[0025] “Substitution”—replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As regards amino acid sequences the substitution may be conservative or non-conservative.

[0026] “Antibody”—refers to IgG, IgM, IgD, IgA, and IgG antibody. The definition includes polyclonal antibodies or monoclonal antibodies. This term refers to whole antibodies or fragments of the antibodies comprising the antigen-binding domain of the anti-variant product antibodies, e.g. antibodies without the Fc portion, single chain antibodies, fragments consisting of essentially only the variable, antigen-binding domain of the antibody, etc.

[0027] “Activator”—as used herein, refers to a molecule which mimics the effect of the natural variant product or at times even increases or prolongs the duration of the biological activity of said product, as compared to that induced by the natural product. The mechanism may be by any mechanism known to prolonging activities of biological molecules such as binding to receptors; prolonging the lifetime of the molecules; increasing the activity of the molecules on its target; increasing the affinity of molecules to its receptor; inhibiting degradation or proteolysis of the molecules, etc. Activators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which can bind to and activate the variant product.

[0028] “Deactivator” or (“Inhibitor”)—refers to a molecule which modulates the activity of the variant product in an opposite manner to that of the activator, by decreasing or shortening the duration of the biological activity of the variant product. This may be done by any mechanism known to deactivate or inhibit biological molecules such as block of the receptor, block of active site, competition on binding site in target, enhancement of degradation, etc. Deactivators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which bind to and modulate the activity of said product.

[0029] “Treating a disease”—refers to administering a therapeutic substance effective to ameliorate symptoms associated with a disease, to lessen the severity or cure the disease, or to prevent the disease from occurring.

[0030] “Detection”—refers to a method of detection of a disease, disorder, pathological or normal condition. This term may refer to detection of a predisposition to a disease as well as for establishing the prognosis of the patient by determining the severity of the disease.

[0031] “Probe”—the variant nucleic acid sequence, or a sequence complementary therewith, when used to detect presence of other similar sequences in a sample. The detection is carried out by identification of hybridization complexes between the probe and the assayed sequence. The probe may be attached to a solid support or to a detectable label.

[0032] “Original sequence”—the amino acid or nucleic acid sequence from which the variant of the invention have been varied as a result of alternative slicing.

SUMMARY OF THE INVENTION

[0033] The present invention is based on the finding of several novel, naturally occurring splice variants, which are naturally occurring sequences obtained by alternative splicing of known genes. The novel splice variants of the invention are not merely truncated forms, fragments or mutations of known genes, but rather novel sequences which naturally occur within the body of individuals.

[0034] The term “alternative splicing” in the context of the present invention and claims refers to: intron inclusion, exon exclusion, addition or deletion of terminal sequences in the variant as compared to the original sequences, as well as to the possibility of “intron retention”. Intron retention is an intermediate stage in the processing of RNA transcripts, where prior to production of fully processed mRNA the intron (naturally spliced in the original sequence) is retained in the variant. These intermediately processed RNAs may have physiological significance and are also within the scope of the invention.

[0035] The novel variant products of the invention may have the same physiological activity as the original peptide from which they are varied (although perhaps at a different level); may have an opposite physiological activity from the activity featured by the original peptide from which they are varied; may have a completely different, unrelated activity to the activity of the original from which they are varied; or alternatively may have no activity at all and this may lead to various diseases or pathological conditions.

[0036] The novel variants may also serve for detection purposes, i.e. their presence or level may be indicative of a disease, disorder, pathological or normal condition or alternatively the ratio between the level variants and the level original peptide from which they were varied, or the ratio to other variants may be indicative to a disease, disorder, pathological or normal condition.

[0037] For example, for detectional purposes, it is possible to establish differential expression of various variants in various tissues. A certain variant may be expressed mainly in one tissue, while the original sequence from which it has been varied, or another variant may, be expressed mainly in another tissue. Understanding of the distribution of the variants in various tissues may be helpful in basic research, for understanding the physiological function of the genes as well as may help in targeting pharmaceuticals or developing pharmaceuticals.

[0038] The study of the variants may also be helpful to distinguish various stages in the life cycles of the same type of cells which may also be helpful for development of pharmaceuticals for various pathological conditions in which cell cycles is un-normal, notably cancer.

[0039] Thus the detection may by determination of the presence or the level of expression of the variant within a specific cell population, comprising said presence or level between various cell types in a tissue, between different tissues and between individuals.

[0040] Thus the present invention provides by its first aspect, a novel isolated nucleic acid molecule comprising or consisting of any one of the coding sequence SEQ ID NO: 1 to SEQ ID NO: 26, fragments of said coding sequence having at least 20 nucleic acids (provided that said fragments are continuous stretches of nucleotides not present in the original sequence from which the variant was varied), or a molecule comprising a sequence having at least 90%, identity to SEQ ID NO: 1 to SEQ ID NO: 26, provided that the molecule is not completely identical to the original sequence from which the variant was varied.

[0041] The present invention further provides a protein or polypeptide comprising or consisting of an amino acid sequence encoded by any of the above nucleic acid sequences, termed herein “variant product”, for example, an amino acid sequence having the sequence as depicted in any one of SEQ ID NO: 27 to SEQ ID NO: 52, fragments of the above amino acid sequence having a length of at least 10 amino acids coded by the above fragments of the nucleic acid sequences, as well as homologues of the above amino acid sequences in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitution) added, deleted, or chemically modified.

[0042] The deletions, insertions and modifications should be in regions, or adjacent to regions, wherein the variant differs from the original sequence.

[0043] For example, where the variant is different from the original sequence by addition of a short stretch of 10 amino acids, in the terminal or non-terminal portion of the peptide, the invention also concerns homologues of that variant where the additional short stretch is altered for example, it includes only 8 additional amino acids, includes 13 additional amino acids, or it includes 10 additional amino acids, however some of them being conservative or non-conservative substitutes of the original additional 10 amino acids of the novel variants. In all cases the changes in the homolog, as compared to the original sequence, are in the same regions where the variant differs from the original sequence, or in regions adjacent to said region.

[0044] Another example is where the variant lacks a non-terminal region (for example of 20 amino acids) which is present in the original sequence (due for example to exon exclusion). The homologues may lack in the same region only 17 amino acids or 23 amino acids. Again the deletion is in the same region where the variant lacks a sequence as compared to the original sequence, or in a region adjacent thereto.

[0045] It should be appreciated that once a man versed in the art's attention is directed to the importance of a specific region, due to the fact that this region differs in the variant as compared to the original sequence, there is no problem in derivating said specific region by addition to it, deleting from it, or substituting some amino acids in it. Thus homologues of variants which are derivated from the variant by changes (deletion, addition, substitution) only in said region as well as in regions adjacent to it are also a part of the present invention. Generally, if the variant is distinguished from the original sequence by some sort of physiological activity, then the homolog is distinguished from the original sequence in essentially the same manner.

[0046] The present invention further provides nucleic acid molecule comprising or consisting of a sequence which encodes the above amino acid sequences, (including the fragments and homologues of the amino acid sequences). Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid sequences, beyond those depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 26, can code for the amino acid sequence of the invention. Those alternative nucleic acid sequences which code for the same amino acid sequences codes by the sequence SEQ ID NO: 27 to SEQ ID NO: 52 are also an aspect of the of the present invention.

[0047] The present invention further provides expression vectors and cloning vectors comprising any of the above nucleic acid sequences, as well as host cells transfected by said vectors.

[0048] The present invention still further provides pharmaceutical compositions comprising, as an active ingredient, said nucleic acid molecules, said expression vectors, or said protein or polypeptide.

[0049] These pharmaceutical compositions are suitable for the treatment of diseases and pathological conditions, which can be ameliorated or cured by raising the level of any one of the variant products of the invention. By a second aspect, the present invention provides a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO: 1 to SEQ ID NO: 26, or complementary to a sequence having at least 90% identity to said sequence (with the proviso added above) or a fragment of said two sequences (according to the above definition of fragment). The complementary sequence may be a DNA sequence which hybridizes with any one of SEQ of ID NO: 1 to SEQ ID NO: 26 or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence. The complementary sequence may be a DNA sequence which can be transcribed into an mRNA being an antisense to the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 26 or into an mRNA which is an antisense to a fragment of the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 26 which has a length sufficient to hybridize with the mRNA transcribed from SEQ ID NO: 1 to SEQ ID NO: 26, so as to inhibit its translation. The complementary sequence may also be the mRNA or the fragment of the mRNA itself.

[0050] The nucleic acids of the second aspect of the invention may be used for therapeutic or diagnostic applications for example as probes used for the detection of the variants of the invention. The presence of the variant transcript or the level of the variant transcript may be indicative of a multitude of diseases, disorders and various pathological as well as normal conditions. In addition, the ratio of the level of the transcripts of the variants of the invention may also be compared to that of the transcripts of the original sequences from which they were varied, or to the level of transcript of other variants, and said ratio may be indicative to a multitude of diseases, disorders and various pathological and normal conditions.

[0051] The present invention also provides expression vectors comprising any one of the above defined complementary nucleic acid sequences and host cells transfected with said nucleic acid sequences or vectors, being complementary to those specified in the first aspect of the invention.

[0052] The invention also provides anti-variant product antibodies, namely antibodies directed against the variant product which specifically bind to said variant product. Said antibodies are useful both for diagnostic and therapeutic purposes. For example said antibodies may be as an active ingredient in a pharmaceutical composition as will be explained below.

[0053] By another alternative, the invention concerns antibodies termed “distinguishing antibodies” which are directed solely to the amino acid sequences which distinguishes the variant from the original amino acid sequence from which it has been varied by alternative splicing. For example, where the variant contains 15 additional amino acids as compared to the original sequence (due to intron inclusion) the antibodies may be directed against these additional amino acids (present in the variant and not present in the original sequence). Another example is here the variant lacks 20 amino acids as compared to the original sequence from which it is varied (for example due to exon exclusion). The distinguishing antibodies in that case may be directed only against these 20 amino acids which are present in the original sequence and absent from the variant sequence.

[0054] The distinguishing antibodies may be used for detection purposes, i.e. to detect individuals, tissue, conditions (both pathological or physiological) wherein the variant sequence or original sequence are evident or abundant. The antibodies may also be used to distinguish conditions where the level, or ratio of the variant to original sequence is altered.

[0055] The distinguishing antibodies may also be used for therapeutical purposes, i.e., to neutralize only the variant product or only the product of the original sequence, as the case may be, without neutralizing the other.

[0056] The present invention also provides pharmaceutical compositions comprising, as an active ingredient, the nucleic acid molecules which comprise or consist of said complementary sequences, or of a vector comprising said complementary sequences. The pharmaceutical composition thus provides pharmaceutical compositions comprising, as an active ingredient, said anti-variant product antibodies.

[0057] The pharmaceutical compositions comprising said anti-variant product antibodies or the nucleic acid molecule comprising said complementary sequence, are suitable for the treatment of diseases and pathological conditions where a therapeutically beneficial effect may be achieved by neutralizing the variant (either at the transcript or product level) or decreasing the amount of the variant product or blocking its binding to its target, for example, by the neutralizing effect of the antibodies, or by the decrease of the effect of the antisense mRNA in decreasing expression level of the variant product.

[0058] According to the third aspect of the invention the present invention provides methods for detecting the level of the transcript (mRNA) of said variant product in a body fluid sample, or in a specific tissue sample, for example by use of probes comprising or consisting of said coding sequences; as well as methods for detecting levels of expression of said product in tissue, e.g. by the use of antibodies capable of specifically reacting with the variant products of the invention. Detection of the level of the expression of the variant of the invention in particular as compared to that of the original sequence from which it was varied or compared to other variant sequences all varied from the same original sequence may be indicative of a plurality of physiological or pathological conditions.

[0059] The method, according to this latter aspect, for detection of a nucleic acid sequence which encodes the variant product in a biological sample, comprises the steps of:

[0060] (a) providing a probe comprising at least one of the nucleic acid sequences defined above;

[0061] (b) contacting the biological sample with said probe under conditions allowing hybridization of nucleic acid sequences thereby enabling formation of hybridization complexes;

[0062] (c) detecting hybridization complexes, wherein the presence of the complex indicates the presence of nucleic acid sequence encoding the variant product in the biological sample.

[0063] The method as described above is qualitative, i.e. indicates whether the transcript is present in or absent from the sample. The method can also be quantitative, by determining the level of hybridization complexes and then calibrating said levels to determining levels of transcripts of the desired variant in the sample.

[0064] Both qualitative and quantitative determination methods can be used for diagnostic, prognostic and therapy planning purposes.

[0065] By a preferred embodiment the probe is part of a nucleic acid chip used for detection purposes, i.e. the probe is a part of an array of probes each present in a known location on a solid support.

[0066] The nucleic acid sequence used in the above method may be a DNA sequence an RNA sequence, etc; it may be a coding or a sequence or a sequence complementary thereto (for respective detection of RNA transcripts or coding-DNA sequences). By quantization of the level of hybridization complexes and calibrating the quantified results it is possible also to detect the level of the transcript in the sample.

[0067] Methods for detecting mutations in the region coding for the variant product are also provided, which may be methods carried-out in a binary fashion, namely merely detecting whether there is any mismatches between the normal variant nucleic acid sequence of the invention and the one present in the sample, or carried-out by specifically detecting the nature and location of the mutation.

[0068] The present invention also concerns a method for detecting variant product in a biological sample, comprising the steps of:

[0069] (a) contacting with said biological sample the antibody of the invention, thereby forming an antibody-antigen complex; and

[0070] (b) detecting said antibody-antigen complex

[0071] wherein the presence of said antibody-antigen complex correlates with the presence of variant product in said biological sample.

[0072] As indicated above, the method can be quantitized to determine the level or the amount of the variant in the sample, alone or in comparison to the level of the original amino acid sequence from which it was varied, and qualitative and quantitative results may be used for diagnostic, prognostic and therapy planning purposes.

[0073] By yet another aspect the invention also provides a method for identifying candidate compounds capable of binding to the variant product and modulating its activity (being either activators or deactivators). The method includes:

[0074] (i) providing a protein or polypeptide comprising an amino acid sequence substantially as depicted in any one of SEQ ID NO: 27 to 52, or a fragment of such a sequence;

[0075] (ii) contacting a candidate compound with said amino acid sequence;

[0076] (iii) measuring the physiological effect of said candidate compound on the activity of the amino acid sequences and selecting those compounds which show a significant effect on said physiological activity.

[0077] The present invention also concerns compounds identified by the above methods described above, which compound may either be an activator of the variant product or a deactivator thereof.

BRIEF DESCRIPTION OF THE DRAWINGS DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT EXAMPLE I Designation of the Original Sequences

[0078] Each novel variant of the invention is varied from an original sequence which has a known designation. The designation of the RNA sequences of the original sequences are given below and for each sequence the SEQ ID's of the nucleic acids and amino acids are also given. It should be noted that many times there exists more than one variant (as evidence by several SEQ ID of nucleic acids and amino acids) for each original sequence due to alternative splicing resulting in several splice variants of the same sequence.

[0079] Designation of original sequence: AA706212—Insulin receptor-related receptor (IRR)—mRNA HUMIRRA: Human insulin receptor-related receptor (IRR) mRNA, 3′ to end

[0080] SEQ ID of nucleic acid: 1

[0081] SEQ ID of amino acid: 43

[0082] Designation of original sequence: H66520: Sodium bicarbonate cotransporter 2—mRNA AB012130: Homo sapiens SBC2 mRNA for sodium bicarbonate cotransporter 2, complete cds.

[0083] SEQ ID of nucleic acid: 10, 11, 12, 13

[0084] SEQ ID of amino acid: 39, 40, 41, 42

[0085] Designation of original sequence: HSBNGFAC: Beta nerve growth factor—mRNA HSBNGFAC—Human mRNA for beta nerve growth factor

[0086] SEQ ID of nucleic acid: 23

[0087] SEQ ID of amino acid: 44

[0088] Designation of original sequence: HUMIGFBA: transforming growth factor-beta (TGF-beta)—mRNA HSTGFB 1: Human mRNA for transforming growth factor-beta (TGF-beta)

[0089] SEQ ID of nucleic acid: 24, 25

[0090] SEQ ID of amino acid: 51, 52

[0091] Designation of original sequence: R49883: growth factor receptor-related B-lymphocyte activation molecule—mRNA HSCDW40: Human CDw40 mRNA for nerve growth factor receptor-related B-lymphocyte activatin molecule

[0092] SEQ ID of nucleic acid: 21

[0093] SEQ ID of amino acid: 33

[0094] Designation of original sequence: HSDHII061: cAMP-specific phosphodiesterase 8B (PDE8B)—mRNA AF079529: Homo sapiens cAMP-specific phosphodiesterase 8B (PDE9B) mRNA, partial cds.

[0095] SEQ ID of nucleic acid: 9

[0096] SEQ ID of amino acid: 50

[0097] Designation of original sequence: HSPDE1A3A: Cyclic nucleotide phosphodiesterase—mRNA HSPDE1A3A: 3′, 5′ cyclic nucleotide phosphodiesterase (HSPDE1A3A) mRNA, complete eds.

[0098] SEQ ID of nucleic acid: 18

[0099] SEQ ID of amino acid: 49

[0100] Designation of original sequence: HSU58130: burnetanide-sensitive Na-K-2CI cotransporter (BKCC2)—mRNA HSU58130: Human burnetanide-sensitive Na-K-2C1 cotransporter (NKCC2) mRNA, complete eds.

[0101] SEQ ID of nucleic acid: 26

[0102] SEQ ID of amino acid: 38

[0103] Designation of original sequence: HUMCLPA: Human bile salt-activated lipase (BAL), cholesterol esterase—mRNA HUMLIPBSA: Human bile salt-activated lipase (BAL) mRNA, complete eds.

[0104] SEQ ID of nucleic acid: 5, 6, 7, 8

[0105] SEQ ID of amino acid: 45, 46, 47, 48

[0106] Designation of original sequence: R53112: PDGF receptor beta-like tumor suppressor (PRLTS)—mRNA HUMPRLTS: Human mRNA for PDGF receptor beta-like tumor suppressor (PRLTS), complete eds.

[0107] SEQ ID of nucleic acid: 22

[0108] SEQ ID of amino acid: 37

[0109] Designation of original sequence: HHEA47M: TNF related apoptosis inducing ligand TRAIL—mRNA HSU37518: Human TNF-related apoptosis inducing ligand TRAIL mRNA, complete eds.

[0110] SEQ ID of nucleic acid: 14, 15, 16, 17

[0111] SEQ ID of amino acid: 29, 30, 31, 32

[0112] Designation of original sequence: R02351: serotonin 5-HT3 receptor—mRNA HUMS5HT3RA: Human mRNA for serotonin 5-HT3 receptor, complete cds.

[0113] SEQ ID of nucleic acid: 19, 20

[0114] SEQ ID of amino acid: 27, 28

[0115] Designation of original sequence: AB005060: NTAK, brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4—mRNA AB005060: Homo sapiens mRNA for NTAK, complete eds.

[0116] SEQ ID of nucleic acid: 2, 3, 4

[0117] SEQ ID of amino acid: 34, 35, 36

EXAMPLE II Variant Nucleic Acid Sequence

[0118] The nucleic acid sequences of the invention include nucleic acid sequences which encode variant product and fragments and analogs thereof. The nucleic acid sequences may alternatively be sequences complementary to the above coding sequence, or to a region of said coding sequence. The length of the complementary sequence is sufficient to avoid the expression of the coding sequence. The nucleic acid sequences may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and genomic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand. The nucleic acid sequences may also both include dNTPs, rNTPs as well as non naturally occurring sequences. The sequence may also be a part of a hybrid between an amino acid sequence and a nucleic acid sequence.

[0119] In a general embodiment, the nucleic acid sequence has at least 90%, identity with any one of the sequence identified as SEQ ID NO: 1 to SEQ ID NO: 26 provided that this sequence is not completely identical with that of the original sequence.

[0120] The nucleic acid sequences may include the coding sequence by itself. By another alternative the coding region may be in combination with additional coding sequences, such as those coding for fusion protein or signal peptides, in combination with non-coding sequences, such as introns and control elements, promoter and terminator elements or 5′ and/or 3′ untranslated regions, effective for expression of the coding sequence in a suitable host, and/or in a vector or host environment in which the variant nucleic acid sequence is introduced as a heterologous sequence.

[0121] The nucleic acid sequences of the present invention may also have the product coding sequence fused in-frame to a marker sequence which allows for purification of the variant product. The marker sequence may be, for example, a hexahistidine tag to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al. Cell 37:767 (1984)).

[0122] Also included in the scope of the invention are fragments as defined above also referred to herein as oligonucleotides, typically having at least 20 bases, preferably 20-30 bases corresponding to a region of the coding-sequence nucleic acid sequence. The fragments may be used as probes, primers, and when complementary also as antisense agents, and the like, according to known methods.

[0123] As indicated above, the nucleic acid sequence may be substantially a depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 26 or fragments thereof or sequences having at least 90% identity to the above sequence as explained above. Alternatively, due to the degenerative nature of the genetic code, the sequence may be a sequence coding for any one of the amino acid sequence of SEQ ID NO: 27 to SEQ ID NO: 52, or fragments or analogs of said amino acid sequence.

[0124] A. Preparation of Nucleic Acid Sequences

[0125] The nucleic acid sequences may be obtained by screening cDNA libraries using oligonucleotide probes which can hybridize to or PCR-amplify nucleic acid sequences which encode the variant products disclosed above cDNA libraries prepared from a variety of tissues are commercially available and procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd Edition), Cold Spring Harbor Press, Plainview, N.Y. and Ausubel FM et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y.

[0126] The nucleic acid sequences may be extended to obtain upstream and downstream sequences such as promoters, regulatory elements, and 5′ and 3′ untranslated regions (UTRs). Extension of the available transcript sequence may be performed by numerous methods known to those of skill in the art, such as PCR or primer extension (Sambrook et al., supra), or by the RACE method using, for example, the Marathon RACE kit (Clontech, Cat. # K1802-1).

[0127] Alternatively, the technique of “restriction-site” PCR (Gobinda et al. PCR Methods Applic. 2:318-22, (1993)), which uses universal primers to retrieve flanking sequence adjacent a known locus, may be employed. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

[0128] Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al., Nucleic Acids Res. 16:8186, (1988)). The primers may be designed using OLIGO(R) 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth, Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

[0129] Capture PCR (Lagerstrom, M. et al., PCR Methods Applic. 1:111-19, (1991)) is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into a flanking part of the DNA molecule before PCR.

[0130] Another method which may be used to retrieve flanking sequences is that of Parker, J. D., et al., Nucleic Acids Res., 19:3055-60, (1991)). Additionally, one can use PCR, nested primers and PromoterFinder™ libraries to “walk in” genomic DNA (PromoterFinder™; Clontech, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the. 5′ and upstream regions of genes.

[0131] A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5′ nontranslated regulatory region.

[0132] The nucleic acid sequences and oligonucleotides of the invention can also be prepared by solid-phase methods, according to known synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined to form continuous sequences up to several hundred bases.

[0133] B. Use of Variant Nucleic Acid Sequence for the Production of Variant Products

[0134] In accordance with the present invention, nucleic acid sequences specified above may be used as recombinant DNA molecules that direct the expression of variant products.

[0135] As will be understood by those of skill in the art, it may be advantageous to produce variant product-encoding nucleotide sequences possessing codons other than those which appear in any one of SEQ ID NO: 1 to SEQ ID NO: 26 which are those which naturally occur in the human genome. Codons preferred by a particular prokaryotic or eukaryotic host (Murray, E. et al. Nuc Acids Res., 17:477-508, (1989)) can be selected, for example, to increase the rate of variant product expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

[0136] The nucleic acid sequences of the present invention can be engineered in order to alter a variant product coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the product. For example, alterations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, etc.

[0137] The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are also described in Sambrook, et al., (supra).

[0138] The present invention also relates to host cells which are genetically engineered with vectors of the invention, and the production of the product of the invention by recombinant techniques. Host cells are genetically engineered (i.e., transduced, transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the expression of the variant nucleic acid sequence. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art.

[0139] The nucleic acid sequences of the present invention may be included in any one of a variety of expression vectors for expressing a product. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host. The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and related sub-cloning procedures are deemed to be within the scope of those skilled in the art.

[0140] The DNA sequence in the expression vector is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis. Examples of such promoters include: LTR or SV40 promoter, the E. coli lac or trp promoter, the phage lambda PL promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation, and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

[0141] The vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. Examples of appropriate expression hosts include: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila and Spodoptera Sf9; animal cells such as CHO, COS, HEK 293 or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. The invention is not limited by the host cells employed.

[0142] In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the variant product. For example, when large quantities of variant product are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as Bluescript(R) (Stratagene), in which the variant polypeptide coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster J. Biol. Chem. 264:5503-5509, (1989)); pET vectors (Novagen, Madison Wis.); and the like.

[0143] In the yeast Saccharomyces cerevisiae a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al., (Methods in Enzymology 153:516-544, (1987)).

[0144] In cases where plant expression vectors are used, the expression of a sequence encoding variant product may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaAfV (Brisson et al., Nature 310:511-514. (1984)) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu et al., EMBO J., 6:307-311, (1987)). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al., EMBO J. 3:1671-1680, (1984); Broglie et al., Science 224:838-843, (1984)); or heat shock promoters (Winter J and Sinibaldi R. M., Results Probl. Cell Differ., 17:85-105, (1991)) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S. or Murry L. E. (1992) in McGraw Hill Yearbook of Science and Technology, McGraw Hill, New York, N.Y., pp 191-196; or Weissbach and Weissbach (1988) Methods for Plant Molecular Biology, Academic Press, New York, N.Y., pp 421-463.

[0145] Variant product may also be expressed in an insect system. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The variant product coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of variant coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect S. frugiperda cells or Trichoplusia larvae in which variant protein is expressed (Smith et al., J. Virol. 46:584, (1983); Engelhard, E. K. et al., Proc. Nat. Acad. Sci. 91:3224-7, (1994)).

[0146] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a variant product coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing variant protein in infected host cells (Logan and Shenk, Proc. Natl. Acad. Sci. 81:3655-59, (1984). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

[0147] Specific initiation signals may also be required for efficient translation of a variant product coding sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where variant product coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf, D. et al., (1994) Results Probl. Cell Differ., 20:125-62, (1994); Bittner et al., Methods in Enzymol 153:516-544, (1987)).

[0148] In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., and Battey, I. (1986) Basic Methods in Molecular Biology). Cell-free translation systems can also be employed to produce polypeptides using RNAs derived from the DNA constructs of the present invention.

[0149] A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a “pre-pro” form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

[0150] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express variant product may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

[0151] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M., et al., Cell 11:223-32, (1977)) and adenine phosphoribosyltransferase (Lowy I., et al., Cell 22:817-23, (1980)) genes which can be employed in tk− or aprt− cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler M., et al., Proc. Natl. Acad. Sci. 77:3567-70, (1980)); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al., J. Mol. Biol., 150:1-14, (1981)) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman S. C. and R. C. Mulligan, Proc. Natl. Acad. Sci. 85:8047-51, (1988)). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrates, luciferin and ATP, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et. al., Methods Mol. Biol., 55:121-131, (1995)).

[0152] Host cells transformed with a nucleotide sequence encoding variant product may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The product produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing nucleic acid sequences encoding variant product can be designed with signal sequences which direct secretion of variant product through a prokaryotic or eukaryotic cell membrane.

[0153] The variant product may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, Wash.). The inclusion of a protease-cleavable polypeptide linker sequence between the purification domain and variant product is useful to facilitate purification. One such expression vector provides for expression of a fusion protein compromising a variant polypeptide fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, as described in Porath, et al., Protein Expression and Purification, 3:263-281, (1992)) while the enterokinase cleavage site provides a means for isolating variant polypeptide from the fusion protein. pGEX vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

[0154] Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well know to those skilled in the art.

[0155] The variant products can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

[0156] C. Diagnostic Applications Utilizing Nucleic Acid Sequences

[0157] The nucleic acid sequences of the present invention may be used for a variety of diagnostic purposes. The nucleic acid sequences may be used to detect and quantitate expression of the variant in patient's cells, e.g. biopsied tissues, by detecting the presence of mRNA coding for variant product. Alternatively, the assay may be used to detect soluble variant in the serum or blood. This assay typically involves obtaining total mRNA from the tissue or serum and contacting the mRNA with a nucleic acid probe. The probe is a nucleic acid molecule of at least 20 nucleotides, preferably 20-30 nucleotides, capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding variant product under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of variant. This assay can be used to distinguish between absence, presence, and excess expression of variant product and to monitor levels of variant expression during therapeutic intervention. In addition, the assay may be used to compare the levels of the variant of the invention to the levels of the original sequence from which it has been varied or to levels of other variants, which comparison may have some physiological meaning.

[0158] The invention also contemplates the use of the nucleic acid sequences as a diagnostic for diseases resulting from inherited defective variant sequences, or diseases in which the ratio of the amount of the original sequence from which the variant was varied to the novel variants of the invention is altered. These sequences can be detected by comparing the sequences of the defective (i.e., mutant) variant coding region with that of a normal coding region. Association of the sequence coding for mutant variant product with abnormal variant product activity may be verified. In addition, sequences encoding mutant variant products can be inserted into a suitable vector for expression in a functional assay system (e.g., calorimetric assay, complementation experiments in a variant protein deficient strain of HEK293 cells) as yet another means to verify or identify mutations. Once mutant genes have been identified, one can then screen populations of interest for carriers of the mutant gene.

[0159] Individuals carrying mutations in the nucleic acid sequence of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including but not limited to such as from blood, urine, saliva, placenta, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki, et al., Nature 324:163-166, (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype.

[0160] Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such RNase and S1 protection or the chemical cleavage method (e.g. Cotton, et al Proc. Natl. Acad. Sci. USA, 85:4397-4401, (1985)), or by differences in melting temperatures. “Molecular beacons” (Kostrikis L. G. et al., Science 279:1228-1229, (1998)), hairpin-shaped, single-stranded synthetic oligo-nucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used to detect point mutations or other sequence changes as well as monitor expression levels of variant product. Such diagnostics would be particularly useful for prenatal testing.

[0161] Another method for detecting mutations uses two DNA probes which are designed to hybridize to adjacent regions of a target, with abutting bases, where the region of known or suspected mutation(s) is at or near the abutting bases. The two probes may be joined at the abutting bases, e.g., in the presence of a ligase enzyme, but only if both probes are correctly base paired in the region of probe junction. The presence or absence of mutations is then detectable by the presence or absence of ligated probe.

[0162] Also suitable for detecting mutations in the variant product coding sequence are oligonucleotide array methods based on sequencing by hybridization (SBH), as described, for example, in U.S. Pat. No. 5,547,839. In a typical method, the DNA target analyte is hybridized with an array of oligonucleotides formed on a microchip. The sequence of the target can then be “read” from the pattern of target binding to the array.

[0163] D. Gene Mapping Utilizing Nucleic Acid Sequences

[0164] The nucleic acid sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

[0165] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 20-30 bp) from the variant cDNA. Computer analysis of the 3′ untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, which would complicate the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

[0166] PCR mapping of somatic cell hybrids or using instead radiation hybrids are rapid procedures for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

[0167] Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma et al., Human Chromosomes: a Manual of Basic Techniques, (1988) Pergamon Press, New York.

[0168] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in the OMIM database (Center for Medical Genetics, Johns Hopkins University, Baltimore, Md. and National Center for Biotechnology Information, National Library of Medicine, Bethesda, Md.). The OMIM gene map presents the cytogenetic map location of disease genes and other expressed genes. The OMIM database provides information on diseases associated with the chromosomal location. Such associations include the results of linkage analysis mapped to this interval, and the correlation of translocations and other chromosomal aberrations in this area with the advent of polygenic diseases, such as cancer, in general and prostate cancer in particular.

[0169] E. Therapeutic Applications of Nucleic Acid Sequences

[0170] Nucleic acid sequences of the invention may also be used for therapeutic purposes. Turning first to the second aspect of the invention (i.e. inhibition of expression of variant), expression of variant product may be modulated through antisense technology, which controls gene expression through hybridization of complementary nucleic acid sequences, i.e. antisense DNA or RNA, to the control, 5′ or regulatory regions of the gene encoding variant product. For example, the 5′ coding portion of the nucleic acid sequence sequence which codes for the product of the present invention is used to design an antisense oligonucleotide of from about 10 to 40 base pairs in length. Oligonucleotides derived from the transcription start site, e.g. between positions −10 and +10 from the start site, are preferred. An antisense DNA oligonucleotide is designed to be complementary to a region of the nucleic acid sequence involved in transcription (Lee et al., Nucl. Acids, Res., 6:3073, (1979); Cooney et al., Science 241:456, (1988); and Dervan et al., Science 251:1360, (1991)), thereby preventing transcription and the production of the variant products. An antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the variant products (Okano J. Neurochem. 56:560, (1991)). The antisense constructs can be delivered to cells by procedures known in the art such that the antisense RNA or DNA may be expressed in vivo. The antisense may be antisense mRNA or DNA sequence capable of coding such antisense mRNA. The antisense mRNA or the DNA coding thereof can be complementary to the full sequence of nucleic acid sequences coding for the variant protein or to a fragment of such a sequence which is sufficient to inhibit production of a protein product.

[0171] Turning now to the first aspect of the invention, i.e. expression of variant, expression of variant product may be increased by providing coding sequences for coding for said product under the control of suitable control elements ending its expression in the desired host.

[0172] The nucleic acid sequences of the invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

[0173] The products of the invention as well as any activators and deactivators compounds (see below) which are polypeptides, may also be employed in accordance with the present invention by expression of such polypeptides in vivo, which is often referred to as “gene therapy.” Cells from a patient may be engineered with a nucleic acid sequence (DNA or RNA) encoding a polypeptide ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

[0174] Similarly, cells may be engineered in vivo for expression of a polypeptide in vivo by procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells in vivo and expression of the polypeptide in vivo. These and other methods for administering a product of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells in vivo after combination with a suitable delivery vehicle.

[0175] Retroviruses from which the retroviral plasmid vectors mentioned above may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

[0176] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, psi-2, psi-AM, PA12, T19-14×, VT-19-17-H2, psi-CRE, psi-CRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller (Human Gene Therapy, Vol. 1, pg. 5-14, (1990)). The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0177] The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

[0178] The genes introduced into cells may be placed under the control of inducible promoters, such as the radiation-inducible Egr-1 promoter, (Maceri, H. J., et al., Cancer Res., 56(19):4311 (1996)), to stimulate variant production or antisense inhibition in response to radiation, eg., radiation therapy for treating tumors.

EXAMPLE III Variant Product

[0179] The substantially purified variant product of the invention has been defined above as the product coded from the nucleic acid sequence of the invention. Preferably the amino acid sequence is an amino acid sequence having at least 90% identity to any one of the sequences identified as SEQ ID NO: 27 to SEQ ID NO: 52 provided that the amino acid sequence is not identical to that of the original sequence from which it has been varied. The protein or polypeptide may be in mature and/or modified form, also as defined above. Also contemplated are protein fragments having at least 10 contiguous amino acid residues, preferably at least 10-20 residues, derived from the variant product, as well as homologues as explained above.

[0180] The sequence variations are preferably those that are considered conserved substitutions, as defined above. Thus, for example, a protein with a sequence having at least 90% sequence identity with any of the products identified as SEQ ID NO: 27 to 52, preferably by utilizing conserved substitutions as defined above is also part of the invention, and provided that it is not identical to the original peptide from which it has been varied. In a more specific embodiment, the protein has or contains any one of the sequence identified as SEQ ID NO: 27 to 52. The variant product may be (i) one in which one or more of the amino acid residues in a sequence listed above are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue), or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the variant product is fused with another compound, such as a compound to increase the half-life of the protein (for example, polyethylene glycol (PEG)), or a moiety which serves as targeting means to direct the protein to its target tissue or target cell population (such as an antibody), or (iv) one in which additional amino acids are fused to the variant product. Such fragments, variants and derivatives are deemed to be within the scope of those skilled in the art from the teachings herein.

[0181] A. Preparation of Variant Product

[0182] Recombinant methods for producing and isolating the variant product, and fragments of the protein are described above.

[0183] In addition to recombinant production, fragments and portions of variant product may be produced by direct peptide synthesis using solid-phase techniques (cf. Stewart et al., (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco; Merrifield J., J. Am. Chem. Soc., 85:2149-2154, (1963)). In vitro peptide synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with the instructions provided by the manufacturer. Fragments of variant product may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

[0184] B. Therapeutic Uses and Compositions Utilizing the Variant Product

[0185] The variant product of the invention is generally useful in treating diseases and disorders which are characterized by a lower than normal level of variant expression, and or diseases which can be cured or ameliorated by raising the level of the variant product, even if the level is normal.

[0186] Variant products or fragments may be administered by any of a number of routes and methods designed to provide a consistent and predictable concentration of compound at the target organ or tissue. The product-containing compositions may be administered alone or in combination with other agents, such as stabilizing compounds, and/or in combination with other pharmaceutical agents such as drugs or hormones.

[0187] Variant product-containing compositions may be administered by a number of routes including, but not limited to oral, intravenous, intramuscular, transdermal, subcutaneous, topical, sublingual, or rectal means as well as by nasal application. variant product-containing compositions may also be administered via liposomes. Such administration routes and appropriate formulations are generally known to those of skill in the art.

[0188] The product can be given via intravenous or intraperitoneal injection. Similarly, the product may be injected to other localized regions of the body. The product may also be administered via nasal insufflation. Enteral administration is also possible. For such administration, the product should be formulated into an appropriate capsule or elixir for oral administration, or into a suppository for rectal administration.

[0189] The foregoing exemplary administration modes will likely require that the product be formulated into an appropriate carrier, including ointments, gels, suppositories. Appropriate formulations are well known to persons skilled in the art.

[0190] Dosage of the product will vary, depending upon the potency and therapeutic index of the particular polypeptide selected.

[0191] A therapeutic composition for use in the treatment method can include the product in a sterile injectable solution, the polypeptide in an oral delivery vehicle, the product in an aerosol suitable for nasal administration, or the product in a nebulized form, all prepared according to well known methods. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The product of the invention may also be used to modulate endothelial differentiation and proliferation as well as to modulate apoptosis either ex vivo or in vitro, for example, in cell cultures.

EXAMPLE IV Screening Methods for Activators and Deactivators (Inhibitors)

[0192] The present invention also includes an assay for identifying molecules, such as synthetic drugs, antibodies, peptides, or other molecules, which have a modulating effect on the activity of the variant product, e.g. activators or deactivators of the variant product of the present invention. Such an assay comprises the steps of providing an variant product encoded by the nucleic acid sequences of the present invention, contacting the variant protein with one or more candidate molecules to determine the candidate molecules modulating effect on the activity of the variant product, and selecting from the molecules a candidate's molecule capable of modulating variant product physiological activity.

[0193] The variant product, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell membrane or located intracellularly. The formation of binding complexes, between variant product and the agent being tested, may be measured. Alternatively, the activator or deactivator may work by serving as agonist or antagonist, respectively, of the variant receptor, binding entity or target site, and their effect may be determined in connection with any of the above.

[0194] Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the variant product is described in detail by Geysen in PCT Application WO 84/03564, published on Sep. 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with the full variant product or with fragments of variant product and washed. Bound variant product is then detected by methods well known in the art. Substantially purified variant product can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0195] Antibodies to the variant product, as described in Example VI below, may also be used in screening assays according to methods well known in the art. For example, a “sandwich” assay may be performed, in which an anti-variant antibody is affixed to a solid surface such as a microtiter plate and variant product is added. Such an assay can be used to capture compounds which bind to the variant product. Alternatively, such an assay may be used to measure the 1 ability of compounds to influence with the binding of variant product to the variant receptor, and then select those compounds which effect the binding.

EXAMPLE VI Anti-Variant Antibodies/Distinguishing Antibodies

[0196] A. Synthesis

[0197] In still another aspect of the invention, the purified variant product is used to produce anti-variant antibodies which have diagnostic and therapeutic uses related to the activity, distribution, and expression of the variant product. As indicated above, the antibodies may also be directed solely to amino acid sequences present in the variant but not present in the original sequence, or to sequences present only in the original sequence but not in the variant (distinguishing antibodies).

[0198] Antibodies to the variant product or to the distinguishing sequence present only in the variant or only in the original sequence (the latter termed “distinguishing antibodies”) may be generated by methods well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library. Antibodies, i.e., those which inhibit dimer formation, are especially preferred for therapeutic use.

[0199] A fragment of the variant product for antibody induction does not require biological activity but have to feature immunological activity; however, the protein fragment or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids of the sequences specified in any one of SEQ ID NO: 27 to SEQ ID NO: 52 or in distinguishing sequences present only in the variant or only in the original sequence as explained above. Preferably they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short-stretches of variant protein amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to variant product.

[0200] For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with variant product or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are potentially useful human adjuvants.

[0201] Monoclonal antibodies to variant protein may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (Nature 256:495-497, (1975)), the human B-cell hybridoma technique (Kosbor et al., Immunol. Today 4:72, (1983); Cote et al., Proc. Natl. Acad. Sci. 80:2026-2030, (1983)) and the EBV-hybridoma technique (Cole, et al., Mol. Cell Biol. 62:109-120, (1984)).

[0202] Techniques developed for the production of “chimeric antibodies”, the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can also be used (Morrison et al., Proc. Natl. Acad. Sci. 81:6851-6855, (1984); Neuberger et al, Nature 312:604-608, (1984); Takeda et al, Nature 314:452-454, (1985)). Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single-chain antibodies specific for the variant protein.

[0203] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al. (Proc. Natl. Acad. Sci. 86:3833-3837, 1989)), and Winter G and Milstein C., (Nature 349:293-299, (1991)).

[0204] Antibody fragments which contain specific binding sites for variant protein may also be generated. For example, such fragments include, but are not limited to, the F(ab′)₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse W. D. et al, Science 256:1275-1281, (1989)).

[0205] B. Diagnostic Applications of Antibodies

[0206] A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between the variant product and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific variant product is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox D. E., et al, (J. Exp. Med. 158:1211, (1983)).

[0207] Antibodies which specifically bind variant product or distinguishing antibodies which bind to sequences which distinguish the variant from the original sequence (as explained above) are useful for the diagnosis of conditions or diseases characterized by expression of the novel variant of the invention (where normally it is not expressed) by over or under expression of variant as well as for detection of diseases in which the proportion between the amount of the variants of the invention and the original sequence from which it varied is altered. Alternatively, such antibodies may be used in assays to monitor patients being treated with variant product, its activators, or its deactivators. Diagnostic assays for variant protein include methods utilizing the antibody and a label to detect variant product in human body fluids or extracts of cells or tissues. The products and antibodies of the present invention may be used with or without modification. Frequently, the proteins and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known in the art.

[0208] A variety of protocols for measuring the variant product, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescent activated cell sorting (FACS). As noted above, a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on variant product is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, et al. (supra). Such protocols provide a basis for diagnosing altered or abnormal levels of variant product expression. Normal or standard values for variant product expression are established by combining body fluids or cell extracts taken from normal subjects, preferably human, with antibody to variant product under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by various methods, preferably by photometric methods. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of disease state.

[0209] The antibody assays are useful to determine the level of variant product present in a body fluid sample, in order to determine whether it is being expressed at all, whether it is being overexpressed or underexpressed in the tissue, or as an indication of how variant levels of variable products are responding to drug treatment.

[0210] C. Therapeutic Uses of Antibodies

[0211] In addition to their diagnostic use the antibodies may have a therapeutical utility in blocking or decreasing the activity of the variant product in pathological conditions where beneficial effect can be achieved by such a decrease. Again, distinguishing antibodies may be used to neutralize differentially either the variant or the original sequence as the case may be.

[0212] The antibody employed is preferably a humanized monoclonal antibody, or a human Mab produced by known globulin-gene library methods. The antibody is administered typically as a sterile solution by IV injection, although other parenteral routes may be suitable. Typically, the antibody is administered in an amount between about 1-15 mg/kg body weight of the subject. Treatment is continued, e.g., with dosing every 1-7 days, until a therapeutic improvement is seen.

[0213] Although the invention has been described with reference to specific methods and embodiments, it is appreciated that various modifications and changes may be made without departing from the invention.

1 52 1 4041 DNA Homo sapiens 1 tgtgccccag cctggatatt cgctcagagg tggcagagct tcgtcagctg gagaactgca 60 gcgtggtgga gggccacctg cagatcctgc tcatgttcac agccaccggg gaggacttcc 120 gcggcctcag cttccctcgc ctcacccagg tcaccgacta cctgctgctc ttccgtgtct 180 acggactgga gagcctgcgc gacctcttcc ccaacctagc agtcatccgc gggacgcgcc 240 tcttcctggg ctatgcactg gtcatctttg agatgccaca tctgcgtgac gtggcactgc 300 ctgcacttgg ggccgtgctg cgtggggctg tgcgtgtgga gaagaaccag gagctctgcc 360 acctctccac cattgactgg ggactgctgc agccagcacc tggcgccaac cacatcgtgg 420 gcaacaagct gggcgaggag tgtgctgacg tgtgccctgg tgtgctgggt gctgctggtg 480 agccctgtgc caagaccacc ttcagcgggc acactgacta cagatgctgg acctccagcc 540 actgccagag agtgtgcccc tgcccccatg ggatggcttg cacagcgagg ggcgagtgct 600 gccacaccga atgcctgggg ggctgcagcc agccagaaga ccctcgtgcc tgtgtagctt 660 gccgccacct ctacttccag ggtgcctgcc tgtgggcctg cccgccaggc acctaccagt 720 atgagtcctg gcgctgtgtc acagctgagc gctgtgccag cctgcactct gtgcccggcc 780 gtgcctccac cttcggcata caccagggca gttgcctggc ccagtgccct tctggcttca 840 cccgtaatag cagcagcata ttctgccaca agtgcgaggg gctgtgccct aaagagtgca 900 aggtaggcac caagaccatc gactccatcc aggcggcaca ggatcttgtg ggctgcacgc 960 atgtggaggg aagcctcatc ctcaaccttc gccagggcta caacctggag ccacagctgc 1020 agcacagcct ggggctggta gaaaccatta ctggcttcct caaaatcaag cactcctttg 1080 ccctcgtgtc cctgggcttt ttcaagaacc tcaaactaat ccggggagac gccatggtgg 1140 atgggaacta cactctctac gtgctggaca accagaacct acaacagcta gggtcctggg 1200 tggccgcggg gctcaccatt cccgtgggca agatctactt cgccttcaac ccgcgcctct 1260 gcttggaaca catctaccga ctggaggagg tgacaggcac gcgaggtcgg cagaacaagg 1320 ctgagatcaa cccccgcacc aacggagacc gcgccgcctg ccagactcgc accctgcgct 1380 tcgtgtccaa cgtgacggag gcagaccgca tcctgctacg ctgggagcgc tatgagccac 1440 tggaggcccg cgacctgctc agcttcatcg tgtactacaa ggagtcccca ttccagaacg 1500 ccacagagca cgtgggtcca gatgcttgtg gaacccagag ctggaacctg ctggatgtgg 1560 agctgcccct aagccgcacc caggagccag gggtgaccct agcctccctc aagccttgga 1620 cacagtacgc agtgtttgtg cgggccatca cgctaaccac tgaggaggac agccctcatc 1680 aaggagccca gagtcccatc gtctacctcc gaacgctgcc tgcagctccc acggtgcccc 1740 aagacgtcat ctccacgtcc aactcctcct cccacctcct ggtgcgctgg aagccaccga 1800 cccagcgcaa tgggaacctc acctactacc tggtgctgtg gcagcggctg gcagaggacg 1860 gcgacctcta cctcaatgac tactgccacc gcggcttgcg gctgcccacc agcaacaacg 1920 atccgcgctt cgacggcgaa gacggggatc ctgaggccga gatggagtcc gactgctgcc 1980 cttgccagca cccacctcct ggtcaggttc tgcccccgct ggaggcgcaa gaggcctcgt 2040 tccagaagaa gtttgaaaac tttctacaca acgcgatcac catccccata tccccttgga 2100 aggtgacgtc catcaacaag agcccccaaa gggactcagg gcggcaccgc cgggcagctg 2160 ggcccctccg gctggggggc aacagctcgg atttcgagat ccaggaggac aaggtgcccc 2220 gtgagcgagc ggtgctgagc ggcctgcgcc acttcacgga ataccggatc gacatccatg 2280 cctgcaacca cgcggcgcac accgtgggct gcagcgccgc caccttcgtc tttgcgcgca 2340 ccatgcccca cagtaggtga tccacacaca caccttctac ccccatcacc gaccccaagg 2400 accctgtgca aaggtttggg gtttgacttc tcgctaaccc cagagccacg ctttgcttgc 2460 ccctctcagt tcccataatc ccaaagcttt ccccacctcc cagctcagcc cagtttagct 2520 tgggtttgaa cataaggtga gatgaaccac ttttggcccg gctgctggat gccccttccc 2580 gcaggagagg ctgatggtat tccaggaaag gtggcctggg aggcctccag caagaacagt 2640 gtccttctgc gctggctcga gccaccagac cccaacggac tcatcctcaa gtacgaaatc 2700 aagtaccgcc gcttgggaga ggaggccaca gtgctgtgtg tgtcccgtct tcgatatgcg 2760 aagtttgggg gagtccacct ggccctgctg ccccctggaa actactctgc cagggttagg 2820 gcaacctcac tggctggcaa tggctcttgg acagacagtg ttgccttcta catccttggc 2880 ccagaggagg aggatgctgg ggggctgcat gtcctcctca ctgccacccc tgtggggctc 2940 acgctgctca tcgttcttgc tgcccttggt ttcttctacg gcaagaagag aaacagaacc 3000 ctgtatgctt ctgtgaatcc agagtacttc agcgcctctg atatgtatgt ccctgatgaa 3060 tgggaggtgc ctcgggagca gatctcgata atccgggaac tgggccaggg ctcttttggg 3120 atggtatatg aggggctggc acgaggactt gaggctggag aggagtccac acccgtggcc 3180 ctgaagacgg tgaatgagct ggccagccca cgggaatgca ttgagttcct caaggaagct 3240 tctgtcatga aagccttcaa gtgtcaccat gtggtgcgtc tcctgggtgt ggtatctcag 3300 ggccagccaa ctctggtcat catggagtta atgacccgtg gggacctcaa gagccatctt 3360 cgatctttgc ggcctgaggc agagaacaac cctgggctcc cacagccagc attgggggaa 3420 atgatccaaa tggctggtga gattgcagac ggcatggcct accttgctgc caacaagttt 3480 gtgcaccgag atctagcagc ccgcaactgc atggtgtccc aggacttcac cgtcaagatc 3540 ggggacttcg ggatgactcg ggacgtgtat gagacagact attaccgcaa gggtgggaag 3600 gggctgctgc ccgtgcgctg gatggccccc gagtccctca aagatgggat cttcaccacc 3660 cactcggatg tctggtcctt tggcgtggta ctctgggaga ttgtgaccct ggcagaacaa 3720 ccctaccagg gcctgtccaa tgagcaggtg ctgaagttcg tcatggatgg cggggtcctg 3780 gaggagctgg agggctgtcc ccttcagctg caggagctga tgagccgctg ctggcagccg 3840 aacccacgcc tgcgcccatc tttcacacac attctggaca gcatacagga ggagctgcgg 3900 ccctccttcc gcctcctctc cttctactac agcccggaat gccggggggc ccggggctcc 3960 ctgcctacca ccgatgcaga gcctgactcc tcacccactc caagagactg cagccctcaa 4020 aatgggggtc cagggcactg a 4041 2 536 DNA Homo sapiens 2 agccacccgg cccaagttga agaagatgaa gagccagacg ggacaggtgg gtgagaagca 60 atcgctgaag tgtgaggcag cagcgggtaa tccccagcct tcctaccgtt ggttcaagga 120 tggcaaggag ctcaaccgca gccgagacat tcgcatcaaa tatggcaacg gcagaaagaa 180 ctcacgacta cagttcaaca aggtgaaggt ggaggacgct ggggagtatg tctgcgaggc 240 cgagaacatc ctggggaagg acaccgtccg gggccggctt tacgtcaaca gcgtgagcac 300 caccctgtca tcctggtcgg ggcacgcccg gaagtgcaac gagacagcca agtcctattg 360 cgtcaatgga ggcgtctgct actacatcga gggcatcaac cagctctcct gcaaggcacc 420 tgggctgcac tgcttagaac ttggtaccca gagccaccac ttccccatct cagcctcccc 480 tggttccagc caaggttcct ggaaccaact tccccaacac cctttgtcag ccctcg 536 3 2157 DNA Homo sapiens 3 gggccgggca agaagcaccc agagggagga agcgggagag ggagcccgat cccgggagaa 60 agccacccgg cccaagttga agaagatgaa gagccagacg ggacaggtgg gtgagaagca 120 atcgctgaag tgtgaggcag cagcgggtaa tccccagcct tcctaccgtt ggttcaagga 180 tggcaaggag ctcaaccgca gccgagacat tcgcatcaaa tatggcaacg gcagaaagaa 240 ctcacgacta cagttcaaca aggtgaaggt ggaggacgct ggggagtatg tctgcgaggc 300 cgagaacatc ctggggaagg acaccgtccg gggccggctt tacgtcaaca gcgtgagcac 360 caccctgtca tcctggtcgg ggcacgcccg gaagtgcaac gagacagcca agtcctattg 420 cgtcaatgga ggcgtctgct actacatcga gggcatcaac cagctctcct gcaaatgtcc 480 aaatggattc ttcggacaga gatgtttgga gaaactgcct ttgcgattgt acatgccaga 540 tcctaagcaa aaagccgagg agctgtacca gaagagggtc ctgaccatca cgggcatctg 600 cgtggctctg ctggtcgtgg gcatcgtctg tgtggtggcc tactgcaaga ccaaaaaaca 660 gcggaagcag atgcacaacc acctccggca gaacatgtgc ccggcccatc agaaccggag 720 cttggccaat gggcccagcc acccccggct ggacccagag gagatccaga tggcagatta 780 tatttccaag aacgtgccag ccacagacca tgtcatcagg agagaaactg agaccacctt 840 ctctgggagc cactcctgtt ctccttctca ccactgctcc acagccacac ccacctccag 900 ccacagacac gagagccaca cgtggagcct ggaacgttct gagagcctga cttctgactc 960 ccagtcgggg atcatgctat catcagtggg taccagcaaa tgcaacagcc cagcatgtgt 1020 ggaggcccgg gcaaggcggg cagcagccta caacctggag gagcggcgca gggccaccgc 1080 gccaccctat cacgattccg tggactccct tcgcgactcc ccacacagcg agaggtacgt 1140 gtcggccctg accacgcccg cgcgcctctc gcccgtggac ttccactact cgctggccac 1200 gcaggtgcca actttcgaga tcacgtcccc caactcggcg cacgccgtgt cgctgccgcc 1260 ggcggcgccc atcagttacc gcctggccga gcagcagccg ttactgcggc acccggcgcc 1320 ccccggcccg ggacccggac ccgggcccgg gcccgggccc ggcgcagaca tgcagcgcag 1380 ctatgacagc tactattacc ccgcggcggg gcccggaccg cggcgcggga cctgcgcgct 1440 cggcggcagc ctgggcagcc tgcctgccag ccccttccgc atccccgagg acgacgagta 1500 cgagaccacg caggagtgcg cgcccccgcc gccgccgcgg ccgcgcgcgc gcggtgcgtc 1560 ccgcaggacg tcggcggggc cccggcgctg gcgccgctcg cgcctcaacg ggctggcggc 1620 gcagcgcgca cgggcggcga gggactcgct gtcgctgagc agcggctcgg gcggcggctc 1680 agcctcggcg tcggacgacg acgcggacga cgcggacggg gcgctggcgg ccgagagcac 1740 acctttcctg ggcctgcgtg gggcgcacga cgcgctgcgc tcggactcgc cgccactgtg 1800 cccggcggcc gacagcagga cttactactc actggacagc cacagcacgc gggccagcag 1860 cagacacagc cgcgggccgc ccccgcgggc caagcaggac tcggcgccac tctagggccc 1920 cgccgcgcgc ccctccgccc cgcccgcccc actatcttta aggagaccag agaccgccta 1980 ctggagagaa aggaggaaaa aagaaataaa aatattttta ttttctataa aaggaaaaaa 2040 gtataacaaa atgttttatt ttcattttag caaaaattgt cttataatac tagctaacgg 2100 caaaggcgtt tttataggga aactatttat atgtaacatc ctgatttaca gcttcgg 2157 4 1459 DNA Homo sapiens 4 cctccaggtc ctggcgcaca gggtgggagc gctgcgctgc gccgcgctgc gcatcgcggc 60 ccgcttgccg cctgccccct gccctagctg ggccacctcc ccgggctgcc ggtggagggc 120 taagaggcgc taacgttacg ctgtttccgg ttttccagcg ggctctgttt cccctcccaa 180 ggcggcggcg gctgagcggc ggagcccccc aaatggcctg gccagatgcg gcaggtttgc 240 tgctcagcgc tgccgccgcc gccactggag aagggtcggt gcagcagcta cagcgacagc 300 agcagcagca gcagcgagag gagcagcagc agcagcagca gcagcagcga gagcggcagc 360 agcagcagga gcagcagcaa caacagcagc atctctcgtc ccgctgcgcc cccagmgccg 420 cggccgcagc aacagccgca gccccgcagc cccgcagccc ggagagccgc cgcccgttcg 480 cgagccgcag ccgccggcgg catgaggcgc gacccggccc ccggcttctc catgctgctc 540 ttcggtgtgt cgctcgcctg ctactcgccc agcctcaagt cagtgcagga ccaggcgtac 600 aaggcacccg tggtggtgga gggcaaggta caggggctgg tcccagccgg cggctccagc 660 tccaacagca cccgagagcc gcccgcctcg ggtcgggtgg cgttggtaaa ggtgctggac 720 aagtggccgc tccggagcgg ggggctgcag cgcgagcagg tgatcagcgt gggctcctgt 780 gtgccgctcg aaaggaacca gcgctacatc tttttcctgg agcccacgga acagccctta 840 gtctttaaga cggcctttgc ccccctcgat accaacggca aaaatctcaa gaaagaggtg 900 ggcaagatcc tgtgcactga ctgcgccacc cggcccaagt tgaagaagat gaagagccag 960 acgggacagg tgggtgagaa gcaatcgctg aagtgtgagg cagcagcggg taatccccag 1020 ccttcctacc gttggttcaa ggatggcaag gagctcaacc gcagccgaga cattcgcatc 1080 aaatatggca acggcagaaa gaactcacga ctacagttca acaaggtgaa ggtggaggac 1140 gctggggagt atgtctgcga ggccgagaac atcctgggga aggacaccgt ccggggccgg 1200 ctttacgtca acagcgtgag caccaccctg tcatcctggt cggggcacgc ccggaagtgc 1260 aacgagacag ccaagtccta ttgcgtcaat ggaggcgtct gctactacat cgagggcatc 1320 aaccagctct cctgcaaggc acctgggctg cactgcttag aacttggtac ccagagccac 1380 cacttcccca tctcagcctc ccctggttcc agccaaggtt cctggaacca acttccccaa 1440 caccctttgt cagccctcg 1459 5 2734 DNA Homo sapiens 5 ttcaaacccc ccttaaacta attgtcacaa agktggataa tattgatgga atycctcaat 60 tggaggatca aagttgagaa aagtaatatt cgacattttt cgattcaacg gagtggccac 120 caagacgatg tcatagaagt ctgaacgagt ctcagttcca atttggtaga ccacttcata 180 catctttgtt ggatttcctg tgtacttggt ctttgttttc tcctcgatgt acattactga 240 gccagatata agattgcttt tggatgcctg cagaagccct gagcaaacaa gtttattgcc 300 accttctact gcccaaaggc cagaatcaga acaggacagt gacaccgccc ccacaaaggc 360 attgatgtcc gtgctttggc cataattgac cctcataaca ggagcaatca tttcattgag 420 gaacttctca gaaaagccgg ccttttgcaa ggtttcaaga agtgttcgat taagcattcc 480 aaggaagtca tctcctccta gagcatgaag taatttttcg acactactga aggcatagtc 540 atgagactgg tagcggtaga tcctcatgaa cttgtctaac acgtcctcta cccacatgtg 600 catacggagg gattgaaatc catagcgcca aactaattta atcacgttaa ttatgaacca 660 gttgctctcc tcaaatacca gagtctctcc attatatatc cccagtaggc cacccagagg 720 ctgatgctca ccatggggcg cctgcaactg gttgtgttgg gcctcacctg ctgctgggca 780 gtggcgagtg ccgcgaagct gggcgccgtg tacacagaag gtgggttcgt ggaaggcgtc 840 aataagaagc tcggcctcct gggtgactct gtggacatct tcaagggcat ccccttcgca 900 gctcccacca aggccctgga aaatcctcag ccacatcctg gctggcaagg gaccctgaag 960 gccaagaact tcaagaagag atgcctgcag gccaccatca cccaggacag cacctacggg 1020 gatgaagact gcctgtacct caacatttgg gtgccccagg gcaggaagca agtctcccgg 1080 gacctgcccg ttatgatctg gatctatgga ggcgccttcc tcatggggtc cggccatggg 1140 gccaacttcc tcaacaacta cctgtatgac ggcgaggaga tcgccacacg cggaaacgtc 1200 atcgtggtca ccttcaacta ccgtgtcggc ccccttgggt tcctcagcac tggggacgcc 1260 aatctgccag gtaactatgg tcttcgggat cagcacatgg ccattgcttg ggtgaagagg 1320 aatatcgcgg ccttcggggg ggaccccaac aacatcacgc tcttcgggga gtctgctgga 1380 ggtgccagcg tctctctgca gaccctctcc ccctacaaca agggcctcat ccggcgagcc 1440 atcagccaga gcggcgtggc cctgagtccc tgggtcatcc agaaaaaccc actcttctgg 1500 gccaaaaagg tggctgagaa ggtgggttgc cctgtgggtg atgccgccag gatggcccag 1560 tgtctgaagg ttactgatcc ccgagccctg acgctggcct ataaggtgcc gctggcaggc 1620 ctggagtacc ccatgctgca ctatgtgggc ttcgtccctg tcattgatgg agacttcatc 1680 cccgctgacc cgatcaacct gtacgccaac gccgccgaca tcgactatat agcaggcacc 1740 aacaacatgg acggccacat cttcgccagc atcgacatgc ctgccatcaa caagggcaac 1800 aagaaagtca cggaggagga cttctacaag ctggtcagtg agttcacaat caccaagggg 1860 ctcagaggcg ccaagacgac ctttgatgtc tacaccgagt cctgggccca ggacccatcc 1920 caggagaata agaagaagac tgtggtggac tttgagaccg atgtcctctt cctggtgccc 1980 accgagattg ccctagccca gcacagagcc aatgccaaga gtgccaagac ctacgcctac 2040 ctgttttccc atccctctcg gatgcccgtc taccccaaat gggtgggggc cgaccatgca 2100 gatgacattc agtacgtttt cgggaagccc ttcgccaccc ccacgggcta ccggccccaa 2160 gacaggacag tctctaaggc catgatcgcc tactggacca actttgccaa aacaggggac 2220 cccaacatgg gcgactcggc tgtgcccaca cactgggaac cctacactac ggaaaacagc 2280 ggctacctgg agatcaccaa gaagatgggc agcagctcca tgaagcggag cctgagaacc 2340 aacttcctgc gctactggac cctcacctat ctggcgctgc ccacagtgac cgaccaggag 2400 gccacccctg tgccccccac aggggactcc gaggccactc ccgtgccccc cacgggtgac 2460 tccgagaccg cccccgtgcc gcccacgggt gactccgggg ccccccccgt gccgcccacg 2520 ggtgactccg gggccccccc cgtgccgccc acgggtgact ccggggcccc ccccgtgccg 2580 cccacgggtg actccaagga agctcagatg cctgcagtca ttaggtttta gcgtcccatg 2640 agccttggta tcaagaggcc acaagagtgg gaccccaggg gctcccctcc catcttgagc 2700 tcttcctgaa taaagcctca tacccctgaa aaaa 2734 6 2781 DNA Homo sapiens 6 ttcaaacccc ccttaaacta attgtcacaa agktggataa tattgatgga atycctcaat 60 tggaggatca aagttgagaa aagtaatatt cgacattttt cgattcaacg gagtggccac 120 caagacgatg tcatagaagt ctgaacgagt ctcagttcca atttggtaga ccacttcata 180 catctttgtt ggatttcctg tgtacttggt ctttgttttc tcctcgatgt acattactga 240 gccagatata agattgcttt tggatgcctg cagaagccct gagcaaacaa gtttattgcc 300 accttctact gcccaaaggc cagaatcaga acaggacagt gacaccgccc ccacaaaggc 360 attgatgtcc gtgctttggc cataattgac cctcataaca ggagcaatca tttcattgag 420 gaacttctca gaaaagccgg ccttttgcaa ggtttcaaga agtgttcgat taagcattcc 480 aaggaagtca tctcctccta gagcatgaag taatttttcg acactactga aggcatagtc 540 atgagactgg tagcggtaga tcctcatgaa cttgtctaac acgtcctcta cccacatgtg 600 catacggagg gattgaaatc catagcgcca aactaattta atcacgttaa ttatgaacca 660 gttgctctcc tcaaatacca gagtctctcc attatatatc cccagtaggc cacccagagg 720 ctgatgctca ccatggggcg cctgcaactg gttgtgttgg gcctcacctg ctgctgggca 780 gtggcgagtg ccgcgaagct gggcgccgtg tacacagaag gtgggttcgt ggaaggcgtc 840 aataagaagc tcggcctcct gggtgactct gtggacatct tcaagggcat ccccttcgca 900 gctcccacca aggccctgga aaatcctcag ccacatcctg gctggcaagg gaccctgaag 960 gccaagaact tcaagaagag atgcctgcag gccaccatca cccaggacag cacctacggg 1020 gatgaagact gcctgtacct caacatttgg gtgccccagg gcaggaagca agtctcccgg 1080 gacctgcccg ttatgatctg gatctatgga ggcgccttcc tcatggggtc cggccatggg 1140 gccaacttcc tcaacaacta cctgtatgac ggcgaggaga tcgccacacg cggaaacgtc 1200 atcgtggtca ccttcaacta ccgtgtcggc ccccttgggt tcctcagcac tggggacgcc 1260 aatctgccag gtaactatgg tcttcgggat cagcacatgg ccattgcttg ggtgaagagg 1320 aatatcgcgg ccttcggggg ggaccccaac aacatcacgc tcttcgggga gtctgctgga 1380 ggtgccagcg tctctctgca gaccctctcc ccctacaaca agggcctcat ccggcgagcc 1440 atcagccaga gcggcgtggc cctgagtccc tgggtcatcc agaaaaaccc actcttctgg 1500 gccaaaaagg tggctgagaa ggtgggttgc cctgtgggtg atgccgccag gatggcccag 1560 tgtctgaagg ttactgatcc ccgagccctg acgctggcct ataaggtgcc gctggcaggc 1620 ctggagtacc ccatgctgca ctatgtgggc ttcgtccctg tcattgatgg agacttcatc 1680 cccgctgacc cgatcaacct gtacgccaac gccgccgaca tcgactatat agcaggcacc 1740 aacaacatgg acggccacat cttcgccagc atcgacatgc ctgccatcaa caagggcaac 1800 aagaaagtca cggaggagga cttctacaag ctggtcagtg agttcacaat caccaagggg 1860 ctcagaggcg ccaagacgac ctttgatgtc tacaccgagt cctgggccca ggacccatcc 1920 caggagaata agaagaagac tgtggtggac tttgagaccg atgtcctctt cctggtgccc 1980 accgagattg ccctagccca gcacagagcc aatgccaaga gtgccaagac ctacgcctac 2040 ctgttttccc atccctctcg gatgcccgtc taccccaaat gggtgggggc cgaccatgca 2100 gatgacattc agtacgtttt cgggaagccc ttcgccaccc ccacgggcta ccggccccaa 2160 gacaggacag tctctaaggc catgatcgcc tactggacca actttgccaa aacaggggac 2220 cccaacatgg gcgactcggc tgtgcccaca cactgggaac cctacactac ggaaaacagc 2280 ggctacctgg agatcaccaa gaagatgggc agcagctcca tgaagcggag cctgagaacc 2340 aacttcctgc gctactggac cctcacctat ctggcgctgc ccacagtgac cgaccaggag 2400 gccacccctg tgccccccac aggggactcc gaggccactc ccgtgccccc cacgggtgac 2460 tccgagaccg cccccgtgcc gcccacgggt gactccgggg ccccccccgt gccgcccacg 2520 ggtgactccg gggccccccc cgtgccgccc acgggtgact ccggggcccc ccccgtgccg 2580 cccacggggt gccccccacg ggtgactctg aggctgcccc tgtgcccccc acagatgact 2640 ccaaggaagc tcagatgcct gcagtcatta ggttttagcg tcccatgagc cttggtatca 2700 agaggccaca agagtgggac cccaggggct cccctcccat cttgagctct tcctgaataa 2760 agcctcatac ccctgaaaaa a 2781 7 1905 DNA Homo sapiens 7 ttcaaacccc ccttaaacta attgtcacaa agktggataa tattgatgga atycctcaat 60 tggaggatca aagttgagaa aagtaatatt cgacattttt cgattcaacg gagtggccac 120 caagacgatg tcatagaagt ctgaacgagt ctcagttcca atttggtaga ccacttcata 180 catctttgtt ggatttcctg tgtacttggt ctttgttttc tcctcgatgt acattactga 240 gccagatata agattgcttt tggatgcctg cagaagccct gagcaaacaa gtttattgcc 300 accttctact gcccaaaggc cagaatcaga acaggacagt gacaccgccc ccacaaaggc 360 attgatgtcc gtgctttggc cataattgac cctcataaca ggagcaatca tttcattgag 420 gaacttctca gaaaagccgg ccttttgcaa ggtttcaaga agtgttcgat taagcattcc 480 aaggaagtca tctcctccta gagcatgaag taatttttcg acactactga aggcatagtc 540 atgagactgg tagcggtaga tcctcatgaa cttgtctaac acgtcctcta cccacatgtg 600 catacggagg gattgaaatc catagcgcca aactaattta atcacgttaa ttatgaacca 660 gttgctctcc tcaaatacca gagtctctcc attatatatc cccagtaggc cacccagagg 720 ctgatgctca ccatggggcg cctgcaactg gttgtgttgg gcctcacctg ctgctgggca 780 gtggcgagtg ccgcgaagac cccatgctgc actatgtggg cttcgtccct gtcattgatg 840 gagacttcat ccccgctgac ccgatcaacc tgtacgccaa cgccgccgac atcgactata 900 tagcaggcac caacaacatg gacggccaca tcttcgccag catcgacatg cctgccatca 960 acaagggcaa caagaaagtc acggaggagg acttctacaa gctggtcagt gagttcacaa 1020 tcaccaaggg gctcagaggc gccaagacga cctttgatgt ctacaccgag tcctgggccc 1080 aggacccatc ccaggagaat aagaagaaga ctgtggtgga ctttgagacc gatgtcctct 1140 tcctggtgcc caccgagatt gccctagccc agcacagagc caatgccaag agtgccaaga 1200 cctacgccta cctgttttcc catccctctc ggatgcccgt ctaccccaaa tgggtggggg 1260 ccgaccatgc agatgacatt cagtacgttt tcgggaagcc cttcgccacc cccacgggct 1320 accggcccca agacaggaca gtctctaagg ccatgatcgc ctactggacc aactttgcca 1380 aaacagggga ccccaacatg ggcgactcgg ctgtgcccac acactgggaa ccctacacta 1440 cggaaaacag cggctacctg gagatcacca agaagatggg cagcagctcc atgaagcgga 1500 gcctgagaac caacttcctg cgctactgga ccctcaccta tctggcgctg cccacagtga 1560 ccgaccagga ggccacccct gtgcccccca caggggactc cgaggccact cccgtgcccc 1620 ccacgggtga ctccgagacc gcccccgtgc cgcccacggg tgactccggg gccccccccg 1680 tgccgcccac gggtgactcc ggggcccccc ccgtgccgcc cacgggtgac tccggggccc 1740 cccccgtgcc gcccacgggt gactccaagg aagctcagat gcctgcagtc attaggtttt 1800 agcgtcccat gagccttggt atcaagaggc cacaagagtg ggaccccagg ggctcccctc 1860 ccatcttgag ctcttcctga ataaagcctc atacccctga aaaaa 1905 8 1952 DNA Homo sapiens 8 ttcaaacccc ccttaaacta attgtcacaa agktggataa tattgatgga atycctcaat 60 tggaggatca aagttgagaa aagtaatatt cgacattttt cgattcaacg gagtggccac 120 caagacgatg tcatagaagt ctgaacgagt ctcagttcca atttggtaga ccacttcata 180 catctttgtt ggatttcctg tgtacttggt ctttgttttc tcctcgatgt acattactga 240 gccagatata agattgcttt tggatgcctg cagaagccct gagcaaacaa gtttattgcc 300 accttctact gcccaaaggc cagaatcaga acaggacagt gacaccgccc ccacaaaggc 360 attgatgtcc gtgctttggc cataattgac cctcataaca ggagcaatca tttcattgag 420 gaacttctca gaaaagccgg ccttttgcaa ggtttcaaga agtgttcgat taagcattcc 480 aaggaagtca tctcctccta gagcatgaag taatttttcg acactactga aggcatagtc 540 atgagactgg tagcggtaga tcctcatgaa cttgtctaac acgtcctcta cccacatgtg 600 catacggagg gattgaaatc catagcgcca aactaattta atcacgttaa ttatgaacca 660 gttgctctcc tcaaatacca gagtctctcc attatatatc cccagtaggc cacccagagg 720 ctgatgctca ccatggggcg cctgcaactg gttgtgttgg gcctcacctg ctgctgggca 780 gtggcgagtg ccgcgaagac cccatgctgc actatgtggg cttcgtccct gtcattgatg 840 gagacttcat ccccgctgac ccgatcaacc tgtacgccaa cgccgccgac atcgactata 900 tagcaggcac caacaacatg gacggccaca tcttcgccag catcgacatg cctgccatca 960 acaagggcaa caagaaagtc acggaggagg acttctacaa gctggtcagt gagttcacaa 1020 tcaccaaggg gctcagaggc gccaagacga cctttgatgt ctacaccgag tcctgggccc 1080 aggacccatc ccaggagaat aagaagaaga ctgtggtgga ctttgagacc gatgtcctct 1140 tcctggtgcc caccgagatt gccctagccc agcacagagc caatgccaag agtgccaaga 1200 cctacgccta cctgttttcc catccctctc ggatgcccgt ctaccccaaa tgggtggggg 1260 ccgaccatgc agatgacatt cagtacgttt tcgggaagcc cttcgccacc cccacgggct 1320 accggcccca agacaggaca gtctctaagg ccatgatcgc ctactggacc aactttgcca 1380 aaacagggga ccccaacatg ggcgactcgg ctgtgcccac acactgggaa ccctacacta 1440 cggaaaacag cggctacctg gagatcacca agaagatggg cagcagctcc atgaagcgga 1500 gcctgagaac caacttcctg cgctactgga ccctcaccta tctggcgctg cccacagtga 1560 ccgaccagga ggccacccct gtgcccccca caggggactc cgaggccact cccgtgcccc 1620 ccacgggtga ctccgagacc gcccccgtgc cgcccacggg tgactccggg gccccccccg 1680 tgccgcccac gggtgactcc ggggcccccc ccgtgccgcc cacgggtgac tccggggccc 1740 cccccgtgcc gcccacgggg tgccccccac gggtgactct gaggctgccc ctgtgccccc 1800 cacagatgac tccaaggaag ctcagatgcc tgcagtcatt aggttttagc gtcccatgag 1860 ccttggtatc aagaggccac aagagtggga ccccaggggc tcccctccca tcttgagctc 1920 ttcctgaata aagcctcata cccctgaaaa aa 1952 9 2690 DNA Homo sapiens 9 cttcctcttc tccacgcagg cttcaacagg agatttatgg agaatagcag cataattgct 60 tgctataatg aactgattca aatagaacat ggggaagttc gctcccagtt caaattacgg 120 gcctgtaatt cagtgtttac agcattagat cactgtcatg aagccataga aataacaagc 180 gatgaccacg tgattcagga gtggcagggg gtttactatg ccagacggaa atccggggac 240 agcatccaac agcacgtgaa gatcacccca gtgattggcc aaggagggaa aattaggcat 300 tttgtctcgc tcaagaaact gtgttgtacc actgacaata ataagcagat tcacaagatt 360 catcgtgatt caggagataa ttctcagaca gagcctcatt cattcagata taagaacagg 420 aggaaagagt ccattgacgt gaaatcgata tcatctcgag gcagtgatgc accaagcctg 480 cagaatcgtc gctatccgtc catggcgagg atccactcca tgaccatcga ggctcccatc 540 acaaaggtta taaatataat caatgcagcc caagaaaaca gcccagtcac agtagcggaa 600 gccttggaca gagttctaga gattttacgg accacagaac tgtactcccc tcagctgggt 660 accaaagatg aagatcccca caccagtgat cttgttggag gcctgatgac tgacggcttg 720 agaagactgt caggaaacga gtatgtgttt actaagaatg tgcaccagag tcacagtcac 780 cttgcaatgc caataaccat caatgatgtt cccccttgta tctctcaatt acttgataat 840 gaggagagtt gggacttcaa catctttgaa ttggaagcca ttacgcataa aaggccattg 900 gtttatctgg gcttaaaggt cttctctcgg tttggagtat gtgagttttt aaactgttct 960 gaaaccactc ttcgggcctg gttccaagtg atcgaagcca actaccactc ttccaatgcc 1020 taccacaact ccacccatgc tgccgacgtc ctgcacgcca ccgctttctt tcttggaaag 1080 gaaagagtaa agggaagcct cgatcagttg gatgaggtgg cagccctcat tgctgccaca 1140 gtccatgacg tggatcaccc gggaaggacc aactctttcc tctgcaatgc aggcagtgag 1200 cttgctgtgc tctacaatga cactgctgtt ctggagagtc accacaccgc cctggccttc 1260 cagctcacgg tcaaggacac caaatgcaac attttcaaga atattgacag gaaccattat 1320 cgaacgctgc gccaggctat tattgacatg gttttggcaa cagagatgac aaaacacttt 1380 gaacatgtga ataagtttgt gaacagcatc aacaagccaa tggcagctga gattgaaggc 1440 agcgactgtg aatgcaaccc tgctgggaag aacttccctg aaaaccaaat cctgatcaaa 1500 cgcatgatga ttaagtgtgc tgacgtggcc aacccatgcc gccccttgga cctgtgcatt 1560 gaatgggctg ggaggatctc tgaggagtat tttgcacaga ctgatgaaga gaagagacag 1620 ggactacctg tggtgatgcc agtgtttgac cggaatacct gtagcatccc caagtctcag 1680 atctctttca ttgactactt cataacagac atgtttgatg cttgggatgc ctttgcacat 1740 ctaccagccc tgatgcaaca tttggctgac aactacaaac actggaagac actagatgac 1800 ctaaagtgca aaagtttgag gcttccatct gacagctaaa gccaagccac agagggggcc 1860 tcttgaccga caaaggacac tgtgaatcac agtagcgtaa acaagaggcc ttcctttcta 1920 atgacaatga caggtattgg tgaaggagct aatgtttaat atttgacctt gaatcattca 1980 agtccccaaa tttcattctt agaaagttat gttccatgaa gaaaaatata tgttcttttg 2040 aatacttaat gacagaacaa atacttggca aactcctttg ctctgctgtc atcctgtgta 2100 cccttgtcaa tccatggagc tggttcactg taactagcag gccacaggaa gcaaagcctt 2160 ggtgcctgtg agctcatctc ccaggatggt gactaagtag cttagctagt gatcagctca 2220 tcctttacca taaaagtcat cattgctgtt tagcttgact gttttcctca agaacatcga 2280 tctgaaggat tcataaggag cttatctgaa cagatttatc taagaaaaaa aaaaaacgac 2340 ataaaataag cgaaacaact aggaccaaat tacagataaa ctagttagct tcacagcctc 2400 tatggctaca tggttcttct ggccgatggt atgacaccta agttagaaca cagccttggc 2460 tggtgggtgc cctctctaga ctggtatcag cagcctgtgt aacccctttc ctgtaaaagg 2520 ggttcatctt aacaaagtca tccatgatga gggaaaaagt ggcatttcat ttttggggaa 2580 tccatgagct tcctttattt ctggctcaca gaggcagcca cgaggcacta caccaagtat 2640 tatataaaag ccattaaatt tgaatgccct tggacaagct tttcttaaaa 2690 10 1502 DNA Homo sapiens 10 ccttggagac tagaaagaaa ctgctagatg gctgtaacac agttcatcca tttccgtgaa 60 gagatcatgg ggaatatgtt cttcatcatc atcttcagta ccaaggataa actgtgttac 120 agagatggag aagaatatga atggaaagaa actgctagat ggctgaaatt tgaagaggat 180 gttgaagatg gcggtgaccg atggagtaaa ccttatgtgg caactctctc tttgcacagt 240 ctttttgaac taaggagttg catcctcaat ggaacagtca tgctggatat gagagcaagc 300 actctagatg aaatagcaga tatggtatta gacaacatga tagcttctgg ccaattagac 360 gagtccatac gagagaatgt cagagaagct cttctgaaga gacatcatca tcagaatgag 420 aaaagattca ccagtcggat tcctcttgtt cgatcttttg cagatatagg caagaaacat 480 tctgaccctc acttgcttga aaggaatggt attttggcct ctccccagtc tgctcctgga 540 aacttggaca atagtaaaag tggagaaatt aaaggtaatg gaagtggtgg aagcagagaa 600 aatagtactg ttgacttcag caaggttgat atgaatttca tgagaaaaat tcctacgggt 660 gctgaggcat ccaacgtcct ggtgggcgaa gtagactttt tggaaaggcc aataattgca 720 tttgtgagac tggctcctgc tgtcctcctt acagggttga ctgaggtccc tgttccaacc 780 aggtttttgt ttttgttatt gggtccagcg ggcaaggcac cacagtacca tgaaattgga 840 cgatcaatag ccactctcat gacagatgag attttccatg atgtagctta taaagcaaaa 900 gacagaaatg acctcttatc tggaattgat gaatttttag atcaagtaac tgtcctacct 960 ccaggagagt gggatccttc tatacgcata gaaccaccaa aaagtgtccc ttctcaggaa 1020 aagagaaaga ttcctgtgtt tcacaatgga tctaccccca cactgggtga gactcctaaa 1080 gaggccgctc atcatgctgg gcctgagcta cagaggactg gacggctttt tggtgggttg 1140 atacttgaca tcaaaaggaa agcacctttt ttcttgagtg acttcaagga tgcattaagc 1200 ctgcagtgcc tggcctcgat tcttttccta tactgtgcct gtatgtctcc tgtaatcact 1260 tttggagggc tgcttggaga agctacagaa ggcagaatag tgagtacaaa gattggtagt 1320 ggccaggctt ttagctcttc agaggcaagt gtctgtatgc atttgtctca ctattcatac 1380 ttttatttga agagtctacc cacagcatga ttaacgtgac ccaaagcaga ctttccccaa 1440 aggtaattgc tgtggaaaac atggggaagc catttgaaca gaagatgcac agttgaggta 1500 aa 1502 11 594 DNA Homo sapiens 11 ccttggagac tagaaagaaa ctgctagatg gctgtaacac agttcatcca tttccgtgaa 60 gagatcatgg ggaatatgtt cttcatcatc atcttcagta ccaaggataa actgtgttac 120 agagatggag aagaatatga atggaaagaa actgctagat ggctgaaatt tgaagaggat 180 gttgaagatg gcggtgaccg atggagtaaa ccttatgtgg caactctctc tttgcacagt 240 ctttttgaac taaggagttg catcctcaat ggaacagtca tgctggatat gagagcaagc 300 actctagatg aaatagcaga tatggtatta gacaacatga tagcttctgg ccaattagac 360 gagtccatac gagagaatgt cagagaagct cttctgaaga gacatcatca tcagaatgag 420 aaaagattca ccagtcggat tcctcttgtt cgatcttttg cagatatagg caagaaacat 480 tctgaccctc acttgcttga aaggaatggt gagataagtt gtggcatcca atttttgcta 540 acacttctac tgtaacagct ttccagtatg ttacgattaa catttgggga tatt 594 12 3166 DNA Homo sapiens 12 aggaaggcta ttagtatata atagtagcct ctttataaat aatagtattt attaaaataa 60 ggcggtcttt gtaattcatt tttattggtt ggataatgtt catttctgca ttgattattt 120 gtgacagaat aaaactttct agagctattt aaggttctaa tttttgtcat aaggtttcac 180 tcacagttta ttcctatatt atggtcatct gagtgtttag taatttattt tttttttcat 240 tgaatagata tggtattaga caacatgata gcttctggcc aattagacga gtccatacga 300 gagaatgtca gagaagctct tctgaagaga catcatcatc agaatgagaa aagattcacc 360 agtcggattc ctcttgttcg atcttttgca gatataggca agaaacattc tgaccctcac 420 ttgcttgaaa ggaatggtat tttggcctct ccccagtctg ctcctggaaa cttggacaat 480 agtaaaagtg gagaaattaa aggtaatgga agtggtggaa gcagagaaaa tagtactgtt 540 gacttcagca aggttgatat gaatttcatg agaaaaattc ctacgggtgc tgaggcatcc 600 aacgtcctgg tgggcgaagt agactttttg gaaaggccaa taattgcatt tgtgagactg 660 gctcctgctg tcctccttac agggttgact gaggtccctg ttccaaccag gtttttgttt 720 ttgttattgg gtccagcggg caaggcacca cagtaccatg aaattggacg atcaatagcc 780 actctcatga cagatgagat tttccatgat gtagcttata aagcaaaaga cagaaatgac 840 ctcttatctg gaattgatga atttttagat caagtaactg tcctacctcc aggagagtgg 900 gatccttcta tacgcataga accaccaaaa agtgtccctt ctcaggaaaa gagaaagatt 960 cctgtgtttc acaatggatc tacccccaca ctgggtgaga ctcctaaaga ggccgctcat 1020 catgctgggc ctgagctaca gaggactgga cggctttttg gtgggttgat acttgacatc 1080 aaaaggaaag cacctttttt cttgagtgac ttcaaggatg cattaagcct gcagtgcctg 1140 gcctcgattc ttttcctata ctgtgcctgt atgtctcctg taatcacttt tggagggctg 1200 cttggagaag ctacagaagg cagaataagt gcaatagagt ctctttttgg agcatcatta 1260 actgggattg cctattcatt gtttgctggg caacctctaa caatattggg gagcacaggt 1320 ccagttctag tgtttgaaaa aattttatat aaattctgca gagattatca actttcttat 1380 ctgtctttaa gaaccagtat tggtctgtgg acttcttttt tgtgcattgt tttggttgca 1440 acagatgcaa gcagccttgt gtgttatatt actcgattta cagaagaggc ttttgcagcc 1500 cttatttgca tcatattcat ctacgaggct ttggagaagc tctttgattt aggagaaaca 1560 tatgcattta atatgcacaa caacttagat aaactgacca gctactcatg tgtatgtact 1620 gaacctccaa accccagcaa tgaaactcta gcacaatgga agaaagataa tataacagca 1680 cacaatattt cctggagaaa tcttactgtt tctgaatgta aaaaacttcg tggtgtattc 1740 ttggggtcag cttgtggtca tcatggacct tatattccag atgtgctctt ttggtgtgtc 1800 atcttgtttt tcacaacatt ttttctgtct tcattcctca agcaatttaa gaccaagcgt 1860 tactttccta ccaaggtgcg atcgacaatc agtgattttg ctgtatttct cacaatagta 1920 ataatggtta caattgacta ccttgtagga gttccatctc ctaaacttca tgttcctgaa 1980 aaatttgagc ctactcatcc agagagaggg tggatcataa gcccactggg agataatcct 2040 tggtggacct tattaatagc tgctattcct gctttgcttt gtaccattct catctttatg 2100 gatcaacaaa tcacagctgt aattataaac agaaaggaac acaaattgaa gaaaggagct 2160 ggctatcacc ttgatttgct catggttggc gttatgttgg gagtttgctc tgtcatggga 2220 cttccatggt ttgtggctgc aacagtgttg tcaataagtc atgtcaacag cttaaaagtt 2280 gaatctgaat gttctgctcc aggggaacaa cccaagtttt tgggaattcg tgaacagcgg 2340 gttacagggc taatgatttt tattctaatg ggcctctctg tgttcatgac ttcagtccta 2400 aagtttattc caatgcctgt tctgtatggt gttttccttt atatgggagt ttcctcatta 2460 aaaggaatcc agttatttga ccggataaaa ttatttggaa tgcctgctaa gcatcagcct 2520 gatttgatat acctccggta tgtgccgctc tggaaggtcc atattttcac agtcattcag 2580 cttacttgct tggtcctttt atgggtgata aaagtttcag ctgctgcagt ggtttttccc 2640 atgatggttc ttgcattagt gtttgtgcgc aaactcatgg acctgtgttt cacgaagaga 2700 gaacttagtt ggcttgatga tcttatgcca gaaagtaaga aaaagaaaga agatgacaaa 2760 aagaaaaaag agaaagagga agctgaacgg atgcttcaag acgatgatga tactgtgcac 2820 cttccatttg aagggggaag tctcttgcaa attccagtca aggccctaaa atatagtggt 2880 gatccctcaa ttggtaacat atcagatgaa atggccaaaa ctgcacagtg gaaggcactt 2940 tccatgaata ctgagaatgc caaagtaacc agatctaaca tgagtcctga taaacctgtg 3000 agtgtgaaat aagtttgaga tgaaccaaga aagaaatacg tggagctgaa acttcatata 3060 gaatggaacc aagaggcata tacatataga tatatacata tgtaagggtg cgatcatggc 3120 actatatata gaatatggag gcaaggcggg taagggggga ctaacc 3166 13 1430 DNA Homo sapiens 13 aggaaggcta ttagtatata atagtagcct ctttataaat aatagtattt attaaaataa 60 ggcggtcttt gtaattcatt tttattggtt ggataatgtt catttctgca ttgattattt 120 gtgacagaat aaaactttct agagctattt aaggttctaa tttttgtcat aaggtttcac 180 tcacagttta ttcctatatt atggtcatct gagtgtttag taatttattt tttttttcat 240 tgaatagata tggtattaga caacatgata gcttctggcc aattagacga gtccatacga 300 gagaatgtca gagaagctct tctgaagaga catcatcatc agaatgagaa aagattcacc 360 agtcggattc ctcttgttcg atcttttgca gatataggca agaaacattc tgaccctcac 420 ttgcttgaaa ggaatggtat tttggcctct ccccagtctg ctcctggaaa cttggacaat 480 agtaaaagtg gagaaattaa aggtaatgga agtggtggaa gcagagaaaa tagtactgtt 540 gacttcagca aggttgatat gaatttcatg agaaaaattc ctacgggtgc tgaggcatcc 600 aacgtcctgg tgggcgaagt agactttttg gaaaggccaa taattgcatt tgtgagactg 660 gctcctgctg tcctccttac agggttgact gaggtccctg ttccaaccag gtttttgttt 720 ttgttattgg gtccagcggg caaggcacca cagtaccatg aaattggacg atcaatagcc 780 actctcatga cagatgagat tttccatgat gtagcttata aagcaaaaga cagaaatgac 840 ctcttatctg gaattgatga atttttagat caagtaactg tcctacctcc aggagagtgg 900 gatccttcta tacgcataga accaccaaaa agtgtccctt ctcaggaaaa gagaaagatt 960 cctgtgtttc acaatggatc tacccccaca ctgggtgaga ctcctaaaga ggccgctcat 1020 catgctgggc ctgagctaca gaggactgga cggctttttg gtgggttgat acttgacatc 1080 aaaaggaaag cacctttttt cttgagtgac ttcaaggatg cattaagcct gcagtgcctg 1140 gcctcgattc ttttcctata ctgtgcctgt atgtctcctg taatcacttt tggagggctg 1200 cttggagaag ctacagaagg cagaatagtg agtacaaaga ttggtagtgg ccaggctttt 1260 agctcttcag aggcaagtgt ctgtatgcat ttgtctcact attcatactt ttatttgaag 1320 agtctaccca cagcatgatt aacgtgaccc aaagcagact ttccccaaag gtaattgctg 1380 tggaaaacat ggggaagcca tttgaacaga agatgcacag ttgaggtaaa 1430 14 678 DNA Homo sapiens 14 tttcctcact gactataaaa gaatagagaa ggaagggctt cagtgaccgg ctgcctggct 60 gacttacagc agtcagactc tgacaggatc atggctatga tggaggtcca ggggggaccc 120 agcctgggac agacctgcgt gctgatcgtg atcttcacag tgctcctgca gtctctctgt 180 gtggctgtaa cttacgtgta ctttaccaac gagctgaagc agatgcagga caagtactcc 240 aaaagtggca ttgcttgttt cttaaaagaa gatgacagtt attgggaccc caatgacgaa 300 gagagtatga acagcccctg ctggcaagtc aagtggcaac tccgtcagct cgttagaaag 360 atgattttga gaacctctga ggaaaccatt tctacagttc aagaaaagca acaaaatatt 420 tctcccctag tgagagaaag aggtcctcag agagtagcag ctcacataac tgggaccaga 480 ggaagaagca acacattgtc ttctccaaac tccaggagaa tcgtttgaac ccgggaggca 540 gaggttgcag tgtggtgaga tcatgccact acactccagc ctggcgacag agcgagactt 600 ggtttcaaaa aaaaaaaaaa aaaaacttca gtaagtacgt gttatttttt tcaataaaat 660 tctattacag tatgtcga 678 15 1711 DNA Homo sapiens 15 tttcctcact gactataaaa gaatagagaa ggaagggctt cagtgaccgg ctgcctggct 60 gacttacagc agtcagactc tgacaggatc atggctatga tggaggtcca ggggggaccc 120 agcctgggac agacctgcgt gctgatcgtg atcttcacag tgctcctgca gtctctctgt 180 gtggctgtaa cttacgtgta ctttaccaac gagctgaagc agatgcagga caagtactcc 240 aaaagtggca ttgcttgttt cttaaaagaa gatgacagtt attgggaccc caatgacgaa 300 gagagtatga acagcccctg ctggcaagtc aagtggcaac tccgtcagct cgttagaaag 360 aaaagcaaca aaatatttct cccctagtga gagaaagagg tcctcagaga gtagcagctc 420 acataactgg gaccagagga agaagcaaca cattgtcttc tccaaactcc aagaatgaaa 480 aggctctggg ccgcaaaata aactcctggg aatcatcaag gagtgggcat tcattcctga 540 gcaacttgca cttgaggaat ggtgaactgg tcatccatga aaaagggttt tactacatct 600 attcccaaac atactttcga tttcaggagg aaataaaaga aaacacaaag aacgacaaac 660 aaatggtcca atatatttac aaatacacaa gttatcctga ccctatattg ttgatgaaaa 720 gtgctagaaa tagttgttgg tctaaagatg cagaatatgg actctattcc atctatcaag 780 ggggaatatt tgagcttaag gaaaatgaca gaatttttgt ttctgtaaca aatgagcact 840 tgatagacat ggaccatgaa gccagttttt tcggggcctt tttagttggc taactgacct 900 ggaaagaaaa agcaataacc tcaaagtgac tattcagttt tcaggatgat acactatgaa 960 gatgtttcaa aaaatctgac caaaacaaac aaacagaaaa cagaaaacaa aaaaacctct 1020 atgcaatctg agtagagcag ccacaaccaa aaaattctac aacacacact gttctgaaag 1080 tgactcactt atcccaagag aatgaaattg ctgaaagatc tttcaggact ctacctcata 1140 tcagtttgct agcagaaatc tagaagactg tcagcttcca aacattaatg caatggttaa 1200 catcttctgt ctttataatc tactccttgt aaagactgta gaagaaagcg caacaatcca 1260 tctctcaagt agtgtatcac agtagtagcc tccaggtttc cttaagggac aacatcctta 1320 agtcaaaaga gagaagaggc accactaaaa gatcgcagtt tgcctggtgc agtggctcac 1380 acctgtaatc ccaacatttt gggaacccaa ggtgggtaga tcacgagatc aagagatcaa 1440 gaccatagtg accaacatag tgaaacccca tctctactga aagtgcaaaa attagctggg 1500 tgtgttggca catgcctgta gtcccagcta cttgagaggc tgaggcagga gaatcgtttg 1560 aacccgggag gcagaggttg cagtgtggtg agatcatgcc actacactcc agcctggcga 1620 cagagcgaga cttggtttca aaaaaaaaaa aaaaaaaact tcagtaagta cgtgttattt 1680 ttttcaataa aattctatta cagtatgtcg a 1711 16 635 DNA Homo sapiens 16 tttcctcact gactataaaa gaatagagaa ggaagggctt cagtgaccgg ctgcctggct 60 gacttacagc agtcagactc tgacaggatc atggctatga tggaggtcca ggggggaccc 120 agcctgggac agacctgcgt gctgatcgtg atcttcacag tgctcctgca gtctctctgt 180 gtggctgtaa cttacgtgta ctttaccaac gagctgaagc agatgcagga caagtactcc 240 aaaagtggca ttgcttgttt cttaaaagaa gatgacagtt attgggaccc caatgacgaa 300 gagagtatga acagcccctg ctggcaagtc aagtggcaac tccgtcagct cgttagaaag 360 aaaagcaaca aaatatttct cccctagtga gagaaagagg tcctcagaga gtagcagctc 420 acataactgg gaccagagga agaagcaaca cattgtcttc tccaaactcc aggagaatcg 480 tttgaacccg ggaggcagag gttgcagtgt ggtgagatca tgccactaca ctccagcctg 540 gcgacagagc gagacttggt ttcaaaaaaa aaaaaaaaaa aacttcagta agtacgtgtt 600 atttttttca ataaaattct attacagtat gtcga 635 17 814 DNA Homo sapiens 17 tttcctcact gactataaaa gaatagagaa ggaagggctt cagtgaccgg ctgcctggct 60 gacttacagc agtcagactc tgacaggatc atggctatga tggaggtcca ggggggaccc 120 agcctgggac agacctgcgt gctgatcgtg atcttcacag tgctcctgca gtctctctgt 180 gtggctgtaa cttacgtgta ctttaccaac gagctgaagc agatgcagga caagtactcc 240 aaaagtggca ttgcttgttt cttaaaagaa gatgacagtt attgggaccc caatgacgaa 300 gagagtatga acagcccctg ctggcaagtc aagtggcaac tccgtcagct cgttagaaag 360 gtaggtaacc tcaccaggtg acctcaccag caggcggaga aggccagaag aattccttaa 420 agcaaaggaa tctttaagat aatcaagtct agactcttca ttttacaaat aagaaaactt 480 aggcccagag tatttaagta attttcccca aattcataga actaggaaaa tggggcatag 540 cagcaaaggg caggacctgg ccgactcctg gtctagagtt cattcctctg ccccggacag 600 cctccacatc tagtctaacc ttttgatctc acattatgga aactgaggca ggagaatcgt 660 ttgaacccgg gaggcagagg ttgcagtgtg gtgagatcat gccactacac tccagcctgg 720 cgacagagcg agacttggtt tcaaaaaaaa aaaaaaaaaa acttcagtaa gtacgtgtta 780 tttttttcaa taaaattcta ttacagtatg tcga 814 18 1868 DNA Homo sapiens 18 gaagtttagt gacttgctga aatgggctag ggaatctaat ttcaaatggg caaaaagata 60 aacaaactat tttgctttaa ttttctagtt cagtgtttta ggggtaaatc aaaaccatcc 120 aaatgtcaga tcagaaagaa agttaaaaat catatagaaa gacttctgga tactgaagat 180 gagctcagtg acattcagac tgactcagtc ccatctgaag tccgggactg gttggcttct 240 acctttacac ggaaaatggg gatgacaaaa aagaaacctg aggaaaaacc aaaatttcgg 300 agcattgtgc atgctgttca agctggaatt tttgtggaaa gaatgtaccg aaaaacatat 360 catatggttg gtttggcata tccagcagct gtcatcgtaa cattaaagga tgttgataaa 420 tggtctttcg atgtatttgc cctaaatgaa gcaagtggag agcatagtct gaagtttatg 480 atttatgaac tgtttaccag atatgatctt atcaaccgtt tcaagattcc tgtttcttgc 540 ctaatcacct ttgcagaagc tttagaagtt ggttacagca agtacaaaaa tccatatcac 600 aatttgattc atgcagctga tgtcactcaa actgtgcatt acataatgct tcatacaggt 660 atcatgcact ggctcactga actggaaatt ttagcaatgg tctttgctgc tgccattcat 720 gattatgagc atacagggac aacaaacaac tttcacattc agacaaggtc agatgttgcc 780 attttgtata atgatcgctc tgtccttgag aatcaccacg tgagtgcagc ttatcgactt 840 atgcaagaag aagaaatgaa tatcttgata aatttatcca aagatgactg gagggatctt 900 cggaacctag tgattgaaat ggttttatct acagacatgt caggtcactt ccagcaaatt 960 aaaaatataa gaaacagttt gcagcagcct gaagggattg acagagccaa aaccatgtcc 1020 ctgattctcc acgcagcaga catcagccac ccagccaaat cctggaagct gcattatcgg 1080 tggaccatgg ccctaatgga ggagtttttc ctgcagggag ataaagaagc tgaattaggg 1140 cttccatttt ccccactttg tgatcggaag tcaaccatgg tggcccagtc acaaataggt 1200 ttcatcgatt tcatagtaga gccaacattt tctcttctga cagactcaac agagaaaatt 1260 gttattcctc ttatagagga agcctcaaaa gccgaaactt cttcctatgt ggcaagcagc 1320 tcaaccacca ttgtggggtt acacattgct gatgcactaa gacgatcaaa tacaaaaggc 1380 tccatgagtg atgggtccta ttccccagac tactcccttg cagcagtgga cctgaagagt 1440 ttcaagaaca acctggtgga catcattcag cagaacaaag agaggtggaa agagttagct 1500 gcacaagaag caagaaccag ttcacagaag tgtgagttta ttcatcagta aacaccttta 1560 agtaaaacct cgtgcatggt ggcagctcta atttgaccaa aagacttgga gattttgatt 1620 atgcttgctg gaaatctacc ctgtcctgtg tgagacagga aatctatttt tgcagattgc 1680 tcaataagca tcatgagcca cataaataac agctgtaaac tccttaattc accgggctca 1740 actgctaccg aacagattca tctagtggct acatcagcac cttgtgcttt cagatatctg 1800 tttcaatggc attttgtggc atttgtcttt accgagtgcc aataaatttt ctttgagcag 1860 ctaaaaaa 1868 19 1140 DNA Homo sapiens 19 ggaaacatga tccagctgaa ggactgattg caggaaaact tggcagctcc ccaaccttgg 60 tggcccaggg agtgtgaggc tgcagcctca gaaggtgtga gcagtggcca cgagaggcag 120 gctggctggg acatgaggtt ggcagagggc aggcaagctg gcccttggtg ggcctcgccc 180 tgagcactcg gaggcactcc tatgcttgga aagctcgcta tgctgctgtg ggtccagcag 240 gcgctgctcg ccttgctcct ccccacactc ctggcacagg gagaagccag gaggagccga 300 aacaccacca ggcccgctct gctgaggctg tcggattacc ttttgaccaa ctacaggaag 360 ggtgtgcgcc ccgtgaggga ctggaggaag ccaaccaccg tatccattga cgtcattgtc 420 tatgccatcc tcaacgtgga tgagaagaat caggtgctga ccacctacat ctggtaccgg 480 cagtactgga ctgatgagtt tctccagtgg aaccctgagg actttgacaa catcaccaag 540 ttgtccatcc ccacggacag catctgggtc ccggacattc tcatcaatga gttcgtggat 600 gtggggaagt ctccaaatat cccgtacgtg tatattcggc atcaaggcga agttcagaac 660 tacaagcccc ttcaggtggt gactgcctgt agcctcgaca tctacaactt ccccttcgat 720 gtccagaact gctcgctgac cttcaccagt tggctgcaca ccacccagta cttcacatct 780 tctttgtgtc gtttgccaga taaagtgtaa atccgacagc agctcaccat ggctttaaaa 840 catgctctct tagatcagga gaaactcggg cactccctaa gtccactcta gttgtggact 900 tttccccatt gaccctcacc tgaataaggg actttggaat tctgcttctc tttcacaact 960 ttgcttttag gttgaaggca aaaccaactc tctactacac aggcctgata actctgtacg 1020 aggcttctct aacccctagt gtcttttttt tcttcacctc acttgtggca gcttccctga 1080 acactcatcc cccatcagat gatgggagtg ggaagaataa aatgcagtga aacccatcaa 1140 20 963 DNA Homo sapiens 20 aattccgggt cactccccct ctctgagctt ggaaagctcg ctatgctgct gtgggtccag 60 caggcgctgc tcgccttgct cctccccaca ctcctggcac agggagaagc caggaggagc 120 cgaaacacca ccaggcccgc tctgctgagg ctgtcggatt accttttgac caactacagg 180 aagggtgtgc gccccgtgag ggactggagg aagccaacca ccgtatccat tgacgtcatt 240 gtctatgcca tcctcaacgt ggatgagaag aatcaggtgc tgaccaccta catctggtac 300 cggcagtact ggactgatga gtttctccag tggaaccctg aggactttga caacatcacc 360 aagttgtcca tccccacgga cagcatctgg gtcccggaca ttctcatcaa tgagttcgtg 420 gatgtgggga agtctccaaa tatcccgtac gtgtatattc ggcatcaagg cgaagttcag 480 aactacaagc cccttcaggt ggtgactgcc tgtagcctcg acatctacaa cttccccttc 540 gatgtccaga actgctcgct gaccttcacc agttggctgc acaccaccca gtacttcaca 600 tcttctttgt gtcgtttgcc agataaagtg taaatccgac agcagctcac catggcttta 660 aaacatgctc tcttagatca ggagaaactc gggcactccc taagtccact ctagttgtgg 720 acttttcccc attgaccctc acctgaataa gggactttgg aattctgctt ctctttcaca 780 actttgcttt taggttgaag gcaaaaccaa ctctctacta cacaggcctg ataactctgt 840 acgaggcttc tctaacccct agtgtctttt ttttcttcac ctcacttgtg gcagcttccc 900 tgaacactca tcccccatca gatgatggga gtgggaagaa taaaatgcag tgaaacccat 960 caa 963 21 1444 DNA Homo sapiens 21 gcctcgctcg ggcgcccagt ggtcctgccg cctggtctca cctcgccatg gttcgtctgc 60 ctctgcagtg cgtcctctgg ggctgcttgc tgaccgctgt ccatccagaa ccacccactg 120 catgcagaga aaaacagtac ctaataaaca gtcagtgctg ttctttgtgc cagccaggac 180 agaaactggt gagtgactgc acagagttca ctgaaacgga atgccttcct tgcggtgaaa 240 gcgaattcct agacacctgg aacagagaga cacactgcca ccagcacaaa tactgcgacc 300 ccaacctagg gcttcgggtc cagcagaagg gcacctcaga aacagacacc atctgcacct 360 gtgaagaagg ctggcactgt acgagtgagg cctgtgagag ctgtgtcctg caccgctcat 420 gctcgcccgg ctttggggtc aagcagattg ctacaggggt ttctgatacc atctgcgagc 480 cctgcccagt cggcttcttc tccaatgtgt catctgcttt cgaaaaatgt cacccttgga 540 caaggtcccc aggatcggct gagagccctg gtggtgatcc ccatcatctt cgggatcctg 600 tttgccatcc tcttggtgct ggtctttatc aaaaaggtgg ccaagaagcc aaccaataag 660 gccccccacc ccaagcagga accccaggag atcaattttc ccgacgatct tcctggctcc 720 aacactgctg ctccagtgca ggagacttta catggatgcc aaccggtcac ccaggaggat 780 ggcaaagaga gtcgcatctc agtgcaggag agacagtgag gctgcaccca cccaggagtg 840 tggccacgtg ggcaaacagg cagttggcca gagagcctgg tgctgctgct gctgtggcgt 900 gagggtgagg ggctggcact gactgggcat agctccccgc ttctgcctgc acccctgcag 960 tttgagacag gagacctggc actggatgca gaaacagttc accttgaaga acctctcact 1020 tcaccctgga gcccatccag tctcccaact tgtattaaag acagaggcag aagtttggtg 1080 gtggtggtgt tggggtatgg tttagtaata tccaccagac cttccgatcc agcagtttgg 1140 tgcccagaga ggcatcatgg tggcttccct gcgcccagga agccatatac acagatgccc 1200 attgcagcat tgtttgtgat agtgaacaac tggaagctgc ttaactgtcc atcagcagga 1260 gactggctaa ataaaattag aatatattta tacaacagaa tctcaaaaac actgttgagt 1320 aaggaaaaaa aggcatgctg ctgaatgatg ggtatggaac tttttaaaaa aagtacatgc 1380 ttttatgtat gtatattgcc tatggatata tgtataaata caatatgcat catatattga 1440 tata 1444 22 1264 DNA Homo sapiens 22 aaaaggaacc ccaaagctga ctgtgtacac aaatgggctt tccataagtt cattacattt 60 ccttttccaa gtcaggaaaa ctcaacagtg gtagctactg tggtctgtcc ttgaagattc 120 tgagcagtgc aaatgtaata tcctgcatca atcgtctcga agtcttccac tgtaatgaca 180 ctctgggaga ttctcgtggt gtgtcccagt cctctgtgga tcaacctcca agtgtcttgg 240 atcgtcacag gcctttcatc cttctgccct gggaagatcc aggtgaactc cacctccaaa 300 acgggctcca cctacatctt ttttacagag aaaggagaac tctttgtacc ttctcccagc 360 tacttcgatg ttgtctactt gaacccggac agacaggctg tggttccttg tcgggtgacc 420 gtgctgtcgg ccaaagtcac gctccacagg gaattcccag ccaaggagat cccagccaat 480 ggaacggaca ttgtttatga catgaagcgg ggctttgtgt atctgcaacc tcattccgag 540 caccagggtg tggtttactg cagggcggag gccgggggca gatctcagat ctccgtcaag 600 taccagctgc tctacgtggc ggttcccagt ggccctccct caacaaccat cttggcttct 660 tcaaacaaag tgaaaagtgg ggacgacatc agtgtgctct gcactgtcct gggggagccc 720 gatgtggagg tggagttcac ctggatcttc ccagggcaga aggatgaaag gcctgtgacg 780 atccaagaca cttggaggtt gatccacaga ggactgggac acaccacgag aatctcccag 840 agtgtcatta cagtggaaga cttcgagacg attgatgcag gatattacat ttgcactgct 900 cagaatcttc aaggacagac cacagtagct accactgttg agttttcctg acttggaaaa 960 ggaaatgtaa tgaacttatg gaaagcccat ttgtgtacac agtcagcttt ggggttcctt 1020 ttattagtgc tttgccagag gctgatgtca agcaccacac cccaacccca gcgtctcgtg 1080 agtccgaccc agacatccaa actaaaagga agtcatccag tctattcaca gaagtgttaa 1140 cttttctaac agaaagcatg attttgattg cttacctaca tacgtgttcc tagtttttat 1200 acatgtgtaa acaattttat ataatcaatc atttctatta aatgagcacg tttttgtaaa 1260 aaat 1264 23 883 DNA Homo sapiens misc_feature (92)..(92) n is a, c, g, or t 23 attgccatcc catggtcagc gccttgacca aaggtgtgga agtcgtggta acaatatgga 60 gttccaagtg cttttgagtc aaatgccccg gnaccngctg tcaaacggga tttgggtcca 120 ggcacttggt ctcaaaaaag tacttgtttg aatacactgt tgttaatgtt cacctctccc 180 aacaccatca cctccttgcc cttgatgtct gtggcggtgg tcttatcccc aacccacacg 240 ctgactccgt tcaccccgtg tgctgtttag cacccagcct ccccgtgaag ctgcagacac 300 tcaggatctg gacttcgagg tcggtggtgc tgcccccttc aacaggactc acaggagcaa 360 gcggtcatca tcccatccca tcttccacag gggcgaattc tcggtgtgtg acagtgtcag 420 cgtgtgggtt ggggataaga ccaccgccac agacatcaag ggcaaggagg tgatggtgtt 480 gggagaggtg aacattaaca acagtgtatt caaacaagta cttttttgag accaagtgcc 540 gggacccaaa tcccgttgac agcgggtgcc ggggcattga ctcaaagcac tggaactcat 600 attgtaccac gactcacacc tttgtcaagg cgctgaccat ggatggcaag caggctgcct 660 ggcggtttat ccggatagat acggcctgtg tgtgtgtgct cagcaggaag gctgtgagaa 720 gagcctgacc tgccgacacg ctccctcccc ctgccccttc tacactctcc tgggcccctc 780 cctacctcaa cctgtaaatt attttaaatt ataaggactg catggtaatt tatagtttat 840 acagttttaa agaatcatta tttattaaat ttttggaagc aaa 883 24 1584 DNA Homo sapiens misc_feature (27)..(27) n is a, c, g, or t 24 tccacccctc ctctcatggg tactgtnggg gaggatgggt gccacaggac cacacaggtg 60 gctgtctgag agggtagtgc ctgggaactt tctggaagcc tgtttgggga agcagatggg 120 gtgaaggatt cagttagtgt atgtggggtc gtgacaccat ctacccactg tctctctcct 180 gccttcatca tcctctagaa atacagcaac aattcctggc gatacctcag caaccggctg 240 ctggcaccca gcgactcgcc agagtggtta tcttttgatg tcaccggagt tgtgcggcag 300 tggttgagcc gtggagggga aattgagggc tttcgcctta gcgcccactg ctcctgtgac 360 agcagggata acacactgca agtggacatc aacgggttca ctaccggccg ccgaggtgac 420 ctggccacca ttcatggcat gaaccggcct ttcctgcttc tcatggccac cccgctggag 480 agggcccagc atctgcaaag ctcccggcac cgccgagccc tggacaccaa ctattgcttc 540 agctccacgg agaagaactg ctgcgtgcgg cagctgtaca ttgacttccg caaggacctc 600 ggctggaagt ggatccacga gcccaagggc taccatgcca acttctgcct cgggccctgc 660 ccctacattt ggagcctgga cacgcagtac agcaaggtcc tggccctgta caaccagcat 720 aacccgggcg cctcggcggc gccgtgctgc gtgccgcagg cgctggagcc gctgcccatc 780 gtgtactacg tgggccgcaa gcccaaggtg gagcagctgt ccaacatgat cgtgcgctcc 840 tgcaagtgca gctgaggtcc cgccccgccc cgccccgccc cggcaggccc ggccccaccc 900 cgccccgccc ccgctgcctt gcccatgggg gctgtattta aggacacccg tgccccaagc 960 ccacctgggg ccccattaaa gatggagaga ggactgcgga tctctgtgtc attgggcgcc 1020 tgcctggggt ctccatccct gacgttcccc cactcccact ccctctctct ccctctctgc 1080 ctcctcctgc ctgtctgcac tattcctttg cccggcatca aggcacaggg gaccagtggg 1140 gaacactact gtagttagat ctatttattg agcaccttgg gcactgttga agtgccttac 1200 attaatgaac tcattcagtc accatagcaa cactctgaga tggcagggac tctgataaca 1260 cccattttaa aggttgagga aacaagccca gagaggttaa gggaggagtt cctgcccacc 1320 aggaacctgc tttagtgggg gatagtgaag aagacaataa aagatagtag ttcaggccag 1380 gcggggtgct cacgcctgta atcctagcac ttttgggagg cagagatggg aggatacttg 1440 aatccaggca tttgagacca gcctgggtaa catagtgaga ccctatctct acaaaacact 1500 tttaaaaaat gtacacctgt ggtcccagct actctggagg ctaaggtggg aggatcactt 1560 gatcctggga ggtcaaggct gcag 1584 25 952 DNA Homo sapiens misc_feature (27)..(27) n is a, c, g, or t 25 tccacccctc ctctcatggg tactgtnggg gaggatgggt gccacaggac cacacaggtg 60 gctgtctgag agggtagtgc ctgggaactt tctggaagcc tgtttgggga agcagatggg 120 gtgaaggatt cagttagtgt atgtggggtc gtgacaccat ctacccactg tctctctcct 180 gccttcatca tcctctagaa atacagcaac aattcctggc gatacctcag caaccggctg 240 ctggcaccca gcgactcgcc agagtggtta tcttttgatg tcaccggagt tgtgcggcag 300 tggttgagcc gtggagggga aattgagggc tttcgcctta gcgcccactg ctcctgtgac 360 agcagggata acacactgca agtggacatc aacgggttca ctaccggccg ccgaggtgac 420 ctggccacca ttcatggcat gaaccggcct ttcctgcttc tcatggccac cccgctggag 480 agggcccagc atctgcaaag ctcccggcac cgccgagccc tggacaccaa ctattgcttc 540 agctccacgg agaagaactg ctgcgtgcgg cagctgtaca ttgacttccg caaggacctc 600 ggctggaagt ggatccacga gcccaagggc taccatgcca acttctgcct cgggccctgc 660 ccctacattt ggagcctgga cacgcagtac agcaagctca atgaacagaa cctcatccag 720 gaagtcccca acatctggca acgtgaagtt ggctaggagg aaggaagtgc cccaaagaga 780 acaagaagaa gaggaccctg cattgacgtt cctctgggaa gcactcattt cctacctttc 840 atttctaaga ccgcatgatc tgggacatcc ttcccttcct cgtcggttcg ctttattgtt 900 cggtctttta ggtcctcgtc cagtgggaca aattacaata ntttgcgctg ga 952 26 756 DNA Homo sapiens 26 aaaaaatcaa ttttggaaga tgtcactgaa caactcttcc aatgtatttc tggattcagt 60 gcccagtaat accaatcgct ttcaagttag tgtcataaat gagaaccatg agagcagtgc 120 agctgcagat gacaatactg acccaccaca ttatgaagaa acctcttttg gggatgaagc 180 tcagaaaaga ctcagaatca gctttaggcc tgggaatcag gagtgctatg acaatttcct 240 ccacagtgga gaaactgcta aaacagatgc cagttttcac gcttatgatt ctcacacaaa 300 cacatactat ctacaaactt ttggccacaa caccatggat gccgttccca agatagagta 360 ctatcgtaac accggcagca tcagtgggcc caaggtcaac cgacccagcc tgcttgagat 420 tcacgagcaa ctcgcaaaga atgtggcagt caccccaagt tcagctgaca gagttgctaa 480 cggtgatggg atacctggag atgaacaagc tgaaaataag gaagatgatc aagctggtgt 540 tgtgaagttt ggatgggtga aaggtgtgct ggtaagatgc atgctgaaca tctggggagt 600 catgctcttc attcgcctct cctggattgt tggagaagct ggaattgagt atccttcttg 660 gcatgattgg taaaacttca ctgaacaaaa ataacttgtg agaaaactgg tgaaaatgtg 720 acctgactaa taaaaatgct gaattgttga actttt 756 27 208 PRT Homo sapiens 27 Ala Leu Gly Gly Thr Pro Met Leu Gly Lys Leu Ala Met Leu Leu Trp 1 5 10 15 Val Gln Gln Ala Leu Leu Ala Leu Leu Leu Pro Thr Leu Leu Ala Gln 20 25 30 Gly Glu Ala Arg Arg Ser Arg Asn Thr Thr Arg Pro Ala Leu Leu Arg 35 40 45 Leu Ser Asp Tyr Leu Leu Thr Asn Tyr Arg Lys Gly Val Arg Pro Val 50 55 60 Arg Asp Trp Arg Lys Pro Thr Thr Val Ser Ile Asp Val Ile Val Tyr 65 70 75 80 Ala Ile Leu Asn Val Asp Glu Lys Asn Gln Val Leu Thr Thr Tyr Ile 85 90 95 Trp Tyr Arg Gln Tyr Trp Thr Asp Glu Phe Leu Gln Trp Asn Pro Glu 100 105 110 Asp Phe Asp Asn Ile Thr Lys Leu Ser Ile Pro Thr Asp Ser Ile Trp 115 120 125 Val Pro Asp Ile Leu Ile Asn Glu Phe Val Asp Val Gly Lys Ser Pro 130 135 140 Asn Ile Pro Tyr Val Tyr Ile Arg His Gln Gly Glu Val Gln Asn Tyr 145 150 155 160 Lys Pro Leu Gln Val Val Thr Ala Cys Ser Leu Asp Ile Tyr Asn Phe 165 170 175 Pro Phe Asp Val Gln Asn Cys Ser Leu Thr Phe Thr Ser Trp Leu His 180 185 190 Thr Thr Gln Tyr Phe Thr Ser Ser Leu Cys Arg Leu Pro Asp Lys Val 195 200 205 28 210 PRT Homo sapiens 28 Asn Ser Gly Ser Leu Pro Leu Ser Glu Leu Gly Lys Leu Ala Met Leu 1 5 10 15 Leu Trp Val Gln Gln Ala Leu Leu Ala Leu Leu Leu Pro Thr Leu Leu 20 25 30 Ala Gln Gly Glu Ala Arg Arg Ser Arg Asn Thr Thr Arg Pro Ala Leu 35 40 45 Leu Arg Leu Ser Asp Tyr Leu Leu Thr Asn Tyr Arg Lys Gly Val Arg 50 55 60 Pro Val Arg Asp Trp Arg Lys Pro Thr Thr Val Ser Ile Asp Val Ile 65 70 75 80 Val Tyr Ala Ile Leu Asn Val Asp Glu Lys Asn Gln Val Leu Thr Thr 85 90 95 Tyr Ile Trp Tyr Arg Gln Tyr Trp Thr Asp Glu Phe Leu Gln Trp Asn 100 105 110 Pro Glu Asp Phe Asp Asn Ile Thr Lys Leu Ser Ile Pro Thr Asp Ser 115 120 125 Ile Trp Val Pro Asp Ile Leu Ile Asn Glu Phe Val Asp Val Gly Lys 130 135 140 Ser Pro Asn Ile Pro Tyr Val Tyr Ile Arg His Gln Gly Glu Val Gln 145 150 155 160 Asn Tyr Lys Pro Leu Gln Val Val Thr Ala Cys Ser Leu Asp Ile Tyr 165 170 175 Asn Phe Pro Phe Asp Val Gln Asn Cys Ser Leu Thr Phe Thr Ser Trp 180 185 190 Leu His Thr Thr Gln Tyr Phe Thr Ser Ser Leu Cys Arg Leu Pro Asp 195 200 205 Lys Val 210 29 169 PRT Homo sapiens 29 Lys Asn Arg Glu Gly Arg Ala Ser Val Thr Gly Cys Leu Ala Asp Leu 1 5 10 15 Gln Gln Ser Asp Ser Asp Arg Ile Met Ala Met Met Glu Val Gln Gly 20 25 30 Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val 35 40 45 Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn 50 55 60 Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile Ala Cys 65 70 75 80 Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser 85 90 95 Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val 100 105 110 Arg Lys Met Ile Leu Arg Thr Ser Glu Glu Thr Ile Ser Thr Val Gln 115 120 125 Glu Lys Gln Gln Asn Ile Ser Pro Leu Val Arg Glu Arg Gly Pro Gln 130 135 140 Arg Val Ala Ala His Ile Thr Gly Thr Arg Gly Arg Ser Asn Thr Leu 145 150 155 160 Ser Ser Pro Asn Ser Arg Arg Ile Val 165 30 271 PRT Homo sapiens 30 Lys Asn Arg Glu Gly Arg Ala Ser Val Thr Gly Cys Leu Ala Asp Leu 1 5 10 15 Gln Gln Ser Asp Ser Asp Arg Ile Met Ala Met Met Glu Val Gln Gly 20 25 30 Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val 35 40 45 Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn 50 55 60 Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile Ala Cys 65 70 75 80 Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser 85 90 95 Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val 100 105 110 Arg Lys Lys Ser Asn Lys Ile Phe Leu Pro Leu Val Arg Glu Arg Gly 115 120 125 Pro Gln Arg Val Ala Ala His Ile Thr Gly Thr Arg Gly Arg Ser Asn 130 135 140 Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu Gly Arg Lys 145 150 155 160 Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser Phe Leu Ser Asn 165 170 175 Leu His Leu Arg Asn Gly Glu Leu Val Ile His Glu Lys Gly Phe Tyr 180 185 190 Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Glu Ile Lys Glu 195 200 205 Asn Thr Lys Asn Asp Lys Gln Met Val Gln Tyr Ile Tyr Lys Tyr Thr 210 215 220 Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys Ser Ala Arg Asn Ser Cys 225 230 235 240 Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Ile 245 250 255 Asp Met Asp His Glu Ala Ser Phe Phe Gly Ala Phe Leu Val Gly 260 265 270 31 122 PRT Homo sapiens 31 Lys Asn Arg Glu Gly Arg Ala Ser Val Thr Gly Cys Leu Ala Asp Leu 1 5 10 15 Gln Gln Ser Asp Ser Asp Arg Ile Met Ala Met Met Glu Val Gln Gly 20 25 30 Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val 35 40 45 Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn 50 55 60 Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile Ala Cys 65 70 75 80 Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser 85 90 95 Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val 100 105 110 Arg Lys Lys Ser Asn Lys Ile Phe Leu Pro 115 120 32 120 PRT Homo sapiens 32 Lys Asn Arg Glu Gly Arg Ala Ser Val Thr Gly Cys Leu Ala Asp Leu 1 5 10 15 Gln Gln Ser Asp Ser Asp Arg Ile Met Ala Met Met Glu Val Gln Gly 20 25 30 Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val 35 40 45 Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn 50 55 60 Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile Ala Cys 65 70 75 80 Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser 85 90 95 Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val 100 105 110 Arg Lys Val Gly Asn Leu Thr Arg 115 120 33 218 PRT Homo sapiens 33 Leu Ala Arg Ala Pro Ser Gly Pro Ala Ala Trp Ser His Leu Ala Met 1 5 10 15 Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr Ala 20 25 30 Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu Ile 35 40 45 Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val Ser 50 55 60 Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu Ser 65 70 75 80 Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His Lys 85 90 95 Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr Ser 100 105 110 Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr Ser 115 120 125 Glu Ala Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly Phe 130 135 140 Gly Val Lys Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu Pro 145 150 155 160 Cys Pro Val Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys Cys 165 170 175 His Pro Trp Thr Arg Ser Pro Gly Ser Ala Glu Ser Pro Gly Gly Asp 180 185 190 Pro His His Leu Arg Asp Pro Val Cys His Pro Leu Gly Ala Gly Leu 195 200 205 Tyr Gln Lys Gly Gly Gln Glu Ala Asn Gln 210 215 34 198 PRT Homo sapiens 34 Gly Arg Ala Arg Ser Thr Gln Arg Glu Glu Ala Gly Glu Gly Ala Arg 1 5 10 15 Ser Arg Glu Lys Ala Thr Arg Pro Lys Leu Lys Lys Met Lys Ser Gln 20 25 30 Thr Gly Gln Val Gly Glu Lys Gln Ser Leu Lys Cys Glu Ala Ala Ala 35 40 45 Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys Asp Gly Lys Glu Leu 50 55 60 Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly Asn Gly Arg Lys Asn 65 70 75 80 Ser Arg Leu Gln Phe Asn Lys Val Lys Val Glu Asp Ala Gly Glu Tyr 85 90 95 Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr Val Arg Gly Arg 100 105 110 Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser Ser Trp Ser Gly His 115 120 125 Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys Val Asn Gly Gly 130 135 140 Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu Ser Cys Lys Ala Pro 145 150 155 160 Gly Leu His Cys Leu Glu Leu Gly Thr Gln Ser His His Phe Pro Ile 165 170 175 Ser Ala Ser Pro Gly Ser Ser Gln Gly Ser Trp Asn Gln Leu Pro Gln 180 185 190 His Pro Leu Ser Ala Leu 195 35 637 PRT Homo sapiens 35 Gly Arg Ala Arg Ser Thr Gln Arg Glu Glu Ala Gly Glu Gly Ala Arg 1 5 10 15 Ser Arg Glu Lys Ala Thr Arg Pro Lys Leu Lys Lys Met Lys Ser Gln 20 25 30 Thr Gly Gln Val Gly Glu Lys Gln Ser Leu Lys Cys Glu Ala Ala Ala 35 40 45 Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys Asp Gly Lys Glu Leu 50 55 60 Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly Asn Gly Arg Lys Asn 65 70 75 80 Ser Arg Leu Gln Phe Asn Lys Val Lys Val Glu Asp Ala Gly Glu Tyr 85 90 95 Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr Val Arg Gly Arg 100 105 110 Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser Ser Trp Ser Gly His 115 120 125 Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys Val Asn Gly Gly 130 135 140 Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu Ser Cys Lys Cys Pro 145 150 155 160 Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys Leu Pro Leu Arg Leu 165 170 175 Tyr Met Pro Asp Pro Lys Gln Lys Ala Glu Glu Leu Tyr Gln Lys Arg 180 185 190 Val Leu Thr Ile Thr Gly Ile Cys Val Ala Leu Leu Val Val Gly Ile 195 200 205 Val Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Gln Met 210 215 220 His Asn His Leu Arg Gln Asn Met Cys Pro Ala His Gln Asn Arg Ser 225 230 235 240 Leu Ala Asn Gly Pro Ser His Pro Arg Leu Asp Pro Glu Glu Ile Gln 245 250 255 Met Ala Asp Tyr Ile Ser Lys Asn Val Pro Ala Thr Asp His Val Ile 260 265 270 Arg Arg Glu Thr Glu Thr Thr Phe Ser Gly Ser His Ser Cys Ser Pro 275 280 285 Ser His His Cys Ser Thr Ala Thr Pro Thr Ser Ser His Arg His Glu 290 295 300 Ser His Thr Trp Ser Leu Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser 305 310 315 320 Gln Ser Gly Ile Met Leu Ser Ser Val Gly Thr Ser Lys Cys Asn Ser 325 330 335 Pro Ala Cys Val Glu Ala Arg Ala Arg Arg Ala Ala Ala Tyr Asn Leu 340 345 350 Glu Glu Arg Arg Arg Ala Thr Ala Pro Pro Tyr His Asp Ser Val Asp 355 360 365 Ser Leu Arg Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Leu Thr 370 375 380 Thr Pro Ala Arg Leu Ser Pro Val Asp Phe His Tyr Ser Leu Ala Thr 385 390 395 400 Gln Val Pro Thr Phe Glu Ile Thr Ser Pro Asn Ser Ala His Ala Val 405 410 415 Ser Leu Pro Pro Ala Ala Pro Ile Ser Tyr Arg Leu Ala Glu Gln Gln 420 425 430 Pro Leu Leu Arg His Pro Ala Pro Pro Gly Pro Gly Pro Gly Pro Gly 435 440 445 Pro Gly Pro Gly Pro Gly Ala Asp Met Gln Arg Ser Tyr Asp Ser Tyr 450 455 460 Tyr Tyr Pro Ala Ala Gly Pro Gly Pro Arg Arg Gly Thr Cys Ala Leu 465 470 475 480 Gly Gly Ser Leu Gly Ser Leu Pro Ala Ser Pro Phe Arg Ile Pro Glu 485 490 495 Asp Asp Glu Tyr Glu Thr Thr Gln Glu Cys Ala Pro Pro Pro Pro Pro 500 505 510 Arg Pro Arg Ala Arg Gly Ala Ser Arg Arg Thr Ser Ala Gly Pro Arg 515 520 525 Arg Trp Arg Arg Ser Arg Leu Asn Gly Leu Ala Ala Gln Arg Ala Arg 530 535 540 Ala Ala Arg Asp Ser Leu Ser Leu Ser Ser Gly Ser Gly Gly Gly Ser 545 550 555 560 Ala Ser Ala Ser Asp Asp Asp Ala Asp Asp Ala Asp Gly Ala Leu Ala 565 570 575 Ala Glu Ser Thr Pro Phe Leu Gly Leu Arg Gly Ala His Asp Ala Leu 580 585 590 Arg Ser Asp Ser Pro Pro Leu Cys Pro Ala Ala Asp Ser Arg Thr Tyr 595 600 605 Tyr Ser Leu Asp Ser His Ser Thr Arg Ala Ser Ser Arg His Ser Arg 610 615 620 Gly Pro Pro Pro Arg Ala Lys Gln Asp Ser Ala Pro Leu 625 630 635 36 421 PRT Homo sapiens misc_feature (74)..(74) Xaa = any amino acid, unknown or other 36 Ala Ala Glu Pro Pro Lys Trp Pro Gly Gln Met Arg Gln Val Cys Cys 1 5 10 15 Ser Ala Leu Pro Pro Pro Pro Leu Glu Lys Gly Arg Cys Ser Ser Tyr 20 25 30 Ser Asp Ser Ser Ser Ser Ser Ser Glu Arg Ser Ser Ser Ser Ser Ser 35 40 45 Ser Ser Ser Glu Ser Gly Ser Ser Ser Arg Ser Ser Ser Asn Asn Ser 50 55 60 Ser Ile Ser Arg Pro Ala Ala Pro Pro Xaa Pro Arg Pro Gln Gln Gln 65 70 75 80 Pro Gln Pro Arg Ser Pro Ala Ala Arg Arg Ala Ala Ala Arg Ser Arg 85 90 95 Ala Ala Ala Ala Gly Gly Met Arg Arg Asp Pro Ala Pro Gly Phe Ser 100 105 110 Met Leu Leu Phe Gly Val Ser Leu Ala Cys Tyr Ser Pro Ser Leu Lys 115 120 125 Ser Val Gln Asp Gln Ala Tyr Lys Ala Pro Val Val Val Glu Gly Lys 130 135 140 Val Gln Gly Leu Val Pro Ala Gly Gly Ser Ser Ser Asn Ser Thr Arg 145 150 155 160 Glu Pro Pro Ala Ser Gly Arg Val Ala Leu Val Lys Val Leu Asp Lys 165 170 175 Trp Pro Leu Arg Ser Gly Gly Leu Gln Arg Glu Gln Val Ile Ser Val 180 185 190 Gly Ser Cys Val Pro Leu Glu Arg Asn Gln Arg Tyr Ile Phe Phe Leu 195 200 205 Glu Pro Thr Glu Gln Pro Leu Val Phe Lys Thr Ala Phe Ala Pro Leu 210 215 220 Asp Thr Asn Gly Lys Asn Leu Lys Lys Glu Val Gly Lys Ile Leu Cys 225 230 235 240 Thr Asp Cys Ala Thr Arg Pro Lys Leu Lys Lys Met Lys Ser Gln Thr 245 250 255 Gly Gln Val Gly Glu Lys Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly 260 265 270 Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn 275 280 285 Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser 290 295 300 Arg Leu Gln Phe Asn Lys Val Lys Val Glu Asp Ala Gly Glu Tyr Val 305 310 315 320 Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr Val Arg Gly Arg Leu 325 330 335 Tyr Val Asn Ser Val Ser Thr Thr Leu Ser Ser Trp Ser Gly His Ala 340 345 350 Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys Val Asn Gly Gly Val 355 360 365 Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu Ser Cys Lys Ala Pro Gly 370 375 380 Leu His Cys Leu Glu Leu Gly Thr Gln Ser His His Phe Pro Ile Ser 385 390 395 400 Ala Ser Pro Gly Ser Ser Gln Gly Ser Trp Asn Gln Leu Pro Gln His 405 410 415 Pro Leu Ser Ala Leu 420 37 270 PRT Homo sapiens 37 Tyr Pro Ala Ser Ile Val Ser Lys Ser Ser Thr Val Met Thr Leu Trp 1 5 10 15 Glu Ile Leu Val Val Cys Pro Ser Pro Leu Trp Ile Asn Leu Gln Val 20 25 30 Ser Trp Ile Val Thr Gly Leu Ser Ser Phe Cys Pro Gly Lys Ile Gln 35 40 45 Val Asn Ser Thr Ser Lys Thr Gly Ser Thr Tyr Ile Phe Phe Thr Glu 50 55 60 Lys Gly Glu Leu Phe Val Pro Ser Pro Ser Tyr Phe Asp Val Val Tyr 65 70 75 80 Leu Asn Pro Asp Arg Gln Ala Val Val Pro Cys Arg Val Thr Val Leu 85 90 95 Ser Ala Lys Val Thr Leu His Arg Glu Phe Pro Ala Lys Glu Ile Pro 100 105 110 Ala Asn Gly Thr Asp Ile Val Tyr Asp Met Lys Arg Gly Phe Val Tyr 115 120 125 Leu Gln Pro His Ser Glu His Gln Gly Val Val Tyr Cys Arg Ala Glu 130 135 140 Ala Gly Gly Arg Ser Gln Ile Ser Val Lys Tyr Gln Leu Leu Tyr Val 145 150 155 160 Ala Val Pro Ser Gly Pro Pro Ser Thr Thr Ile Leu Ala Ser Ser Asn 165 170 175 Lys Val Lys Ser Gly Asp Asp Ile Ser Val Leu Cys Thr Val Leu Gly 180 185 190 Glu Pro Asp Val Glu Val Glu Phe Thr Trp Ile Phe Pro Gly Gln Lys 195 200 205 Asp Glu Arg Pro Val Thr Ile Gln Asp Thr Trp Arg Leu Ile His Arg 210 215 220 Gly Leu Gly His Thr Thr Arg Ile Ser Gln Ser Val Ile Thr Val Glu 225 230 235 240 Asp Phe Glu Thr Ile Asp Ala Gly Tyr Tyr Ile Cys Thr Ala Gln Asn 245 250 255 Leu Gln Gly Gln Thr Thr Val Ala Thr Thr Val Glu Phe Ser 260 265 270 38 223 PRT Homo sapiens 38 Lys Asn Gln Phe Trp Lys Met Ser Leu Asn Asn Ser Ser Asn Val Phe 1 5 10 15 Leu Asp Ser Val Pro Ser Asn Thr Asn Arg Phe Gln Val Ser Val Ile 20 25 30 Asn Glu Asn His Glu Ser Ser Ala Ala Ala Asp Asp Asn Thr Asp Pro 35 40 45 Pro His Tyr Glu Glu Thr Ser Phe Gly Asp Glu Ala Gln Lys Arg Leu 50 55 60 Arg Ile Ser Phe Arg Pro Gly Asn Gln Glu Cys Tyr Asp Asn Phe Leu 65 70 75 80 His Ser Gly Glu Thr Ala Lys Thr Asp Ala Ser Phe His Ala Tyr Asp 85 90 95 Ser His Thr Asn Thr Tyr Tyr Leu Gln Thr Phe Gly His Asn Thr Met 100 105 110 Asp Ala Val Pro Lys Ile Glu Tyr Tyr Arg Asn Thr Gly Ser Ile Ser 115 120 125 Gly Pro Lys Val Asn Arg Pro Ser Leu Leu Glu Ile His Glu Gln Leu 130 135 140 Ala Lys Asn Val Ala Val Thr Pro Ser Ser Ala Asp Arg Val Ala Asn 145 150 155 160 Gly Asp Gly Ile Pro Gly Asp Glu Gln Ala Glu Asn Lys Glu Asp Asp 165 170 175 Gln Ala Gly Val Val Lys Phe Gly Trp Val Lys Gly Val Leu Val Arg 180 185 190 Cys Met Leu Asn Ile Trp Gly Val Met Leu Phe Ile Arg Leu Ser Trp 195 200 205 Ile Val Gly Glu Ala Gly Ile Glu Tyr Pro Ser Trp His Asp Trp 210 215 220 39 460 PRT Homo sapiens 39 Met Ala Val Thr Gln Phe Ile His Phe Arg Glu Glu Ile Met Gly Asn 1 5 10 15 Met Phe Phe Ile Ile Ile Phe Ser Thr Lys Asp Lys Leu Cys Tyr Arg 20 25 30 Asp Gly Glu Glu Tyr Glu Trp Lys Glu Thr Ala Arg Trp Leu Lys Phe 35 40 45 Glu Glu Asp Val Glu Asp Gly Gly Asp Arg Trp Ser Lys Pro Tyr Val 50 55 60 Ala Thr Leu Ser Leu His Ser Leu Phe Glu Leu Arg Ser Cys Ile Leu 65 70 75 80 Asn Gly Thr Val Met Leu Asp Met Arg Ala Ser Thr Leu Asp Glu Ile 85 90 95 Ala Asp Met Val Leu Asp Asn Met Ile Ala Ser Gly Gln Leu Asp Glu 100 105 110 Ser Ile Arg Glu Asn Val Arg Glu Ala Leu Leu Lys Arg His His His 115 120 125 Gln Asn Glu Lys Arg Phe Thr Ser Arg Ile Pro Leu Val Arg Ser Phe 130 135 140 Ala Asp Ile Gly Lys Lys His Ser Asp Pro His Leu Leu Glu Arg Asn 145 150 155 160 Gly Ile Leu Ala Ser Pro Gln Ser Ala Pro Gly Asn Leu Asp Asn Ser 165 170 175 Lys Ser Gly Glu Ile Lys Gly Asn Gly Ser Gly Gly Ser Arg Glu Asn 180 185 190 Ser Thr Val Asp Phe Ser Lys Val Asp Met Asn Phe Met Arg Lys Ile 195 200 205 Pro Thr Gly Ala Glu Ala Ser Asn Val Leu Val Gly Glu Val Asp Phe 210 215 220 Leu Glu Arg Pro Ile Ile Ala Phe Val Arg Leu Ala Pro Ala Val Leu 225 230 235 240 Leu Thr Gly Leu Thr Glu Val Pro Val Pro Thr Arg Phe Leu Phe Leu 245 250 255 Leu Leu Gly Pro Ala Gly Lys Ala Pro Gln Tyr His Glu Ile Gly Arg 260 265 270 Ser Ile Ala Thr Leu Met Thr Asp Glu Ile Phe His Asp Val Ala Tyr 275 280 285 Lys Ala Lys Asp Arg Asn Asp Leu Leu Ser Gly Ile Asp Glu Phe Leu 290 295 300 Asp Gln Val Thr Val Leu Pro Pro Gly Glu Trp Asp Pro Ser Ile Arg 305 310 315 320 Ile Glu Pro Pro Lys Ser Val Pro Ser Gln Glu Lys Arg Lys Ile Pro 325 330 335 Val Phe His Asn Gly Ser Thr Pro Thr Leu Gly Glu Thr Pro Lys Glu 340 345 350 Ala Ala His His Ala Gly Pro Glu Leu Gln Arg Thr Gly Arg Leu Phe 355 360 365 Gly Gly Leu Ile Leu Asp Ile Lys Arg Lys Ala Pro Phe Phe Leu Ser 370 375 380 Asp Phe Lys Asp Ala Leu Ser Leu Gln Cys Leu Ala Ser Ile Leu Phe 385 390 395 400 Leu Tyr Cys Ala Cys Met Ser Pro Val Ile Thr Phe Gly Gly Leu Leu 405 410 415 Gly Glu Ala Thr Glu Gly Arg Ile Val Ser Thr Lys Ile Gly Ser Gly 420 425 430 Gln Ala Phe Ser Ser Ser Glu Ala Ser Val Cys Met His Leu Ser His 435 440 445 Tyr Ser Tyr Phe Tyr Leu Lys Ser Leu Pro Thr Ala 450 455 460 40 175 PRT Homo sapiens 40 Met Ala Val Thr Gln Phe Ile His Phe Arg Glu Glu Ile Met Gly Asn 1 5 10 15 Met Phe Phe Ile Ile Ile Phe Ser Thr Lys Asp Lys Leu Cys Tyr Arg 20 25 30 Asp Gly Glu Glu Tyr Glu Trp Lys Glu Thr Ala Arg Trp Leu Lys Phe 35 40 45 Glu Glu Asp Val Glu Asp Gly Gly Asp Arg Trp Ser Lys Pro Tyr Val 50 55 60 Ala Thr Leu Ser Leu His Ser Leu Phe Glu Leu Arg Ser Cys Ile Leu 65 70 75 80 Asn Gly Thr Val Met Leu Asp Met Arg Ala Ser Thr Leu Asp Glu Ile 85 90 95 Ala Asp Met Val Leu Asp Asn Met Ile Ala Ser Gly Gln Leu Asp Glu 100 105 110 Ser Ile Arg Glu Asn Val Arg Glu Ala Leu Leu Lys Arg His His His 115 120 125 Gln Asn Glu Lys Arg Phe Thr Ser Arg Ile Pro Leu Val Arg Ser Phe 130 135 140 Ala Asp Ile Gly Lys Lys His Ser Asp Pro His Leu Leu Glu Arg Asn 145 150 155 160 Gly Glu Ile Ser Cys Gly Ile Gln Phe Leu Leu Thr Leu Leu Leu 165 170 175 41 922 PRT Homo sapiens 41 Ile Asp Met Val Leu Asp Asn Met Ile Ala Ser Gly Gln Leu Asp Glu 1 5 10 15 Ser Ile Arg Glu Asn Val Arg Glu Ala Leu Leu Lys Arg His His His 20 25 30 Gln Asn Glu Lys Arg Phe Thr Ser Arg Ile Pro Leu Val Arg Ser Phe 35 40 45 Ala Asp Ile Gly Lys Lys His Ser Asp Pro His Leu Leu Glu Arg Asn 50 55 60 Gly Ile Leu Ala Ser Pro Gln Ser Ala Pro Gly Asn Leu Asp Asn Ser 65 70 75 80 Lys Ser Gly Glu Ile Lys Gly Asn Gly Ser Gly Gly Ser Arg Glu Asn 85 90 95 Ser Thr Val Asp Phe Ser Lys Val Asp Met Asn Phe Met Arg Lys Ile 100 105 110 Pro Thr Gly Ala Glu Ala Ser Asn Val Leu Val Gly Glu Val Asp Phe 115 120 125 Leu Glu Arg Pro Ile Ile Ala Phe Val Arg Leu Ala Pro Ala Val Leu 130 135 140 Leu Thr Gly Leu Thr Glu Val Pro Val Pro Thr Arg Phe Leu Phe Leu 145 150 155 160 Leu Leu Gly Pro Ala Gly Lys Ala Pro Gln Tyr His Glu Ile Gly Arg 165 170 175 Ser Ile Ala Thr Leu Met Thr Asp Glu Ile Phe His Asp Val Ala Tyr 180 185 190 Lys Ala Lys Asp Arg Asn Asp Leu Leu Ser Gly Ile Asp Glu Phe Leu 195 200 205 Asp Gln Val Thr Val Leu Pro Pro Gly Glu Trp Asp Pro Ser Ile Arg 210 215 220 Ile Glu Pro Pro Lys Ser Val Pro Ser Gln Glu Lys Arg Lys Ile Pro 225 230 235 240 Val Phe His Asn Gly Ser Thr Pro Thr Leu Gly Glu Thr Pro Lys Glu 245 250 255 Ala Ala His His Ala Gly Pro Glu Leu Gln Arg Thr Gly Arg Leu Phe 260 265 270 Gly Gly Leu Ile Leu Asp Ile Lys Arg Lys Ala Pro Phe Phe Leu Ser 275 280 285 Asp Phe Lys Asp Ala Leu Ser Leu Gln Cys Leu Ala Ser Ile Leu Phe 290 295 300 Leu Tyr Cys Ala Cys Met Ser Pro Val Ile Thr Phe Gly Gly Leu Leu 305 310 315 320 Gly Glu Ala Thr Glu Gly Arg Ile Ser Ala Ile Glu Ser Leu Phe Gly 325 330 335 Ala Ser Leu Thr Gly Ile Ala Tyr Ser Leu Phe Ala Gly Gln Pro Leu 340 345 350 Thr Ile Leu Gly Ser Thr Gly Pro Val Leu Val Phe Glu Lys Ile Leu 355 360 365 Tyr Lys Phe Cys Arg Asp Tyr Gln Leu Ser Tyr Leu Ser Leu Arg Thr 370 375 380 Ser Ile Gly Leu Trp Thr Ser Phe Leu Cys Ile Val Leu Val Ala Thr 385 390 395 400 Asp Ala Ser Ser Leu Val Cys Tyr Ile Thr Arg Phe Thr Glu Glu Ala 405 410 415 Phe Ala Ala Leu Ile Cys Ile Ile Phe Ile Tyr Glu Ala Leu Glu Lys 420 425 430 Leu Phe Asp Leu Gly Glu Thr Tyr Ala Phe Asn Met His Asn Asn Leu 435 440 445 Asp Lys Leu Thr Ser Tyr Ser Cys Val Cys Thr Glu Pro Pro Asn Pro 450 455 460 Ser Asn Glu Thr Leu Ala Gln Trp Lys Lys Asp Asn Ile Thr Ala His 465 470 475 480 Asn Ile Ser Trp Arg Asn Leu Thr Val Ser Glu Cys Lys Lys Leu Arg 485 490 495 Gly Val Phe Leu Gly Ser Ala Cys Gly His His Gly Pro Tyr Ile Pro 500 505 510 Asp Val Leu Phe Trp Cys Val Ile Leu Phe Phe Thr Thr Phe Phe Leu 515 520 525 Ser Ser Phe Leu Lys Gln Phe Lys Thr Lys Arg Tyr Phe Pro Thr Lys 530 535 540 Val Arg Ser Thr Ile Ser Asp Phe Ala Val Phe Leu Thr Ile Val Ile 545 550 555 560 Met Val Thr Ile Asp Tyr Leu Val Gly Val Pro Ser Pro Lys Leu His 565 570 575 Val Pro Glu Lys Phe Glu Pro Thr His Pro Glu Arg Gly Trp Ile Ile 580 585 590 Ser Pro Leu Gly Asp Asn Pro Trp Trp Thr Leu Leu Ile Ala Ala Ile 595 600 605 Pro Ala Leu Leu Cys Thr Ile Leu Ile Phe Met Asp Gln Gln Ile Thr 610 615 620 Ala Val Ile Ile Asn Arg Lys Glu His Lys Leu Lys Lys Gly Ala Gly 625 630 635 640 Tyr His Leu Asp Leu Leu Met Val Gly Val Met Leu Gly Val Cys Ser 645 650 655 Val Met Gly Leu Pro Trp Phe Val Ala Ala Thr Val Leu Ser Ile Ser 660 665 670 His Val Asn Ser Leu Lys Val Glu Ser Glu Cys Ser Ala Pro Gly Glu 675 680 685 Gln Pro Lys Phe Leu Gly Ile Arg Glu Gln Arg Val Thr Gly Leu Met 690 695 700 Ile Phe Ile Leu Met Gly Leu Ser Val Phe Met Thr Ser Val Leu Lys 705 710 715 720 Phe Ile Pro Met Pro Val Leu Tyr Gly Val Phe Leu Tyr Met Gly Val 725 730 735 Ser Ser Leu Lys Gly Ile Gln Leu Phe Asp Arg Ile Lys Leu Phe Gly 740 745 750 Met Pro Ala Lys His Gln Pro Asp Leu Ile Tyr Leu Arg Tyr Val Pro 755 760 765 Leu Trp Lys Val His Ile Phe Thr Val Ile Gln Leu Thr Cys Leu Val 770 775 780 Leu Leu Trp Val Ile Lys Val Ser Ala Ala Ala Val Val Phe Pro Met 785 790 795 800 Met Val Leu Ala Leu Val Phe Val Arg Lys Leu Met Asp Leu Cys Phe 805 810 815 Thr Lys Arg Glu Leu Ser Trp Leu Asp Asp Leu Met Pro Glu Ser Lys 820 825 830 Lys Lys Lys Glu Asp Asp Lys Lys Lys Lys Glu Lys Glu Glu Ala Glu 835 840 845 Arg Met Leu Gln Asp Asp Asp Asp Thr Val His Leu Pro Phe Glu Gly 850 855 860 Gly Ser Leu Leu Gln Ile Pro Val Lys Ala Leu Lys Tyr Ser Gly Asp 865 870 875 880 Pro Ser Ile Gly Asn Ile Ser Asp Glu Met Ala Lys Thr Ala Gln Trp 885 890 895 Lys Ala Leu Ser Met Asn Thr Glu Asn Ala Lys Val Thr Arg Ser Asn 900 905 910 Met Ser Pro Asp Lys Pro Val Ser Val Lys 915 920 42 364 PRT Homo sapiens 42 Ile Asp Met Val Leu Asp Asn Met Ile Ala Ser Gly Gln Leu Asp Glu 1 5 10 15 Ser Ile Arg Glu Asn Val Arg Glu Ala Leu Leu Lys Arg His His His 20 25 30 Gln Asn Glu Lys Arg Phe Thr Ser Arg Ile Pro Leu Val Arg Ser Phe 35 40 45 Ala Asp Ile Gly Lys Lys His Ser Asp Pro His Leu Leu Glu Arg Asn 50 55 60 Gly Ile Leu Ala Ser Pro Gln Ser Ala Pro Gly Asn Leu Asp Asn Ser 65 70 75 80 Lys Ser Gly Glu Ile Lys Gly Asn Gly Ser Gly Gly Ser Arg Glu Asn 85 90 95 Ser Thr Val Asp Phe Ser Lys Val Asp Met Asn Phe Met Arg Lys Ile 100 105 110 Pro Thr Gly Ala Glu Ala Ser Asn Val Leu Val Gly Glu Val Asp Phe 115 120 125 Leu Glu Arg Pro Ile Ile Ala Phe Val Arg Leu Ala Pro Ala Val Leu 130 135 140 Leu Thr Gly Leu Thr Glu Val Pro Val Pro Thr Arg Phe Leu Phe Leu 145 150 155 160 Leu Leu Gly Pro Ala Gly Lys Ala Pro Gln Tyr His Glu Ile Gly Arg 165 170 175 Ser Ile Ala Thr Leu Met Thr Asp Glu Ile Phe His Asp Val Ala Tyr 180 185 190 Lys Ala Lys Asp Arg Asn Asp Leu Leu Ser Gly Ile Asp Glu Phe Leu 195 200 205 Asp Gln Val Thr Val Leu Pro Pro Gly Glu Trp Asp Pro Ser Ile Arg 210 215 220 Ile Glu Pro Pro Lys Ser Val Pro Ser Gln Glu Lys Arg Lys Ile Pro 225 230 235 240 Val Phe His Asn Gly Ser Thr Pro Thr Leu Gly Glu Thr Pro Lys Glu 245 250 255 Ala Ala His His Ala Gly Pro Glu Leu Gln Arg Thr Gly Arg Leu Phe 260 265 270 Gly Gly Leu Ile Leu Asp Ile Lys Arg Lys Ala Pro Phe Phe Leu Ser 275 280 285 Asp Phe Lys Asp Ala Leu Ser Leu Gln Cys Leu Ala Ser Ile Leu Phe 290 295 300 Leu Tyr Cys Ala Cys Met Ser Pro Val Ile Thr Phe Gly Gly Leu Leu 305 310 315 320 Gly Glu Ala Thr Glu Gly Arg Ile Val Ser Thr Lys Ile Gly Ser Gly 325 330 335 Gln Ala Phe Ser Ser Ser Glu Ala Ser Val Cys Met His Leu Ser His 340 345 350 Tyr Ser Tyr Phe Tyr Leu Lys Ser Leu Pro Thr Ala 355 360 43 785 PRT Homo sapiens 43 Cys Pro Ser Leu Asp Ile Arg Ser Glu Val Ala Glu Leu Arg Gln Leu 1 5 10 15 Glu Asn Cys Ser Val Val Glu Gly His Leu Gln Ile Leu Leu Met Phe 20 25 30 Thr Ala Thr Gly Glu Asp Phe Arg Gly Leu Ser Phe Pro Arg Leu Thr 35 40 45 Gln Val Thr Asp Tyr Leu Leu Leu Phe Arg Val Tyr Gly Leu Glu Ser 50 55 60 Leu Arg Asp Leu Phe Pro Asn Leu Ala Val Ile Arg Gly Thr Arg Leu 65 70 75 80 Phe Leu Gly Tyr Ala Leu Val Ile Phe Glu Met Pro His Leu Arg Asp 85 90 95 Val Ala Leu Pro Ala Leu Gly Ala Val Leu Arg Gly Ala Val Arg Val 100 105 110 Glu Lys Asn Gln Glu Leu Cys His Leu Ser Thr Ile Asp Trp Gly Leu 115 120 125 Leu Gln Pro Ala Pro Gly Ala Asn His Ile Val Gly Asn Lys Leu Gly 130 135 140 Glu Glu Cys Ala Asp Val Cys Pro Gly Val Leu Gly Ala Ala Gly Glu 145 150 155 160 Pro Cys Ala Lys Thr Thr Phe Ser Gly His Thr Asp Tyr Arg Cys Trp 165 170 175 Thr Ser Ser His Cys Gln Arg Val Cys Pro Cys Pro His Gly Met Ala 180 185 190 Cys Thr Ala Arg Gly Glu Cys Cys His Thr Glu Cys Leu Gly Gly Cys 195 200 205 Ser Gln Pro Glu Asp Pro Arg Ala Cys Val Ala Cys Arg His Leu Tyr 210 215 220 Phe Gln Gly Ala Cys Leu Trp Ala Cys Pro Pro Gly Thr Tyr Gln Tyr 225 230 235 240 Glu Ser Trp Arg Cys Val Thr Ala Glu Arg Cys Ala Ser Leu His Ser 245 250 255 Val Pro Gly Arg Ala Ser Thr Phe Gly Ile His Gln Gly Ser Cys Leu 260 265 270 Ala Gln Cys Pro Ser Gly Phe Thr Arg Asn Ser Ser Ser Ile Phe Cys 275 280 285 His Lys Cys Glu Gly Leu Cys Pro Lys Glu Cys Lys Val Gly Thr Lys 290 295 300 Thr Ile Asp Ser Ile Gln Ala Ala Gln Asp Leu Val Gly Cys Thr His 305 310 315 320 Val Glu Gly Ser Leu Ile Leu Asn Leu Arg Gln Gly Tyr Asn Leu Glu 325 330 335 Pro Gln Leu Gln His Ser Leu Gly Leu Val Glu Thr Ile Thr Gly Phe 340 345 350 Leu Lys Ile Lys His Ser Phe Ala Leu Val Ser Leu Gly Phe Phe Lys 355 360 365 Asn Leu Lys Leu Ile Arg Gly Asp Ala Met Val Asp Gly Asn Tyr Thr 370 375 380 Leu Tyr Val Leu Asp Asn Gln Asn Leu Gln Gln Leu Gly Ser Trp Val 385 390 395 400 Ala Ala Gly Leu Thr Ile Pro Val Gly Lys Ile Tyr Phe Ala Phe Asn 405 410 415 Pro Arg Leu Cys Leu Glu His Ile Tyr Arg Leu Glu Glu Val Thr Gly 420 425 430 Thr Arg Gly Arg Gln Asn Lys Ala Glu Ile Asn Pro Arg Thr Asn Gly 435 440 445 Asp Arg Ala Ala Cys Gln Thr Arg Thr Leu Arg Phe Val Ser Asn Val 450 455 460 Thr Glu Ala Asp Arg Ile Leu Leu Arg Trp Glu Arg Tyr Glu Pro Leu 465 470 475 480 Glu Ala Arg Asp Leu Leu Ser Phe Ile Val Tyr Tyr Lys Glu Ser Pro 485 490 495 Phe Gln Asn Ala Thr Glu His Val Gly Pro Asp Ala Cys Gly Thr Gln 500 505 510 Ser Trp Asn Leu Leu Asp Val Glu Leu Pro Leu Ser Arg Thr Gln Glu 515 520 525 Pro Gly Val Thr Leu Ala Ser Leu Lys Pro Trp Thr Gln Tyr Ala Val 530 535 540 Phe Val Arg Ala Ile Thr Leu Thr Thr Glu Glu Asp Ser Pro His Gln 545 550 555 560 Gly Ala Gln Ser Pro Ile Val Tyr Leu Arg Thr Leu Pro Ala Ala Pro 565 570 575 Thr Val Pro Gln Asp Val Ile Ser Thr Ser Asn Ser Ser Ser His Leu 580 585 590 Leu Val Arg Trp Lys Pro Pro Thr Gln Arg Asn Gly Asn Leu Thr Tyr 595 600 605 Tyr Leu Val Leu Trp Gln Arg Leu Ala Glu Asp Gly Asp Leu Tyr Leu 610 615 620 Asn Asp Tyr Cys His Arg Gly Leu Arg Leu Pro Thr Ser Asn Asn Asp 625 630 635 640 Pro Arg Phe Asp Gly Glu Asp Gly Asp Pro Glu Ala Glu Met Glu Ser 645 650 655 Asp Cys Cys Pro Cys Gln His Pro Pro Pro Gly Gln Val Leu Pro Pro 660 665 670 Leu Glu Ala Gln Glu Ala Ser Phe Gln Lys Lys Phe Glu Asn Phe Leu 675 680 685 His Asn Ala Ile Thr Ile Pro Ile Ser Pro Trp Lys Val Thr Ser Ile 690 695 700 Asn Lys Ser Pro Gln Arg Asp Ser Gly Arg His Arg Arg Ala Ala Gly 705 710 715 720 Pro Leu Arg Leu Gly Gly Asn Ser Ser Asp Phe Glu Ile Gln Glu Asp 725 730 735 Lys Val Pro Arg Glu Arg Ala Val Leu Ser Gly Leu Arg His Phe Thr 740 745 750 Glu Tyr Arg Ile Asp Ile His Ala Cys Asn His Ala Ala His Thr Val 755 760 765 Gly Cys Ser Ala Ala Thr Phe Val Phe Ala Arg Thr Met Pro His Ser 770 775 780 Arg 785 44 131 PRT Homo sapiens misc_feature (7)..(7) Xaa = any amino acid, unknown or other 44 Val Lys Cys Pro Gly Thr Xaa Cys Gln Thr Gly Phe Gly Ser Arg His 1 5 10 15 Leu Val Ser Lys Lys Tyr Leu Phe Glu Tyr Thr Val Val Asn Val His 20 25 30 Leu Ser Gln His His His Leu Leu Ala Leu Asp Val Cys Gly Gly Gly 35 40 45 Leu Ile Pro Asn Pro His Ala Asp Ser Val His Pro Val Cys Cys Leu 50 55 60 Ala Pro Ser Leu Pro Val Lys Leu Gln Thr Leu Arg Ile Trp Thr Ser 65 70 75 80 Arg Ser Val Val Leu Pro Pro Ser Thr Gly Leu Thr Gly Ala Ser Gly 85 90 95 His His Pro Ile Pro Ser Ser Thr Gly Ala Asn Ser Arg Cys Val Thr 100 105 110 Val Ser Ala Cys Gly Leu Gly Ile Arg Pro Pro Pro Gln Thr Ser Arg 115 120 125 Ala Arg Arg 130 45 640 PRT Homo sapiens 45 Ala Thr Gln Arg Leu Met Leu Thr Met Gly Arg Leu Gln Leu Val Val 1 5 10 15 Leu Gly Leu Thr Cys Cys Trp Ala Val Ala Ser Ala Ala Lys Leu Gly 20 25 30 Ala Val Tyr Thr Glu Gly Gly Phe Val Glu Gly Val Asn Lys Lys Leu 35 40 45 Gly Leu Leu Gly Asp Ser Val Asp Ile Phe Lys Gly Ile Pro Phe Ala 50 55 60 Ala Pro Thr Lys Ala Leu Glu Asn Pro Gln Pro His Pro Gly Trp Gln 65 70 75 80 Gly Thr Leu Lys Ala Lys Asn Phe Lys Lys Arg Cys Leu Gln Ala Thr 85 90 95 Ile Thr Gln Asp Ser Thr Tyr Gly Asp Glu Asp Cys Leu Tyr Leu Asn 100 105 110 Ile Trp Val Pro Gln Gly Arg Lys Gln Val Ser Arg Asp Leu Pro Val 115 120 125 Met Ile Trp Ile Tyr Gly Gly Ala Phe Leu Met Gly Ser Gly His Gly 130 135 140 Ala Asn Phe Leu Asn Asn Tyr Leu Tyr Asp Gly Glu Glu Ile Ala Thr 145 150 155 160 Arg Gly Asn Val Ile Val Val Thr Phe Asn Tyr Arg Val Gly Pro Leu 165 170 175 Gly Phe Leu Ser Thr Gly Asp Ala Asn Leu Pro Gly Asn Tyr Gly Leu 180 185 190 Arg Asp Gln His Met Ala Ile Ala Trp Val Lys Arg Asn Ile Ala Ala 195 200 205 Phe Gly Gly Asp Pro Asn Asn Ile Thr Leu Phe Gly Glu Ser Ala Gly 210 215 220 Gly Ala Ser Val Ser Leu Gln Thr Leu Ser Pro Tyr Asn Lys Gly Leu 225 230 235 240 Ile Arg Arg Ala Ile Ser Gln Ser Gly Val Ala Leu Ser Pro Trp Val 245 250 255 Ile Gln Lys Asn Pro Leu Phe Trp Ala Lys Lys Val Ala Glu Lys Val 260 265 270 Gly Cys Pro Val Gly Asp Ala Ala Arg Met Ala Gln Cys Leu Lys Val 275 280 285 Thr Asp Pro Arg Ala Leu Thr Leu Ala Tyr Lys Val Pro Leu Ala Gly 290 295 300 Leu Glu Tyr Pro Met Leu His Tyr Val Gly Phe Val Pro Val Ile Asp 305 310 315 320 Gly Asp Phe Ile Pro Ala Asp Pro Ile Asn Leu Tyr Ala Asn Ala Ala 325 330 335 Asp Ile Asp Tyr Ile Ala Gly Thr Asn Asn Met Asp Gly His Ile Phe 340 345 350 Ala Ser Ile Asp Met Pro Ala Ile Asn Lys Gly Asn Lys Lys Val Thr 355 360 365 Glu Glu Asp Phe Tyr Lys Leu Val Ser Glu Phe Thr Ile Thr Lys Gly 370 375 380 Leu Arg Gly Ala Lys Thr Thr Phe Asp Val Tyr Thr Glu Ser Trp Ala 385 390 395 400 Gln Asp Pro Ser Gln Glu Asn Lys Lys Lys Thr Val Val Asp Phe Glu 405 410 415 Thr Asp Val Leu Phe Leu Val Pro Thr Glu Ile Ala Leu Ala Gln His 420 425 430 Arg Ala Asn Ala Lys Ser Ala Lys Thr Tyr Ala Tyr Leu Phe Ser His 435 440 445 Pro Ser Arg Met Pro Val Tyr Pro Lys Trp Val Gly Ala Asp His Ala 450 455 460 Asp Asp Ile Gln Tyr Val Phe Gly Lys Pro Phe Ala Thr Pro Thr Gly 465 470 475 480 Tyr Arg Pro Gln Asp Arg Thr Val Ser Lys Ala Met Ile Ala Tyr Trp 485 490 495 Thr Asn Phe Ala Lys Thr Gly Asp Pro Asn Met Gly Asp Ser Ala Val 500 505 510 Pro Thr His Trp Glu Pro Tyr Thr Thr Glu Asn Ser Gly Tyr Leu Glu 515 520 525 Ile Thr Lys Lys Met Gly Ser Ser Ser Met Lys Arg Ser Leu Arg Thr 530 535 540 Asn Phe Leu Arg Tyr Trp Thr Leu Thr Tyr Leu Ala Leu Pro Thr Val 545 550 555 560 Thr Asp Gln Glu Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Ala 565 570 575 Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro Pro 580 585 590 Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly 595 600 605 Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro 610 615 620 Pro Thr Gly Asp Ser Lys Glu Ala Gln Met Pro Ala Val Ile Arg Phe 625 630 635 640 46 659 PRT Homo sapiens 46 Ala Thr Gln Arg Leu Met Leu Thr Met Gly Arg Leu Gln Leu Val Val 1 5 10 15 Leu Gly Leu Thr Cys Cys Trp Ala Val Ala Ser Ala Ala Lys Leu Gly 20 25 30 Ala Val Tyr Thr Glu Gly Gly Phe Val Glu Gly Val Asn Lys Lys Leu 35 40 45 Gly Leu Leu Gly Asp Ser Val Asp Ile Phe Lys Gly Ile Pro Phe Ala 50 55 60 Ala Pro Thr Lys Ala Leu Glu Asn Pro Gln Pro His Pro Gly Trp Gln 65 70 75 80 Gly Thr Leu Lys Ala Lys Asn Phe Lys Lys Arg Cys Leu Gln Ala Thr 85 90 95 Ile Thr Gln Asp Ser Thr Tyr Gly Asp Glu Asp Cys Leu Tyr Leu Asn 100 105 110 Ile Trp Val Pro Gln Gly Arg Lys Gln Val Ser Arg Asp Leu Pro Val 115 120 125 Met Ile Trp Ile Tyr Gly Gly Ala Phe Leu Met Gly Ser Gly His Gly 130 135 140 Ala Asn Phe Leu Asn Asn Tyr Leu Tyr Asp Gly Glu Glu Ile Ala Thr 145 150 155 160 Arg Gly Asn Val Ile Val Val Thr Phe Asn Tyr Arg Val Gly Pro Leu 165 170 175 Gly Phe Leu Ser Thr Gly Asp Ala Asn Leu Pro Gly Asn Tyr Gly Leu 180 185 190 Arg Asp Gln His Met Ala Ile Ala Trp Val Lys Arg Asn Ile Ala Ala 195 200 205 Phe Gly Gly Asp Pro Asn Asn Ile Thr Leu Phe Gly Glu Ser Ala Gly 210 215 220 Gly Ala Ser Val Ser Leu Gln Thr Leu Ser Pro Tyr Asn Lys Gly Leu 225 230 235 240 Ile Arg Arg Ala Ile Ser Gln Ser Gly Val Ala Leu Ser Pro Trp Val 245 250 255 Ile Gln Lys Asn Pro Leu Phe Trp Ala Lys Lys Val Ala Glu Lys Val 260 265 270 Gly Cys Pro Val Gly Asp Ala Ala Arg Met Ala Gln Cys Leu Lys Val 275 280 285 Thr Asp Pro Arg Ala Leu Thr Leu Ala Tyr Lys Val Pro Leu Ala Gly 290 295 300 Leu Glu Tyr Pro Met Leu His Tyr Val Gly Phe Val Pro Val Ile Asp 305 310 315 320 Gly Asp Phe Ile Pro Ala Asp Pro Ile Asn Leu Tyr Ala Asn Ala Ala 325 330 335 Asp Ile Asp Tyr Ile Ala Gly Thr Asn Asn Met Asp Gly His Ile Phe 340 345 350 Ala Ser Ile Asp Met Pro Ala Ile Asn Lys Gly Asn Lys Lys Val Thr 355 360 365 Glu Glu Asp Phe Tyr Lys Leu Val Ser Glu Phe Thr Ile Thr Lys Gly 370 375 380 Leu Arg Gly Ala Lys Thr Thr Phe Asp Val Tyr Thr Glu Ser Trp Ala 385 390 395 400 Gln Asp Pro Ser Gln Glu Asn Lys Lys Lys Thr Val Val Asp Phe Glu 405 410 415 Thr Asp Val Leu Phe Leu Val Pro Thr Glu Ile Ala Leu Ala Gln His 420 425 430 Arg Ala Asn Ala Lys Ser Ala Lys Thr Tyr Ala Tyr Leu Phe Ser His 435 440 445 Pro Ser Arg Met Pro Val Tyr Pro Lys Trp Val Gly Ala Asp His Ala 450 455 460 Asp Asp Ile Gln Tyr Val Phe Gly Lys Pro Phe Ala Thr Pro Thr Gly 465 470 475 480 Tyr Arg Pro Gln Asp Arg Thr Val Ser Lys Ala Met Ile Ala Tyr Trp 485 490 495 Thr Asn Phe Ala Lys Thr Gly Asp Pro Asn Met Gly Asp Ser Ala Val 500 505 510 Pro Thr His Trp Glu Pro Tyr Thr Thr Glu Asn Ser Gly Tyr Leu Glu 515 520 525 Ile Thr Lys Lys Met Gly Ser Ser Ser Met Lys Arg Ser Leu Arg Thr 530 535 540 Asn Phe Leu Arg Tyr Trp Thr Leu Thr Tyr Leu Ala Leu Pro Thr Val 545 550 555 560 Thr Asp Gln Glu Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Ala 565 570 575 Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro Pro 580 585 590 Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly 595 600 605 Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro 610 615 620 Pro Thr Gly Cys Pro Pro Arg Val Thr Leu Arg Leu Pro Leu Cys Pro 625 630 635 640 Pro Gln Met Thr Pro Arg Lys Leu Arg Cys Leu Gln Ser Leu Gly Phe 645 650 655 Ser Val Pro 47 381 PRT Homo sapiens 47 Thr Ser Cys Ser Pro Gln Ile Pro Glu Ser Leu His Tyr Ile Ser Pro 1 5 10 15 Val Gly His Pro Glu Ala Asp Ala His His Gly Ala Pro Ala Thr Gly 20 25 30 Cys Val Gly Pro His Leu Leu Leu Gly Ser Gly Glu Cys Arg Glu Asp 35 40 45 Pro Met Leu His Tyr Val Gly Phe Val Pro Val Ile Asp Gly Asp Phe 50 55 60 Ile Pro Ala Asp Pro Ile Asn Leu Tyr Ala Asn Ala Ala Asp Ile Asp 65 70 75 80 Tyr Ile Ala Gly Thr Asn Asn Met Asp Gly His Ile Phe Ala Ser Ile 85 90 95 Asp Met Pro Ala Ile Asn Lys Gly Asn Lys Lys Val Thr Glu Glu Asp 100 105 110 Phe Tyr Lys Leu Val Ser Glu Phe Thr Ile Thr Lys Gly Leu Arg Gly 115 120 125 Ala Lys Thr Thr Phe Asp Val Tyr Thr Glu Ser Trp Ala Gln Asp Pro 130 135 140 Ser Gln Glu Asn Lys Lys Lys Thr Val Val Asp Phe Glu Thr Asp Val 145 150 155 160 Leu Phe Leu Val Pro Thr Glu Ile Ala Leu Ala Gln His Arg Ala Asn 165 170 175 Ala Lys Ser Ala Lys Thr Tyr Ala Tyr Leu Phe Ser His Pro Ser Arg 180 185 190 Met Pro Val Tyr Pro Lys Trp Val Gly Ala Asp His Ala Asp Asp Ile 195 200 205 Gln Tyr Val Phe Gly Lys Pro Phe Ala Thr Pro Thr Gly Tyr Arg Pro 210 215 220 Gln Asp Arg Thr Val Ser Lys Ala Met Ile Ala Tyr Trp Thr Asn Phe 225 230 235 240 Ala Lys Thr Gly Asp Pro Asn Met Gly Asp Ser Ala Val Pro Thr His 245 250 255 Trp Glu Pro Tyr Thr Thr Glu Asn Ser Gly Tyr Leu Glu Ile Thr Lys 260 265 270 Lys Met Gly Ser Ser Ser Met Lys Arg Ser Leu Arg Thr Asn Phe Leu 275 280 285 Arg Tyr Trp Thr Leu Thr Tyr Leu Ala Leu Pro Thr Val Thr Asp Gln 290 295 300 Glu Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Ala Thr Pro Val 305 310 315 320 Pro Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro Pro Thr Gly Asp 325 330 335 Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro 340 345 350 Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly 355 360 365 Asp Ser Lys Glu Ala Gln Met Pro Ala Val Ile Arg Phe 370 375 380 48 400 PRT Homo sapiens 48 Thr Ser Cys Ser Pro Gln Ile Pro Glu Ser Leu His Tyr Ile Ser Pro 1 5 10 15 Val Gly His Pro Glu Ala Asp Ala His His Gly Ala Pro Ala Thr Gly 20 25 30 Cys Val Gly Pro His Leu Leu Leu Gly Ser Gly Glu Cys Arg Glu Asp 35 40 45 Pro Met Leu His Tyr Val Gly Phe Val Pro Val Ile Asp Gly Asp Phe 50 55 60 Ile Pro Ala Asp Pro Ile Asn Leu Tyr Ala Asn Ala Ala Asp Ile Asp 65 70 75 80 Tyr Ile Ala Gly Thr Asn Asn Met Asp Gly His Ile Phe Ala Ser Ile 85 90 95 Asp Met Pro Ala Ile Asn Lys Gly Asn Lys Lys Val Thr Glu Glu Asp 100 105 110 Phe Tyr Lys Leu Val Ser Glu Phe Thr Ile Thr Lys Gly Leu Arg Gly 115 120 125 Ala Lys Thr Thr Phe Asp Val Tyr Thr Glu Ser Trp Ala Gln Asp Pro 130 135 140 Ser Gln Glu Asn Lys Lys Lys Thr Val Val Asp Phe Glu Thr Asp Val 145 150 155 160 Leu Phe Leu Val Pro Thr Glu Ile Ala Leu Ala Gln His Arg Ala Asn 165 170 175 Ala Lys Ser Ala Lys Thr Tyr Ala Tyr Leu Phe Ser His Pro Ser Arg 180 185 190 Met Pro Val Tyr Pro Lys Trp Val Gly Ala Asp His Ala Asp Asp Ile 195 200 205 Gln Tyr Val Phe Gly Lys Pro Phe Ala Thr Pro Thr Gly Tyr Arg Pro 210 215 220 Gln Asp Arg Thr Val Ser Lys Ala Met Ile Ala Tyr Trp Thr Asn Phe 225 230 235 240 Ala Lys Thr Gly Asp Pro Asn Met Gly Asp Ser Ala Val Pro Thr His 245 250 255 Trp Glu Pro Tyr Thr Thr Glu Asn Ser Gly Tyr Leu Glu Ile Thr Lys 260 265 270 Lys Met Gly Ser Ser Ser Met Lys Arg Ser Leu Arg Thr Asn Phe Leu 275 280 285 Arg Tyr Trp Thr Leu Thr Tyr Leu Ala Leu Pro Thr Val Thr Asp Gln 290 295 300 Glu Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Ala Thr Pro Val 305 310 315 320 Pro Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro Pro Thr Gly Asp 325 330 335 Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro 340 345 350 Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly 355 360 365 Cys Pro Pro Arg Val Thr Leu Arg Leu Pro Leu Cys Pro Pro Gln Met 370 375 380 Thr Pro Arg Lys Leu Arg Cys Leu Gln Ser Leu Gly Phe Ser Val Pro 385 390 395 400 49 503 PRT Homo sapiens 49 Phe Gln Met Gly Lys Lys Ile Asn Lys Leu Phe Cys Phe Asn Phe Leu 1 5 10 15 Val Gln Cys Phe Arg Gly Lys Ser Lys Pro Ser Lys Cys Gln Ile Arg 20 25 30 Lys Lys Val Lys Asn His Ile Glu Arg Leu Leu Asp Thr Glu Asp Glu 35 40 45 Leu Ser Asp Ile Gln Thr Asp Ser Val Pro Ser Glu Val Arg Asp Trp 50 55 60 Leu Ala Ser Thr Phe Thr Arg Lys Met Gly Met Thr Lys Lys Lys Pro 65 70 75 80 Glu Glu Lys Pro Lys Phe Arg Ser Ile Val His Ala Val Gln Ala Gly 85 90 95 Ile Phe Val Glu Arg Met Tyr Arg Lys Thr Tyr His Met Val Gly Leu 100 105 110 Ala Tyr Pro Ala Ala Val Ile Val Thr Leu Lys Asp Val Asp Lys Trp 115 120 125 Ser Phe Asp Val Phe Ala Leu Asn Glu Ala Ser Gly Glu His Ser Leu 130 135 140 Lys Phe Met Ile Tyr Glu Leu Phe Thr Arg Tyr Asp Leu Ile Asn Arg 145 150 155 160 Phe Lys Ile Pro Val Ser Cys Leu Ile Thr Phe Ala Glu Ala Leu Glu 165 170 175 Val Gly Tyr Ser Lys Tyr Lys Asn Pro Tyr His Asn Leu Ile His Ala 180 185 190 Ala Asp Val Thr Gln Thr Val His Tyr Ile Met Leu His Thr Gly Ile 195 200 205 Met His Trp Leu Thr Glu Leu Glu Ile Leu Ala Met Val Phe Ala Ala 210 215 220 Ala Ile His Asp Tyr Glu His Thr Gly Thr Thr Asn Asn Phe His Ile 225 230 235 240 Gln Thr Arg Ser Asp Val Ala Ile Leu Tyr Asn Asp Arg Ser Val Leu 245 250 255 Glu Asn His His Val Ser Ala Ala Tyr Arg Leu Met Gln Glu Glu Glu 260 265 270 Met Asn Ile Leu Ile Asn Leu Ser Lys Asp Asp Trp Arg Asp Leu Arg 275 280 285 Asn Leu Val Ile Glu Met Val Leu Ser Thr Asp Met Ser Gly His Phe 290 295 300 Gln Gln Ile Lys Asn Ile Arg Asn Ser Leu Gln Gln Pro Glu Gly Ile 305 310 315 320 Asp Arg Ala Lys Thr Met Ser Leu Ile Leu His Ala Ala Asp Ile Ser 325 330 335 His Pro Ala Lys Ser Trp Lys Leu His Tyr Arg Trp Thr Met Ala Leu 340 345 350 Met Glu Glu Phe Phe Leu Gln Gly Asp Lys Glu Ala Glu Leu Gly Leu 355 360 365 Pro Phe Ser Pro Leu Cys Asp Arg Lys Ser Thr Met Val Ala Gln Ser 370 375 380 Gln Ile Gly Phe Ile Asp Phe Ile Val Glu Pro Thr Phe Ser Leu Leu 385 390 395 400 Thr Asp Ser Thr Glu Lys Ile Val Ile Pro Leu Ile Glu Glu Ala Ser 405 410 415 Lys Ala Glu Thr Ser Ser Tyr Val Ala Ser Ser Ser Thr Thr Ile Val 420 425 430 Gly Leu His Ile Ala Asp Ala Leu Arg Arg Ser Asn Thr Lys Gly Ser 435 440 445 Met Ser Asp Gly Ser Tyr Ser Pro Asp Tyr Ser Leu Ala Ala Val Asp 450 455 460 Leu Lys Ser Phe Lys Asn Asn Leu Val Asp Ile Ile Gln Gln Asn Lys 465 470 475 480 Glu Arg Trp Lys Glu Leu Ala Ala Gln Glu Ala Arg Thr Ser Ser Gln 485 490 495 Lys Cys Glu Phe Ile His Gln 500 50 612 PRT Homo sapiens 50 Leu Pro Leu Leu His Ala Gly Phe Asn Arg Arg Phe Met Glu Asn Ser 1 5 10 15 Ser Ile Ile Ala Cys Tyr Asn Glu Leu Ile Gln Ile Glu His Gly Glu 20 25 30 Val Arg Ser Gln Phe Lys Leu Arg Ala Cys Asn Ser Val Phe Thr Ala 35 40 45 Leu Asp His Cys His Glu Ala Ile Glu Ile Thr Ser Asp Asp His Val 50 55 60 Ile Gln Glu Trp Gln Gly Val Tyr Tyr Ala Arg Arg Lys Ser Gly Asp 65 70 75 80 Ser Ile Gln Gln His Val Lys Ile Thr Pro Val Ile Gly Gln Gly Gly 85 90 95 Lys Ile Arg His Phe Val Ser Leu Lys Lys Leu Cys Cys Thr Thr Asp 100 105 110 Asn Asn Lys Gln Ile His Lys Ile His Arg Asp Ser Gly Asp Asn Ser 115 120 125 Gln Thr Glu Pro His Ser Phe Arg Tyr Lys Asn Arg Arg Lys Glu Ser 130 135 140 Ile Asp Val Lys Ser Ile Ser Ser Arg Gly Ser Asp Ala Pro Ser Leu 145 150 155 160 Gln Asn Arg Arg Tyr Pro Ser Met Ala Arg Ile His Ser Met Thr Ile 165 170 175 Glu Ala Pro Ile Thr Lys Val Ile Asn Ile Ile Asn Ala Ala Gln Glu 180 185 190 Asn Ser Pro Val Thr Val Ala Glu Ala Leu Asp Arg Val Leu Glu Ile 195 200 205 Leu Arg Thr Thr Glu Leu Tyr Ser Pro Gln Leu Gly Thr Lys Asp Glu 210 215 220 Asp Pro His Thr Ser Asp Leu Val Gly Gly Leu Met Thr Asp Gly Leu 225 230 235 240 Arg Arg Leu Ser Gly Asn Glu Tyr Val Phe Thr Lys Asn Val His Gln 245 250 255 Ser His Ser His Leu Ala Met Pro Ile Thr Ile Asn Asp Val Pro Pro 260 265 270 Cys Ile Ser Gln Leu Leu Asp Asn Glu Glu Ser Trp Asp Phe Asn Ile 275 280 285 Phe Glu Leu Glu Ala Ile Thr His Lys Arg Pro Leu Val Tyr Leu Gly 290 295 300 Leu Lys Val Phe Ser Arg Phe Gly Val Cys Glu Phe Leu Asn Cys Ser 305 310 315 320 Glu Thr Thr Leu Arg Ala Trp Phe Gln Val Ile Glu Ala Asn Tyr His 325 330 335 Ser Ser Asn Ala Tyr His Asn Ser Thr His Ala Ala Asp Val Leu His 340 345 350 Ala Thr Ala Phe Phe Leu Gly Lys Glu Arg Val Lys Gly Ser Leu Asp 355 360 365 Gln Leu Asp Glu Val Ala Ala Leu Ile Ala Ala Thr Val His Asp Val 370 375 380 Asp His Pro Gly Arg Thr Asn Ser Phe Leu Cys Asn Ala Gly Ser Glu 385 390 395 400 Leu Ala Val Leu Tyr Asn Asp Thr Ala Val Leu Glu Ser His His Thr 405 410 415 Ala Leu Ala Phe Gln Leu Thr Val Lys Asp Thr Lys Cys Asn Ile Phe 420 425 430 Lys Asn Ile Asp Arg Asn His Tyr Arg Thr Leu Arg Gln Ala Ile Ile 435 440 445 Asp Met Val Leu Ala Thr Glu Met Thr Lys His Phe Glu His Val Asn 450 455 460 Lys Phe Val Asn Ser Ile Asn Lys Pro Met Ala Ala Glu Ile Glu Gly 465 470 475 480 Ser Asp Cys Glu Cys Asn Pro Ala Gly Lys Asn Phe Pro Glu Asn Gln 485 490 495 Ile Leu Ile Lys Arg Met Met Ile Lys Cys Ala Asp Val Ala Asn Pro 500 505 510 Cys Arg Pro Leu Asp Leu Cys Ile Glu Trp Ala Gly Arg Ile Ser Glu 515 520 525 Glu Tyr Phe Ala Gln Thr Asp Glu Glu Lys Arg Gln Gly Leu Pro Val 530 535 540 Val Met Pro Val Phe Asp Arg Asn Thr Cys Ser Ile Pro Lys Ser Gln 545 550 555 560 Ile Ser Phe Ile Asp Tyr Phe Ile Thr Asp Met Phe Asp Ala Trp Asp 565 570 575 Ala Phe Ala His Leu Pro Ala Leu Met Gln His Leu Ala Asp Asn Tyr 580 585 590 Lys His Trp Lys Thr Leu Asp Asp Leu Lys Cys Lys Ser Leu Arg Leu 595 600 605 Pro Ser Asp Ser 610 51 218 PRT Homo sapiens 51 Lys Tyr Ser Asn Asn Ser Trp Arg Tyr Leu Ser Asn Arg Leu Leu Ala 1 5 10 15 Pro Ser Asp Ser Pro Glu Trp Leu Ser Phe Asp Val Thr Gly Val Val 20 25 30 Arg Gln Trp Leu Ser Arg Gly Gly Glu Ile Glu Gly Phe Arg Leu Ser 35 40 45 Ala His Cys Ser Cys Asp Ser Arg Asp Asn Thr Leu Gln Val Asp Ile 50 55 60 Asn Gly Phe Thr Thr Gly Arg Arg Gly Asp Leu Ala Thr Ile His Gly 65 70 75 80 Met Asn Arg Pro Phe Leu Leu Leu Met Ala Thr Pro Leu Glu Arg Ala 85 90 95 Gln His Leu Gln Ser Ser Arg His Arg Arg Ala Leu Asp Thr Asn Tyr 100 105 110 Cys Phe Ser Ser Thr Glu Lys Asn Cys Cys Val Arg Gln Leu Tyr Ile 115 120 125 Asp Phe Arg Lys Asp Leu Gly Trp Lys Trp Ile His Glu Pro Lys Gly 130 135 140 Tyr His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu 145 150 155 160 Asp Thr Gln Tyr Ser Lys Val Leu Ala Leu Tyr Asn Gln His Asn Pro 165 170 175 Gly Ala Ser Ala Ala Pro Cys Cys Val Pro Gln Ala Leu Glu Pro Leu 180 185 190 Pro Ile Val Tyr Tyr Val Gly Arg Lys Pro Lys Val Glu Gln Leu Ser 195 200 205 Asn Met Ile Val Arg Ser Cys Lys Cys Ser 210 215 52 185 PRT Homo sapiens 52 Lys Tyr Ser Asn Asn Ser Trp Arg Tyr Leu Ser Asn Arg Leu Leu Ala 1 5 10 15 Pro Ser Asp Ser Pro Glu Trp Leu Ser Phe Asp Val Thr Gly Val Val 20 25 30 Arg Gln Trp Leu Ser Arg Gly Gly Glu Ile Glu Gly Phe Arg Leu Ser 35 40 45 Ala His Cys Ser Cys Asp Ser Arg Asp Asn Thr Leu Gln Val Asp Ile 50 55 60 Asn Gly Phe Thr Thr Gly Arg Arg Gly Asp Leu Ala Thr Ile His Gly 65 70 75 80 Met Asn Arg Pro Phe Leu Leu Leu Met Ala Thr Pro Leu Glu Arg Ala 85 90 95 Gln His Leu Gln Ser Ser Arg His Arg Arg Ala Leu Asp Thr Asn Tyr 100 105 110 Cys Phe Ser Ser Thr Glu Lys Asn Cys Cys Val Arg Gln Leu Tyr Ile 115 120 125 Asp Phe Arg Lys Asp Leu Gly Trp Lys Trp Ile His Glu Pro Lys Gly 130 135 140 Tyr His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu 145 150 155 160 Asp Thr Gln Tyr Ser Lys Leu Asn Glu Gln Asn Leu Ile Gln Glu Val 165 170 175 Pro Asn Ile Trp Gln Arg Glu Val Gly 180 185 

1. An isolated nucleic acid sequence, of an alternative splicing variant, selected from the group consisting of: (i) the nucleic acid sequence depicted in any one of SEQ ID NO:1 to SEQ ID NO:26; (ii) nucleic acid sequences having at least 90% identity with the sequence of (i) with the proviso that each sequence is different than the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing; and (iii) fragments of (i) or (ii) of at least 20 b.p., provided that said fragment contains a sequence which is not present, as a continuous stretch of nucleotides, in the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing.
 2. An isolated nucleic acid sequence complementary to the nucleic acid sequence of claim
 1. 3. An amino acid sequence selected from the group consisting of: (i) an amino acid sequence coded by the isolated nucleic acid sequence of alternative splice variants of claim 1; (ii) homologues of the amino acid sequences of (i) in which one or more amino acids has been added, deleted, replaced or chemically modified in the region, or adjacent to the region, where the amino acid sequences differs from the original amino acid sequence, coded by the original nucleic acid sequence from which the variant has been varied by alternative splicing.
 4. An amino acid sequence according to claim 3, as depicted in any one of SEQ ID NO:27 to SEQ ID NO:52.
 5. An isolated nucleic acid sequence coding for any one of the amino acid sequences of claim 3 or
 4. 6. A purified antibody which binds specifically to any of the amino acid sequence of claim 3 or
 4. 7. A purified antibody which binds to an amino acid sequence which is present only in the alternative splice variant depicted in the amino acid of claims 3 or 4, but is not present in the original amino sequence.
 8. A purified antibody which binds to an amino acid sequence present in the original amino acid sequence, which amino acid sequence is not present in the amino acid sequence of claims 3 or
 4. 9. An expression vector comprising any one of the nucleic acid sequences of claim 1 or 5 and control elements for the expression of the nucleic acid sequence in a suitable host.
 10. An expression vector comprising any one of the nucleic acid sequences of claim 2, and control elements for the expression of the nucleic acid sequences in a suitable host.
 11. A host cell transfected by the expression vector of claim 9 or
 10. 12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of: (i) the expression vector of claim 9; and (ii) any one of the amino acid sequences of claim 3 or
 4. 13. A pharmaceutical composition according to claim 12, for treatment of diseases which can be ameliorated or cured by raising the level of any one of the amino acid sequences depicted in SEQ ID NO:27 to SEQ ID NO:52.
 14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected form the group consisting of: (i) any one of the nucleic acid sequences of claim 2; (ii) the expression vector of claim 10; and (iii) the purified antibody of claim 6 or
 7. 15. A pharmaceutical composition according to claim 14, for treatment of diseases which can be ameliorated or cured by decreasing the level of any one of the amino acid sequences depicted in SEQ ID NO:27 to SEQ ID NO:52.
 16. A method for detecting a variant nucleic acid sequence in a biological sample, comprising the steps of: (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of claim 1 or 2; and (b) detecting said hybridization complex; wherein the presence of said hybridization complex correlates with the presence of a variant nucleic acid sequence in the said biological sample.
 17. A method for determining the level of variant nucleic acid sequences in a biological sample comprising the steps of: (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of claim 1 or 2; and (b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the variant nucleic acid sequences in the sample.
 18. A method for determining the ratio between the level of variant of the nucleic acid sequence in a first biological sample and the level of the original sequence from which the variant has been varied by alternative splicing in a second biological sample comprising: (a) determining the level of the variant nucleic acid sequence in the first biological sample according to the method of claim 17; (b) determining the level of the original sequence in the second biological sample; and (c) comprising the levels obtained in (a) and (b) to give said ratio.
 19. A method according to claim 18, wherein said first and said second biological samples are the same sample.
 20. A method according to any of claims 16 to 19, wherein the nucleic acid material of said biological sample are mRNA transcripts.
 21. A method according to claim 20, where the nucleic acid sequence is present in a nucleic acid chip.
 22. A method for identifying candidate compounds capable of binding to the variant product and modulating its activity, the method comprising: (i) providing any one of the amino acid sequences as defined in claim 3 or 4; (ii) contacting a candidate compound with said amino acid sequence; (iii) determining the effect of said candidate compound on the biological activity of said protein or polypeptide and selecting those compounds which show a significant effect on said biological activity.
 23. A method according to claim 22, wherein the compound is an activator and the measured effect is increase in the biological activity.
 24. A method according to claim 22, wherein the compound is a deactivator and the effect is decrease in the biological activity.
 25. An activator of any one of the amino acid sequences of claim 3 or
 4. 25. A deactivator of any one of the amino acid sequences of claims 3 or
 4. 27. A method for detecting any one of the amino acid sequences of claim 3 or 4 in a biological sample, comprising the steps of: (a) contacting with said biological sample the antibody of claim 6 or 7, thereby forming an antibody-antigen complex; and (b) detecting said antibody-antigen complex wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.
 28. A method for detecting the level of the amino acid sequence of any one of claim 3 or 4 in a biological sample, comprising the steps of: (a) contacting with said biological sample the antibody of claim 6 or 7, thereby forming an antibody-antigen complex; and (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.
 29. A method for determining the ratio between the level of any one of the amino acid sequences of claims 3 or 4 present in a first biological sample and the level of the original amino acid sequences from which they were varied by alternative splicing, present in a second biological sample, the method comprising: (a) determining the level of the amino acid sequences of claims 3 or 4 into a first sample by the method of claim 28; (b) determining the level of the original amino acid sequence in the second sample; and (c) comparing the level obtained in (a) and (b) to give said ratio.
 30. A method according to claim 29, wherein said first and said second biological samples are the same sample.
 31. An isolated nucleic acid sequence comprising SEQ ID NO:
 21. 32. An isolated nucleic acid sequence which is complementary to the nucleic acid sequence of claim
 31. 33. An amino acid sequence encoded by the isolated nucleic acid sequence of claim
 31. 34. The amino acid sequence according to claim 33, wherein said amino acid sequence comprises SEQ ID NO:
 33. 35. An isolated nucleic acid sequence coding for the amino acid sequence of claim
 33. 36. A purified antibody which bind specifically to the amino acid sequence of claim
 33. 37. A purified antibody which binds to an amino acid sequence which is present only in the alternative splice variant depicted in the amino acid of claim 33, but is not present in the original amino acid sequence.
 38. An expression vector comprising the nucleic acid sequence of claim 31 and control elements for the expression of the nucleic acid sequence in a suitable host.
 39. An expression vector comprising the nucleic acid sequence of claim 32 and control elements for the expression of the nucleic acid sequence in a suitable host.
 40. An expression vector comprising any one of the nucleic acid sequences of claim 32, and control elements for the expression of the nucleic acid sequence in a suitable host.
 41. A host cell transfected by the expression vector of claim
 38. 42. A host cell transfected by the expression vector of claim
 39. 43. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the expression vector of claim
 36. 44. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the amino acid sequence of claim
 33. 45. A composition according to claim 44 for the treatment of diseases which can be ameliorated or cured by raising the level of the amino acid sequence depicted in SEQ ID NO:
 33. 46. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the nucleic acid sequence of claim
 32. 47. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the expression vector of claim
 38. 48. A pharmaceutical composition comprising a pharmaceutically acceptable carrier as an active ingredient the purified antibody of claim
 34. 49. A pharmaceutical composition according to claim 44 for the treatment of diseases which can be ameliorated or cured by decreasing the level of the amino acid sequence depicted in SEQ ID NO:
 33. 50. A pharmaceutical composition according to claim 45 for the treatment of diseases which can be ameliorated or cured by decreasing the level of the amino acid sequence depicted in SEQ ID NO:
 33. 51. A pharmaceutical composition according to claim 46 for the treatment of diseases which can be ameliorated or cured by decreasing the level of the amino acid sequence depicted in SEQ ID NO:
 33. 52. A method for detecting a variant nucleic acid sequence in a biological sample, comprising: (a) hybridizing to nucleic acid material of said biological sample the nucleic acid sequence of claim 31 or an isolated nucleic acid complementary to the nucleic acid of claim 31; and (b) detecting the hybridization complex; wherein the presence of said hybridization complex correlates with the presence of a variant nucleic acid sequence in the said biological sample.
 53. A method for determining the level of variant nucleic acid sequence in a biological sample comprising: (a) hybridizing to a nucleic acid material of said biological sample the nucleic acid sequence of claim 31 or an isolated nucleic acid sequence complementary to the nucleic acid sequence of claim 31; and (b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the variant nucleic acid sequences in the sample.
 54. A method for determining the ratio between the level of variant of the nucleic acid sequence in a first biological sample and the level of the original sequence from which the variant has been varied by alternative splicing in a second biological sample, comprising: (a) determining the level of the variant nucleic acid sequence in the first biological sample according to the method of claim 51; (b) determining the level of the original sequence in a second biological sample; and (c) comparing the levels obtained in (a) and (b) to give said ratio.
 55. A method according to claim 52, wherein said first and second biological samples are the same sample.
 56. A method according to claim 50, wherein the nucleic acid material of said biological sample are mRNA transcripts.
 57. A method according to claim 51, wherein the nucleic acid material of said biological sample are mRNA transcripts.
 58. A method according to claim 52, wherein the nucleic acid material of said biological sample are mRNA transcripts.
 59. A method according to claim 52, wherein the nucleic acid material of said biological sample are mRNA transcripts.
 60. A method according to claim 52, wherein the nucleic acid sequence is present in a nucleic acid chip.
 61. A method according to claim 53, wherein the nucleic acid sequence is present in a nucleic acid chip.
 62. A method according to claim 53, wherein the nucleic acid sequence is present in a nucleic acid chip.
 63. A method according to claim 53, wherein the nucleic acid sequence is present in a nucleic acid chip.
 64. A method for identifying candidate compounds capable of binding to the variant product and modulating its activity, the method comprising: (a) providing the amino acid sequence as defined in claim 33; (b) contacting a candidate compound with said amino acid sequence; and (c) determining the effect of said candidate compound on the biological activity of said protein or polypeptide and selecting those compounds which show a significant effect on said biological activity.
 65. A method according to claim 55, wherein the compound is an activator and the measured effect is increased in the biological activity.
 66. A method according to claim 55, wherein the compound is a deactivator and effect is decreased in the biological activity.
 67. An activator of the amino acid sequence of claim
 33. 68. A deactivator of the amino acid sequence of claim
 33. 69. A method for detecting the amino acid sequence of claim 33 in a biological sample, comprising: (a) contacting with said biological sample the antibody of claim 34, thereby forming an antibody-antigen complex; and (b) detecting said antibody-antigen complex wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.
 70. A method for detecting the level of the amino acid sequence of claim 33 in a biological sample, comprising: (a) contacting with same biological sample the antibody of claim 34, thereby forming an antibody-antigen complex; and (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.
 71. A method for determining the ratio between the level of the amino acid sequence of claim 33 present in a first biological sample and the level of the original amino acid sequence from which they were varied by alternative splicing, present in a second biological sample, the method comprising: (a) determining the level of the amino acid sequence of claim 33 into a first sample by the method of claim 61; (b) determining the level of the original amino acid sequence in the second sample; and (c) comparing the level obtained in (a) and (b) to give said ratio.
 72. A method according to claim 62, wherein said first and said second biological samples are the same samples.
 73. An expression vector comprising a nucleic acid which is complementary to an isolated nucleic acid consisting essentially of exons 1-5 and 7-9 of a nucleotide sequence encoding CD40, and control elements for the expression of the nucleic acid in a suitable host.
 74. A host cell transfected by the expression vector of claim
 73. 75. A composition comprising a pharmaceutically acceptable carrier and as an active ingredient the expression vector of claim
 73. 76. A composition comprising a pharmaceutically acceptable carrier and as an active ingredient the expression vector of claim
 39. 